An Injectable Stem Cell Delivery System for Treatment of Musculoskeletal Defects by Leslie, Shirae
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2016
An Injectable Stem Cell Delivery System for
Treatment of Musculoskeletal Defects
Shirae Leslie
Virginia Commonwealth University, lesliesk@vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biomaterials Commons, and the Chemical Engineering Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/4472
  
 
 
 
 
 
 
 
 
 
 
© Shirae K. Leslie 2016 
All Rights Reserved 
  
ii 
 
An Injectable Stem Cell Delivery System for Treatment of Musculoskeletal Defects 
 
 
 
 
 
 
 
A Thesis Submitted 
in the Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy at 
Virginia Commonwealth University 
 
 
 
By 
 
 
 
 
Shirae Kerisha Leslie  
Master of Science in Biomedical Engineering, Georgia Institute of Technology, 2013 
Bachelor of Science in Chemistry, Randolph College, 2009 
 
 
 
 
 
Director: Dr. Barbara D. Boyan, 
Dean 
School of Engineering 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
February, 2016 
  
iii 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my parents Mr. and Mrs. D. Leslie whole heartedly for their 
continuous support throughout my graduate studies, without them by my side I would not have 
completed graduate school. My deepest gratitude goes toward my brother, one of my greatest 
supporters and cheerleaders, giving me numerous motivational speeches along my graduate school 
journey. To my remaining family members, I am very grateful for your various calls, and texts to 
offer encouragement and prayers for the protection of my sanity. Thanks to my friends across the 
globe with their never ending support, assuring me that the end is near. Chantel for her 
encouragement, chocolates to fuel the late nights. I am very grateful for Debbie providing 
encouragement and home cooked meals when I was not able to do so. 
Dr. Boyan and Dr. Schwartz, thank you for your mentorship during graduate school and 
taking your time to coach me in developing my scientific skills. Thanks for providing funding for 
my graduate research as my thesis project developed and guiding me as I solved problems directly 
related to my thesis work by thinking outside of the box. Thanks to my committee members who 
have guided me in completing my thesis and played a major role in some experiments of the thesis. 
Dr. Sundaresan, thank you for aiding and conducting the analysis of the migration study. I am 
grateful for the support of the present and past members of the Boyan-Schwartz laboratory in 
conducting experiments and troubleshooting various experimental problems. Thanks to Sharon 
Hyzy for ensuring that all components of the experiments were ordered in a timely fashion. Thanks 
to Dr. Cohen for aiding in the in vivo experiments, MicroCT and processing histological samples. 
Thanks to my undergraduates Eric Pinsker and Nathan Kirby for their work on projects that 
iv 
 
contributed to the thesis. The remaining members of the laboratory thanks for helping with animal 
surgeries and editing my written work. 
 
 
  
v 
 
TABLE OF CONTENTS 
 
Page 
 
ACKNOWLEDGMENTS  ........................................................................................................ iii 
LIST OF TABLES ................................................................................................................... viii 
LIST OF FIGURES ................................................................................................................... ix 
LIST OF SYMBOLS AND ABBREVIATIONS ..................................................................... xi 
ABSTRACT ............................................................................................................................... 14 
CHAPTER 
 
1 Specific Aims  .......................................................................................................... 15 
2 Background and Literature Review ..................................................................... 18 
Bone ............................................................................................................. 18 
Stem Cells and Fracture Repair  .................................................................. 18 
Non-unions .................................................................................................. 19 
Stem Cells and Cartilage Repair.................................................................. 20 
Therapies for Fracture Repair ...................................................................... 21 
Cell-based Therapies for Fracture Repair.................................................... 21 
Cell-based Therapies for Cartilage Repair .................................................. 23 
Microencapsulating Stem Cells for Therapy ............................................... 23 
 
3 Development of a Cell Delivery System Using Alginate Microbeads for Tissue   
Regeneration ........................................................................................................... 27 
 
Introduction ................................................................................................. 27 
 
Methods ....................................................................................................... 30 
 
Results ......................................................................................................... 38 
vi 
 
 
Discussion ................................................................................................... 49 
 
4 The Production of Osteogenic and Angiogenic Factors from Microencapsulated 
ASCs is Species Dependent and can be Modified by the Pretreatment of Media 
used .......................................................................................................................... 54 
Introduction ................................................................................................. 55 
 
Methods ....................................................................................................... 58 
 
Results ......................................................................................................... 62 
 
Discussion ................................................................................................... 71 
 
5 The Development of a Degradable Alginate Microbead System for Bone 
Regeneration ........................................................................................................... 75 
Introduction ................................................................................................. 75 
 
Methods ....................................................................................................... 78 
 
Results ......................................................................................................... 86 
 
Discussion ................................................................................................... 99 
 
 
6 Microencapsulated rabbit ASCs support Chondrogenesis in a Rabbit Auricular 
Defect Model ......................................................................................................... 106 
 
Introduction ............................................................................................... 107 
 
Methods ..................................................................................................... 108 
 
Results ....................................................................................................... 117 
 
Discussion ................................................................................................. 127 
 
vii 
 
7 Discussion .............................................................................................................. 131 
 
 
REFERENCES ........................................................................................................................ 135 
 
APPENDICES ...................................................................................................................... cxlvii 
 
 
A. Osteoinductive Nature of Microencapsulated ASCs ...................................... cxlvii 
Introduction ............................................................................................ cxlvii 
 
Methods ................................................................................................... cxlix 
 
Results ........................................................................................................ clii 
 
Discussion ................................................................................................ clvii 
 
B. Microencapsulated rASCs Support Osteogenesis  in a Unicortical Diaphyseal 
Defect ...................................................................................................................... clx 
 
Introduction ................................................................................................ clx 
 
Methods .................................................................................................... clxii 
 
Results ...................................................................................................... clxv 
 
Discussion .............................................................................................. clxvii 
  
viii 
 
LIST OF TABLES 
 
 Page 
 
Table 3.1:  Growth factor secreted in media and retained in the microbeads by microencapsulated 
cells treated with chondrogenic media. .....................................................................41 
 
Table 3.2: Effects of microbead number per well and number of cells per microbead on cell 
viability……….……………………………………………………………………. 45 
 
Table 4.1: Primer sequences used for the analysis of mRNA levels…………………………... 62 
Table 5.1: Primer sequences used for the analysis of mRNA levels……………………………85 
Table 6.1: Primer sequences used for the analysis of mRNA levels……………………..……111 
Table 6.2: Microencapsulated rbASCs induced new tissue ………………………………. .... 120 
 
 
  
ix 
 
LIST OF FIGURES 
Pages 
 
Figure 2.1:  Microencapsulated ASCs derived from rat and human…………………………… 24 
 
Figure 2.2:  Schematic of electrostatic potential based microencapsulation……………………25 
 
Figure 2.3:  Release of ASCs from alginate (medical grade) microbeads with different 
formulations of alginate lyase (U): alginate (g) over a 12 day period……………...26 
 
Figure 3.1:  The diameter of alginate microbeads crosslinked in calcium chloride solutions  
 made with different osmolytes……………………………………………………. 39 
 
Figure 3.2:  Viability of microencapsulated rASCs crosslinked in calcium chloride solutions 
 made with different osmolytes……………………………………………………. 40 
 
Figure 3.3:  Effect of microbead density per unit volume on growth factor production 
 by microencapsulated hASCs……………………………………………………... 42 
 
Figure 3.4:  Effect of cell number per microbead on growth factor production by 
microencapsulated hASCs………………………………………………………… 43 
 
Figure 3.5:  The effect of microbead density per well on cell release from microbeads………. 44 
 
Figure 3.6:  In Vivo localization of rASCs……………………………………………………... 46 
 
Figure 3.7:  Ex vivo organ assessment…………………………………………………………. 47 
 
Figure 3.8:  H&E staining of subcutaneous site of alginate microbead implantation  
   after 6 weeks……………………………………………………………………… 48 
 
Figure 4.1:  DNA content……………………………………………………………………….63 
 
Figure 4.2:  VEGF/FGF/BMP2 levels produced in the media by rASCs cultured on TCPS                    
and outside microencapsulated rASCs…………………………………………….64 
Figure 4.3:  VEGF/FGF/BMP 2 levels produced within microbeads………………………….66 
 
Figure 4.4:  mRNA levels of Vegfa/Fgf2/Tgfβ1 in rASCs cultured on TCPS and     
microencapsulated rASCs…………………………………………………………67 
 
Figure 4.5:  mRNA levels of Vegfa/Fgf2/Tgfβ1 in rASCs cultured on TCPS and    
microencapsulated rASCs…………………………………………………………68 
 
 
x 
 
Figure 4.6:  VEGF and BMP2 levels produced in the media by microencapsulated rASCs,  
                    mASCs, rbASCs and hASCs…………………………………………….………70 
 
Figure 5.1:  Degradation of alginate (wound healing grade) microbeads with different  
    formulations of alginate lyase (U): alginate (g).of alginate microbeads crosslinked 
    in calcium chloride solutions…………………………………………………..….87 
 
Figure 5.2: Degradation of alginate (medical grade) microbeads with different formulations of 
alginate lyase (U): alginate (g).in calcium chloride solutions………………….….89 
 
Figure 5.3:  Release of ASCs from alginate (medical grade) microbeads with different 
formulations of alginate lyase (U): alginate (g) over a 12 day period…………....91 
Figure 5.4:  Release of GFP-conjugated ASCs and MG63 osteoblast-like cells from alginate 
(medical grade) microbeads with different formulations of alginate lyase (U): 
alginate (g) over 12 days…………………………………...………………….…92 
Figure 5.5:  The diameter of alginate microbeads crosslinked in calcium chloride solutions  
    made with different osmolytes……………………………………………….…..93 
 
Figure 5.6:  Viability of ASCs in microbeads without alginate lyase………………………...94 
Figure 5.7:  Viability of ASCs released from alginate (medical grade) microbeads made with 
different formulations of alginate-lyase (U): alginate (g)…………………….….96 
 
Figure 5.8:  The osteogenic potential of ASCs released from alginate microbeads…………..97 
 
Figure 5.9:  mRNA expression in ASCs released from alginate microbeads………………....99 
 
Figure 6.1:  Schematic outlining the experimental method……………………………...…...115 
Figure 6.2:  Multipotency of rbASCs………………………………………………………...118 
Figure 6.3:  Phenotype of rbASCs after microencapsulation………………………………...119 
Figure 6.4:  Critical size defect in auricular cartilage…………………………...……….......120 
Figure 6.5:  MicroCT analysis of tissue in defects at 12 weeks post surgery………………..121 
Figure 6.6:  Defects after 12 weeks…………………………………………………..……...122 
Figure 6.7:  Defects filled with degradable microbeads incorporating rbASCs………..…....123 
Figure 6.8: Elastin staining of cartilage…………….......…….……….…………....……......124 
Figure 6.9: Histomorphometric Analysis……..……………….……….…………....…….....125 
Figure A.1:  H&E staining of DBM implanted in male White New Zealand rabbits after 6 
weeks……………………………………………………………………….…..cliii 
xi 
 
 
Figure A.2:  H&E staining of microbeads in rabbits after 6 weeks……………………….....cliii 
Figure A.3:  Volume of radio-opaque tissue from micro CT analysis…………………..…...cliv 
Figure A.4:  H&E staining of DBM implanted in male athymic nude mice after 8 
weeks…………………………………………………………………………....clv 
Figure A.5:  H&E staining of rASC osteoinductivity in athymic nude mice after 8 
weeks…………………………………………………………………….….…..clv 
Figure A.6:  H&E staining of mASC osteoinductivity in athymic nude mice after 8 
weeks…………………………………………………………………..……....clvi 
Figure A.7:  Area of adipose tissue after microencapsulated mASCs were implanted in 
gastrocnemius of mice for 8 weeks………………………………………...….clvii 
Figure B.1:  H&E staining of the defect site in the femur after 8 
weeks……………………………………………………………….…………clxvi 
 
Figure B.2: H&E staining of unicortical defects receiving non-degradable microencapsulated 
rASCs………………………………………………………………………...clxvii 
Figure B.3:  Histomorphometric analysis of cortical bone, trabecular bone and marrow cavity      
of the unicortical diaphyseal defect after 8 weeks……..……………………clxviii 
 
 
 
 
  
xii 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
 
ACAN     Aggrecan 
 
AM     Adipogenic differentiation medium 
 
ANOVA    Analysis of Variance 
 
BMP2  Bone morphogenetic protein 2 
 
CM  Chondrogenic differentiation medium 
 
Col 1 ` Collagen Type I 
 
Col 2     Collagen Type II 
 
Col 10     Collagen Type X 
 
DiR      1,1’-dioctadecyltetramethyl indotricarbocyanine iodide 
 
DMEM    Dulbecco’s modified Eagle’s medium 
 
FBS  Fetal Bovine Serum 
 
FGF  Fibroblast Growth Factor 
 
GFP  Green Fluorescent Protein 
 
HBSS  Hanks Balanced Salt Solution 
 
IGF-1  Insulin-like Growth Factor 
 
LEPR     Leptin receptor 
 
MicroCT    Micro computed tomography 
 
MG-63    Human osteosarcoma cell line 
 
MSCGM    Mesenchymal Stem Cell Growth Medium 
 
OCN  Osteocalcin 
 
OM  Osteogenic Differentiation Medium 
 
OPG  Osteoprotegerin 
 
xiii 
 
Osx  Osterix 
 
PBS  Phosphate Buffered Saline 
 
PCR  Polymer Chain Reaction 
 
PLGA  Poly-lactide co-glycolide  
 
PPAR-γ  Peroxisome proliferation-activated receptor gamma 
 
rASCs  Rat Adipose Derived Stem Cells 
 
RUNX2  Runt-related Transcription Factor 2 
 
TGFβ-1    Transforming growth factor beta 1 
 
TGFβ-2    Transforming growth factor beta 2 
 
TGFβ-3    Transforming growth factor beta 3 
 
TUNEL     Terminal Deoxynucleotidyl Transferase Nick-End   
     Labeling  
 
VEGF  Vascular endothelial growth factor
14 
 
ABSTRACT 
AN INJECTABLE STEM CELL DELIVERY SYSTEM FOR TREATMENT OF 
MUSCULOSKELETAL DEFECTS 
 
By 
 
Shirae K. Leslie, M.S. 
 
A Thesis Submitted to in the Partial Fulfillment of the Requirements for the Degree Doctor of 
Philosophy at 
Virginia Commonwealth University 2016 
 
Director: Dr. Barbara D. Boyan, Dean, School of Engineering 
 
Virginia Commonwealth University 
 
 
The goal of this research was to develop a system of injectable hydrogels to deliver stem 
cells to musculoskeletal defects, thereby allowing cells to remain at the treatment site and secrete 
soluble factors that will facilitate tissue regeneration. First, production parameters for 
encapsulating cells in microbeads were determined. This involved investigating the effects of 
osmolytes on alginate microbead properties, and the effects of alginate microbead cell density, 
alginate microbead density, and effects of osteogenic media on microencapsulated cells. Although 
cells remained viable in the microbeads, alginate does not readily degrade in vivo for six months. 
Therefore, a method to incorporate alginate lyase in microbeads was developed and optimized to 
achieve controlled release of viable cells. Effectiveness of this strategy was determined through 
cell release studies and measuring proteins and expression of genes that are characteristic of the 
cell’s phenotype. Lastly, in vivo studies were done to assess the ability of alginate microbeads to 
localize microencapsulated cells and support chondrogenesis and osteogenesis. This project will 
provide insight to the tissue engineering field regarding cell-based therapies and healing 
musculoskeletal defects.  
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CHAPTER 1 
 
Specific Aims 
 
57 million musculoskeletal injuries occur each year, of which 26% are fractures [1]. Five 
to 20% of the total fractures result in nonunion [1]. A fracture results in non-union when the bone 
fails to heal completely with bone. Despite the prevalence of fractures resulting in non-unions, 
there are no methods that currently exist to prevent their occurrence.  
Cartilage injuries can occur in ear, nose, and areas articulating joints. In addition, there is 
a high demand for cartilage replacement in musculoskeletal diseases and congenital birth defects. 
Unlike bone, cartilage is avascular and tissue regeneration is difficult to achieve.  
For defects in both tissue types, current therapies include a surgical procedure involving 
the implanting of a cell-laden scaffold, an allograft, or a biomaterial. However, these therapies do 
not lead to total repair due to the inability for the delivered cells or biomaterial to integrate 
completely. In addition, donor site morbidity may limit the number of autologous cells available, 
necessitating the use of allogeneic cells, which may be rejected by the host.  Injectable cell-based 
therapies would be especially advantageous for these patients since it’s less invasive and possess 
the potential to have greater success.  
Cell-based therapies using adipose-derived stem cells (ASCs) provide one possible form 
of treatment for bone defects.  ASCs are known to be multipotent [2], easily isolated, and readily 
available. One disadvantage of cell-based therapies is cells tend to disperse to other tissues [3]. It 
is critical that a method of delivery is developed to allow cells to remain at the injury site, maintain 
their ability to differentiate and release cells after a given period. One option is to use alginate, a 
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well-known biocompatible hydrogel. Alginate is known to maintain cell viability after injection 
and thus could be used as a delivery platform [4, 5].  In addition, alginate provides a system that 
allows for the exchange of nutrients, wastes and secreted factors. However, alginate does not 
readily degrade in vivo for six months. Therefore before it can be used to deliver cells, a method 
of controlled degradation must be established. Prior to this research, there were no methods to 
control the degradation of alginate hydrogels in vivo. Several attempts have been made by using 
gamma irradiation, oxidization and a bifunctional crosslinker, however they have not been 
successful [6, 7]. The objective of this project was to develop an injectable stem cell delivery 
technology for treatment of musculoskeletal defects. 
Specific Aim 1: Determine production parameters for encapsulating stem cells in 
injectable alginate microbeads.  
Task 1.1 Determine the effects of osmolytes on alginate microbead properties. 
Task 1.2 Determine the effects of alginate microbead cell density and alginate microbead density 
on microencapsulated cells. 
Task 1.3 Determine the effects of osteogenic media on microencapsulated cells. 
Specific Aim 2: Develop a method of achieving a controlled release of rASCs from 
alginate microbeads.  
Task 2.1 Develop and optimize a method of incorporating alginate lyase in alginate microbeads. 
Task 2.2 Establish degradation parameters to achieve controlled release of cells. 
Task 2.3 Determine the viability of rASCs released from alginate microbeads. 
Task 2.4 Determine the effect of alginate degradation on the phenotype of released rASCs. 
Task 2.5 Investigate the ability of alginate microbeads incorporating alginate lyase to degrade in 
vivo without an inflammatory response. 
17 
 
Specific Aim 3: To determine the ability of alginate microbeads to localize cells at the site 
of interest and support chondrogenesis and osteogenesis. 
Task 3.1 Investigate the ability of alginate microbeads to localize cells. 
Task 3.2 Determine the ability of microencapsulated rASCs to produce ectopic bone in vivo. 
Task 3.3 Determine the ability of microencapsulated rASCs to regenerate bone in a unicortical 
diaphyseal defect.  
Task 3.4 Illustrate the multipotency of rbASCs. 
Task 3.5 Demonstrate the ability of rbASCs to initiate cartilage regeneration. 
Locally treating defects with injections provides a less invasive repair method than surgical 
interventions for treating skeletal injuries. The use of these injectable hydrogels to deliver stem 
cells will improve the success of cell-based therapies. 
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CHAPTER 2  
 
Background and Literature Review 
 
2.1 Bone 
Bone is a major organ in the body and a major part of the skeletal system. Over 200 bones 
are present in the human skeletal system. Bone is a tough supporting tissue that functions in both 
movement and structural stability in conjunction with muscles [8]. Bone is a dynamic tissue, which 
includes a mineralized matrix embedded with blood vessels, bone cells, and nerves. There are three 
types of bone specific cells – osteocytes, osteoblasts, and osteoclasts. Osteocytes sense mechanical 
stress and send signals to osteoblasts for bone remodeling. Osteoblasts are able to secrete collagen 
rich extracellular matrix that enables mineralization. Osteoclasts are responsible for bone 
remodeling by localized acidification and protease secretion. Bone is formed by endochondral 
ossification or intramembranous ossification. In endochondral ossification, cartilage is formed first 
by mesenchymal progenitor cells differentiating to chondrocytes. Chondrocytes go through 
hypertrophy and the extracellular matrix mineralizes. The invasion of blood vessels delivers cells 
that degrade the extracellular matrix and osteoprogenitor cells to form bone. Intramembranous 
ossification occurs directly where osteoprogenitors form bone directly. Long bones (femur, tibia) 
are formed by endochondral ossification while flat bones (bones of the skull) are formed by 
intramembranous ossification. 
 
2.2 Stem Cells and Fracture Repair 
Fracture repair is controlled by an appropriate cellular response and fracture mechanics, 
which include how much the ends of the bone can move relative to each other (stable or unstable). 
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There are three phases of fracture repair; inflammation, reparative and remodeling. During the 
acute period of fracture healing, inflammation leads to the release of bone-derived growth factors. 
These growth factors contributes to the chemotaxis and aggregation of mesenchymal stem cells 
(MSCs) to form a repair tissue known as a repair blastema. Acute inflammation results in 
vasodilation and exudation of plasma and leukocytes. Inflammatory cells begin debris removal. In 
the reparative phase, an increased cell division occurs first in the periosteum and tissues 
immediately surrounding it and later extends throughout the fractured bone [9]. A mechanically 
stable fracture has vasculature spanning the repair blastema and MSCs will differentiate into 
osteoblasts to form woven bone, which later becomes remodeled. In the case of mechanically 
unstable fractures, MSCs congregate in the repair blastema and form cartilage, which spans the 
gap thereby providing flexible stability. Simultaneously, MSCs from the periosteum will produce 
subperiosteal bone, which forms an outer bridge between the two ends of the fracture thus 
providing more stability. At this stage, the cartilage starts to undergo hypertrophy, veins begin to 
invade delivering resorptive elements to the hypertrophic cartilage and MSCs on the surface of the 
hypertrophied and resorbing cartilage. In the presence of the new vasculature, MSCs undergo 
osteogenic differentiation and new bone spicules are laid down to replace the cartilage. This 
cartilage is replaced by woven marrow filled bone, which undergoes remodeling to become 
cortical bone concluding the remodeling phase [10]. 
 
2.3 Non-unions 
Long bone fractures are typically difficult and slow to heal (the initial bridging process) 
primarily due to the lack of establishing an intact bony bridge between the fragments and providing 
mechanical stability [9]. A rate of 5-10% of bone fractures result in the formation of a non-union. 
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A normal fracture heals within 6 to 8 weeks. Fractures in bones with thicker cortices may need a 
few additional weeks to heal. However, if no healing occurs after 6 months it can be considered a 
non-union. There are two types of non-unions: hypertrophic and atrophic non-unions. A 
hypertrophic non-union has a large broadened callus that is not capable of regenerating a bony 
union. The underlying reason for the hypertrophic non-union is the instability of the fracture, 
which allows multidirectional motion of the fracture fragments. An atrophic non-union is 
completely different. The underlying reasons for an atrophic non-union is a combination of 
biological impairment and mechanical factors. The impaired biological factors include damaged 
vascular supply and the destruction of the periosteum and endosteum. This impairment is also 
coupled with soft tissue damage and detraction of the surrounding tissue. The mechanical 
underlying reasons for atrophic non-unions include rigid fixation, insufficient compressive forces, 
and a fracture gap that is too wide for a bony bridge to be formed [10]. 
 
2.4 Stem Cells and Cartilage Repair 
Tissues that are continuously being remodeled like bone and liver, easily heal unlike other 
tissues that do not constantly replace themselves. Complete repair of all types of cartilage is rarely 
seen. There are three types of cartilage - hyaline cartilage, elastic cartilage and fibrocartilage. 
Hyaline cartilage covers the bone in joints, elastic cartilage is present in the epiglottis and ear, 
while fibrocartilage is found between the discs in the spine and between the bones of the hips and 
pelvis. Once there is a lesion or break in the cartilage, there is no immediate presence of bioactive 
factors and stem cells. Instead, for cartilage damage that does not go all the way to the underlying 
bone, the cartilage rarely repairs. In contrast, in a full thickness cartilage injury, blood from the 
underlying bone marrow fills the injured site carrying osteochondrprogenitor cells, which forms 
fibrocartilage and restores the underlying bone [11].  
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2.5 Therapies for Fracture Repair 
The gold standard for bone repair is using an autologous bone graft. The graft can take the 
form of cancellous or cortico-cancellous bone, and may include vasculature. In addition, 
osteoinductive materials like demineralized bone matrix (DBM) or osteoconductive synthetic 
materials can be used. Exogenous growth factors can supplement any deficiency of endogenous 
factors at the fracture site.  
In cases where current bone graft substitutes fail, other interventions must take place. 
Primary intervention fails sometimes because of a lack of host stem cells or compromised health 
of the host. In some cases, implants can be used with modified surfaces to ensure that the bone 
integrates well. Alternatively, implanting scaffolds that allow cell invasion and proliferation as 
well as aiding in the regeneration process can be ued [12].  These scaffolds may or may not be 
previously seeded with cells. In the cases where cell insufficiency is a problem, cell-based 
therapies would be an appropriate solution.  
 
2.6 Cell-based Therapies for Fracture Repair 
Cell-based therapies for bone repair are beneficial for patients where there is a diminished 
pool of progenitor cells or the host tissue is compromised [1]. There are many clinical trials 
underway to investigate the efficacy of cell-based therapies for bone regeneration and repair. These 
trials may take three forms – a cell suspension, a cell suspension coupled with a biomaterial or a 
cell suspension with a biomaterial previously conditioned in a non-bony site. For the clinical trials 
with cells only, stem cells may be derived from the bone marrow or adipose tissue. However very 
little success has been seen the injection of stem cells intravenously or directly to the defect site. 
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Most cells tend migrate to the lung [13]. Alternatively, some scientists have taken the approach of 
delivering a concentrated mass of cells solely or combined with platelet rich plasma [14].  
To achieve optimum results using cell suspensions, the cell suspension must be coupled 
with a scaffold. Cell-based therapies have coupled cells with cancellous bone, platelet gel, β-tri-
calcium phosphate, calcium sulfate, DBM, collagen matrix or hydroxyapatite, as examples [14]. 
The results from these studies have shown greater bone formation with the presence of cells. In 
fact, tricalcium phosphate and hydroxyapatite loaded with rat MSCs placed within a segmental 
defect showed more radio opaque tissue within the defect compared to the scaffold alone [15]. For 
trials with animals, the scaffold is sometimes loaded with cells and cultured in a muscle or 
bioreactor for few weeks and later transplanted to an orthotopic site. This approach has led to good 
results.  
A number of different types of cells have been delivered to bone sites including: 
unfractionated bone marrow stem cells, mesenchymal stem cells, differentiated osteoblasts or 
chondrocytes, or genetically modified cells [16]. Hydroxyapatite loaded with culture expanded 
progenitor cells was implanted in diaphyseal defects within humans. Most patients healed well 
with good integration of the implant into the bone and regained functionality [17]. Other human 
trials reporting the use of bone marrow-derived multipotent cells with macro-porous 
hydroxyapatite scaffolds were placed within defects. The results showed the progressive 
integration of implants in addition to more bone being present on the external surface. After a 7 
year follow up a good integration of the implants were observed [18]. Most of the clinical trials 
investigating cell-based therapies for fractures have employed bone marrow derived mesenchymal 
stem cells. To date, results have shown the safety and effectiveness of the approach, however to 
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get the optimum results it is still unknown how many progenitors from the bone marrow are needed 
and raises the question if there is a large enough supply.  
 
2.7 Cell-based Therapies for Cartilage Regeneration 
There have been previous studies using cells for cartilage regeneration in animal models. 
However most studies have focused on hyaline cartilage where MSCs have been combined with 
biomaterials like polycaprolactone, polylactic acid, PLGA or fibrin gel. The results showed no 
adverse effects and some repair of the cartilage within osteochondral defects. Additional studies 
need to be carried out to determine if the new cartilage was indeed from the cells delivered. There 
is no evidence in literature that this approach has been used for elastic cartilage however studies 
have initiated that path for auricular cartilage by showing the presence of stem cells in the 
perichondrium [19]. 
 
2.8 Microencapsulation of Stem Cells for Therapy 
The therapeutic nature of stem cells derives from their ability to self-renew as well as 
maintain the ability to differentiate along various lineages. In addition to differentiating into tissue 
specific cells and contributing directly to tissue repair, stem cells can create a microenvironment 
to support the regeneration of tissues or organs by secreting factors that elicit a regenerative 
response from surrounding cells. Both of these roles require stem cells to be delivered to the 
desired site and to remain at the site long enough to achieve the therapeutic goal.  
The most common method of delivery is to infuse a stem cell suspension via the vasculature 
[20]. Even when cell suspensions are injected directly to the intended site, most of the cells are 
gone within 24 hours. There are a number of reasons for this, including cell migration and necrosis 
resulting from the harsh environment. Additionally, the host’s immune system may reject the 
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newly introduced stem cells. A delivery system that shields and creates a temporary home for the 
cells can improve their viability and increase their residence time at the delivery site. 
Porous polymer hydrogels like alginate and gelatin have been used as cell-delivery vehicles 
for some time [21]. Cells can be incorporated into the gels by simple dripping, vibration assisted 
dripping, and emulsion based encapsulation [22]. These methods result in microbeads that are 
generally about 500 µm in diameter. Microbeads of this size can limit the exchange of nutrients 
and waste products and may not be injectable. To overcome these limitations, we developed an 
electrostatic encapsulation method that results in microbeads that are 200 µm in diameter, are 
easily injectable, and do not have reduced diffusivity of nutrients and waste products [23]. 
Alginate is an accessible, block co-polymer that consists of pure mannuronic acid (M) 
blocks or pure guluronic acid (G) blocks, or alternating MG blocks [24]. Due to its ability to 
instantaneously crosslink after exposure to divalent cations, alginate is used as a hydrogel. We 
have successfully produced microbeads using a variety of alginate formulations including: high 
mannuronate content alginate with low, medium and high viscosities [23] (Fig. 2.1).  
 
 
Figure 2.1: Microencapsulated ASCs derived from (A) rat and (B) human. 
 
Here we report the microencapsulation of cells using low viscosity, high mannuronate 
content alginate. The crosslinking solution contains calcium chloride and glucose and is buffered 
using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Calcium chloride provides 
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divalent cations to crosslink alginate between mannuronate residues. Glucose is added as nutrient 
osmolyte in order to maintain physiological osmolality of the crosslinking solution for the cells, 
thus enabling reduced Ca++ content and enhancing cell viability [23]. HEPES prevents in vivo 
calcification by maintaining pH at or below pH 7.3 (Fig. 2.2) [5]. This method produces 
microbeads with a high surface area to volume ratio, which is beneficial for molecular transport. 
Using this method adipose stem cells (ASCs) retain high viability during microencapsulation and 
remain viable for up to 3 weeks in culture [5].  
 
Figure 2.2: Schematic of electrostatic potential based microencapsulation. 
 
Depending on the desired therapeutic use of the microencapsulated cells, the residence time 
for cells within the microbeads may vary. In order for this to be possible the material used to 
encapsulate the cells must be able to undergo controlled degradation in vivo. For example, a non-
degradable polymer can be used if the therapeutic use of microencapsulated stem cells is  insulin 
production in the case of diabetic patients [25]. A degradable polymer can be used if it is required 
for the stem cells to be released to support tissue regeneration. To control the rate of cell release, 
we have developed a method by which the degradation of alginate can be modulated enzymatically 
(Fig. 2.3). Alginate lyase cleaves the glycosidic bonds in alginate specifically between the 
mannuronate and guluronate residues through a β-elimination reaction [26]. 
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Figure 2.3:  Release of ASCs from alginate (medical grade) microbeads with different 
formulations of alginate lyase (U): alginate (g) over a 12 day period. 
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CHAPTER 3 
 
Development of a Cell Delivery System Using Alginate Microbeads for Tissue   
Regeneration 
 
Summary 
Alginate microbeads incorporating adipose-derived stem cells (ASCs) have potential for 
delivering viable cells capable of facilitating tissue regeneration. These microbeads are formed in 
calcium crosslinking solutions containing organic osmolytes to ensure physiological osmolality, 
but the comparative effects of these osmolytes on the microencapsulated cells are not known. In 
addition, delivery parameters needed to use microencapsulated cells for tissue regeneration remain 
unknown. We investigated the following parameters: 1) osmolyte effects on microbead diameter, 
cell viability and growth factor production; 2) the effect of the number of cells per microbead and 
the number of microbeads per unit volume on cell viability, growth factor production, and 
microbead degradation; 3) the ability of both degradable and non-degradable alginate microbeads 
to localize cells at the delivery site in vivo; and 4) whether alginate microbeads containing alginate-
lyase elicit an inflammatory response after repeated exposure. Smallest microbead diameters were 
achieved using glucose as the osmolyte but cell viability and growth factor production did not 
depend on osmolyte type. As cell number per microbead or microbead number per well increased, 
growth factor production per cell decreased although percent cell viability was unchanged. The 
rate of cell release varied with the number of beads per well and with the number of cells per 
microbeads. At the highest microbead density and at the lowest density of cells per microbead, cell 
release was delayed. Therefore fewer microbeads may be sufficient for clinical applications. Both 
degradable (0.22 U/g) and non-degradable (0 U/g) alginate microbeads localized cells at the 
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delivery site. Degradable alginate microbeads delivered subcutaneously elicited a mild chronic 
inflammatory response on second exposure, but how this might impact repeated use of the 
technology remains to be determined. 
3.1 Introduction 
Optimized production and delivery parameters for cell-based therapies are critical to their 
regenerative capability. One goal for cell-based therapies is to use the minimal number of a 
patient’s cells while maintaining cell viability, phenotype and function. For some cell-based 
therapies it is important that the cells remain at the treatment site and that the material used as the 
delivery vehicle does not have an adverse effect on the surrounding tissue or elicit an inflammatory 
response.  
We have shown that adipose-derived stem cells (ASCs) can be encapsulated in alginate 
microbeads and remain viable for at least three weeks in culture [4]. Alginate is a block co-polymer 
consisting of mannuronic acid, guluronic acid or alternating mannuronic and guluronic blocks 
[27]. A hydrogel is formed instantaneously once alginate is exposed to divalent cations by forming 
ionic bonds between the divalent cation and guluronic acid. Alginate hydrogels have been used in 
a variety medical applications to deliver therapeutic agents and to encapsulate cells to deliver 
endogenous proteins or aid in tissue regeneration and organ repair [28-30]. Typically, these 
microbeads have diameters of 500µm or more [31]. By generating microbeads using an 
electrostatic potential, 200µm diameters can be achieved, enabling the microbeads to be injected 
through 18 gauge needles and facilitating greater mass transport of nutrients and waste [32]. 
Subsequent studies showed that these smaller beads necessitated reduced Ca++ content in the 
crosslinking solution than is commonly used to generate the larger diameter microbeads to 
preserve cell viability during the crosslinking process. To maintain osmolality of the cross-linking 
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solution at physiological range, the nutrient glucose was included as an osmolyte [23]. However 
whether other organic osmolytes could be used was not known, nor was it known what effect these 
osmolytes might have on the beads themselves or on ASCs within the microbeads. The presence 
of a nutrient osmolyte in the crosslinking solution also serves as an energy source, which can affect 
the production of growth factors by the encapsulated cells. Therefore, one goal of the present study 
was to compare the effects of glucose on microbead diameter as well as on cell viability and growth 
factor production with those of two non-nutrient sugar osmolytes, mannitol and trehalose, and an 
inorganic osmolyte - sodium chloride.  
The number of cells required to achieve a therapeutic outcome is not known. Some studies 
have shown that using a high cell dose leads to favorable response while the opposite has also been 
observed [33]. The number of cells per microbead can be varied by altering the number of cells in 
the original suspension, but how this might impact the overall viability of the cells or the 
production of therapeutic factors per bead is not known. Moreover, it is not known whether the 
number of beads per unit volume can affect these parameters. Finally it isn’t known if the release 
of cells from the beads is affected by either the number of cells per bead or the number of beads 
per unit volume.  
Alginate microbeads can be injected directly to the desired treatment site and retain cells 
at the site for at least 3 months [4]. Although alginate stability eventually decreases as Ca++ ions 
diffuse from the hydrogel, this can occur much slower than tissue regeneration requires. Recently 
we showed that alginate lyase can be used to provide controlled degradation of the hydrogel [34]. 
Here, we compared the ability of alginate microbeads that contain alginate lyase to localize rASCs 
within tissue with alginate microbeads that do not contain the enzyme. Finally, we examined 
whether the alginate lyase microbeads elicit an acute inflammatory response typical of many 
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biomaterials [35] or if they elicit a delayed hypersensitivity reaction. This is important because 
ultrapure alginate is not known to elicit an inflammatory response in vivo. However it is unknown 
if the by-products of alginate lyase mediated digestion elicit an inflammatory response. 
This study explores production and delivery parameters for microencapsulated ASCs. Cell-
based therapies should be efficient in using the minimum number of cells required to achieve 
regeneration, especially in cases where availability of autologous cells is low.  
3.2. Methods 
3.2.1 Adipose Derived Stem Cells 
ASCs were isolated from six 100-125g male Sprague-Dawley rats under an Institutional 
Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute of 
Technology and Virginia Commonwealth University and cultured using a previously described 
method [2, 36]. Briefly, the inguinal fat pad was removed and transferred to a container with 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3% 
sterile-filtered L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with 
Hank’s balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich, St. Louis, MO) for 30 minutes on a 
rocker at 37°C. Following trypsinization, the supernatant was discarded. Adipose tissue was cut 
into small pieces and incubated in a digestive cocktail containing collagenase type I (365 units/mL) 
(Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. After incubation, 
the oily upper layer was removed and the digest was quenched with an equal amount of 
mesenchymal stem cell growth medium (MSCGM, Lonza Biosciences, Walkersville, MD). The 
cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C 
and 5% CO2. For the next two days the monolayers were washed with Dulbecco’s phosphate 
buffered saline (DPBS) (Invitrogen) and fed with MSCGM every 24 hours. Thereafter media were 
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changed every 48 hours and cells were cultured to confluence. First passaged cells were used for 
studies. 
Human ASCs (hASCs) were obtained from Lonza. The hASCs were cultured in MSCGM 
(Lonza) and passaged as needed until enough cells were obtained for microencapsulation.  
For the localization study, ASCs were isolated from green fluorescent protein (GFP) 
positive rats (Rat Resource and Research Center, Columbia, MO) under IACUC approval at the 
Virginia Commonwealth University and cultured up to passage one. 
3.2.2 Alginate Microbead Production  
To investigate the effect of osmolyte on alginate microbead formation, sodium chloride 
(Sigma Aldrich), mannitol (Sigma Aldrich), glucose (Sigma Aldrich), and trehalose (Sigma 
Aldrich) were used in the calcium crosslinking solution. Medical grade alginate (50% mannuronate 
units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC BioPolymer, Sandvika, 
Norway) was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX at a concentration of 
20 mg/ml, resulting in a 2% alginate solution. Microbeads were created using a Nisco Encapsulator 
VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle 
with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a crosslinking solution 
containing 50 mM CaCl2, 150 mM osmolyte (sodium chloride, mannitol, glucose, or trehalose) 
with 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer) at pH 7.3 [23, 
32]. Alginate microbeads were allowed to crosslink for an additional 10 minutes, washed with 
0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the culture media.  
3.2.2.1 Degradable Alginate Microbead Production 
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of 
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml. 
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Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was 
mixed at 1000 rpm for one minute to produce 0.22 U alginate lyase/g alginate. The 
alginate/alginate lyase mixture was used to form microbeads using a crosslinking solution 
containing 75 mM CaCl2, 90 mM glucose and 10 mM HEPES using the same flow rate, nozzle 
and electrostatic potential described above. 
3.2.3 Effect of Osmolytes 
ASCs were encapsulated in UV-sterilized medical grade alginate at a concentration of 10 
x 106 cells/ml and crosslinked in a calcium solution containing one of the four osmolytes. MG63 
osteoblast-like cells (American Type Culture Collection, Rockville, MD) were used as a control 
population for comparison.  
3.2.3.1 Alginate Microbead Morphometrics 
Immediately after microbead production, images were made of microbeads suspended in 
crosslinking solution. A second set of images was made once the microbeads were transferred to 
the culture media (MSCGM for microencapsulated rASCs and DMEM supplemented with 10% 
fetal bovine serum for microencapsulated MG63s) for at least 24 hours. The diameter of the 
microbeads was analyzed with Image-Pro Plus software (version 4.5.1.22, Media Cybernetics). 
Three images per well were taken using a Leica DMIL microscope connected to a Leica DC 300 
camera (Leica, Solms, Germany).  
3.2.3.2 LIVE/DEAD Assay 
Viability of microencapsulated rASCs was measured using a LIVE/DEAD Viability kit 
(Invitrogen). Samples (200 µl) were collected at weeks 1 and 2. Aliquots were transferred to a 
chamber slide and incubated for 30 minutes at 37°C in 0.9% (w/v) saline containing 4 μM ethidium 
homodimer-1 and 2 μM calcein-AM.  Images were obtained using a Zeiss LSM 700-405 confocal 
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microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY). Three images were obtained for 
each well and then red and green cells were counted using Image-Pro Plus software. 
3.2.3.3 Soluble Factor Quantification 
To investigate the effects of osmolytes on factor production, microencapsulated hASCs 
(Lonza) were cultured for 3 days in MSCGM (GM) and then treated with chondrogenic 
differentiation media (CM) for 7 days. The CM consisted of high glucose DMEM (4.5 g/L glucose) 
with 110 mg/L sodium pyruvate (Sigma), 50 µg/mL ascorbic acid 2-phosphate (Sigma Aldrich), 
10 nM dexamethasone (Sigma Aldrich), 1% ITS+ (Sigma Aldrich), 40 µg/mL proline (Sigma 
Aldrich), 100 ng/mL of the recombinant human bone morphogenetic protein 6 (BMP6, Rocky Hill, 
NJ), and 10 ng/mL recombinant human transforming growth factor beta-1 (TGFβ1, R&D Systems, 
Minneapolis, MN). Enzyme-linked immunosorbent assays (ELISA) were used to measure the 
levels of insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), TGFβ2, 
and TGFβ3 (R&D Systems) in the conditioned media and retained in the microbeads. To measure 
growth factor retention within microbeads, beads were collected, uncrosslinked in 82.5 mM 
sodium citrate, lyophilized, resuspended and digested in alginate lyase (1 U/ml) (Sigma Aldrich) 
for an hour and assayed using ELISAs [37]. All data were normalized by the DNA content of the 
cells. 
3.2.3.4 DNA Quantification 
Cells collected from the digested microbeads were used to determine DNA content of the 
microencapsulated cells (Quant-iT™ Picogreen® ds DNA Reagent, Invitrogen).  
3.2.4 Cells/Microbead and Microbeads per Unit Volume 
3.2.4.1 Microbeads per Unit Volume 
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To investigate the effect of the number of microbeads per unit volume, microencapsulated 
hASCs (10 x 106 cells/ml alginate) were suspended in CM resulting in densities of  60,000, 12,000, 
6,000, and 1,200 microbeads per well. A control group of 12,000 microbeads per well was 
suspended in GM. CM or GM was added to each well, resulting in a total volume of 2 ml.  On day 
7 of culture, fresh media were added to each culture.  Conditioned media were collected 24 hours 
later and growth factor content determined by ELISA.  The microbeads were collected and any 
retained growth factor determined as well. Data were normalized to DNA content. Total growth 
factor levels were calculated by not normalizing by the DNA content.  Cell viability was 
determined as described above. 
3.2.4.2 Cells per Microbead  
To investigate the effect of cell number per bead, hASC suspensions (20, 10, 5 and 2 x 106 
cells/ml alginate) were microencapsulated to produce microbeads containing 71, 37, 21, and 7 cells 
respectively. Microbeads were cultured in CM. A control group (37 cells per microbead) was 
cultured in GM.  Growth factor production was determined as described above.  Cell viability was 
determined. 
3.2.4.3 Cell Release 
To determine if alginate lyase mediated degradation was altered by the number of cells per 
bead or the number of beads per well, hASCs were encapsulated in microbeads containing 0 or 
0.06 units of enzyme per g of UV-sterilized medical grade alginate. The microbeads were 
suspended in 40 µm cell strainers (BD Falcon, Franklin Lakes, NJ) and cultured in CM in non-
tissue culture treated 6-well plates to limit proliferation of released cells in the well. Media were 
changed every 48 hours and each cell strainer was washed twice with 0.9% (w/v) saline to ensure 
that all the cells released were collected. Any additional cells on the plate’s surface were collected 
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by trypsinization. For the groups where alginate microbeads did not fully degrade by the end of 
the 12 day period, 82.5 mM sodium citrate was used to release the remaining cells. DNA was 
quantified as described previously. Alginate microbead degradation was monitored using light 
microscopy. At each time point one image per group was taken. 
3.2.5 Retention of Cells In Vivo 
3.2.5.1 Cell Labeling 
  GFP-rASCs were labelled with DiR (1,1’-dioctadecyltetramethyl indotricarbocyanine 
iodide) fluorescent dye (PerkinElmer, Waltham, MA) to more effectively distinguish their 
fluorescence (Absorption\Emission: 748/780 nm) from the autofluorescence of the surrounding 
tissue which also fluoresces green [38]. The optimal dye concentration for labeling GFP-rASCs 
while maintaining viability was previously determined over a two week period with dye 
concentrations ranging from 4.2 µg/ml to 135 µg/ml. A million cells were incubated in the 
respective dye concentration for 30 minutes at 37°C. After labeling was complete, cells were 
washed with PBS twice. Immediately after staining with DiR, a portion of the cells were used for 
viability measurements. The viability was quantified with a cell counter (Countess, Invitrogen) 
and trypan blue (Lonza). The remaining cells were then plated at 5000 cells/cm2 in 24-well plates 
and 96-well black with a clear bottom for viability and fluorescence measurements on days 7 and 
14. At each time point, DiR fluorescence was quantified using Odyssey Infrared Imaging System 
(Li-Cor, Lincoln, NE) while the GFP fluorescence was quantified using a plate Synergy H1 reader 
(BioTek, Winooski, VT). 
3.2.5.2 Microbead Injection Protocol 
  Microencapsulated GFP-rASCs were delivered intramuscularly to athymic nude mice 
under a protocol approved by the IACUC at Virginia Commonwealth University. GFP-rASCs 
were labelled using 33.8 µg/ml DiR dye and then microencapsulated in microbeads containing 0 
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U, 0.06 U, 0.22 U and 1.75 U per g medical grade alginate microbeads. Microbeads were 
suspended in 1 ml saline and 100 µl were injected into the right gastrocnemius and left deltoid of 
each mouse using a 27 gauge needle. An equivalent number of cells in a suspension were injected 
as a control. (n=4, per variable) 
3.2.5.3 Analysis of Results 
  Retention of microencapsulated cells at the injection site was followed with a Maestro 2 
Imaging System (PerkinElmer, Waltham, MA) [38].  Images were taken on days 0 (immediately 
after the injection), 1, 2, 4, 6, 8, 10, 12 and 14. Animals were placed in a prone or either lateral 
recumbent positions on the imaging platform while under anesthesia (2% isoflurane in oxygen). 
On the final day, animals were euthanized and an ex vivo organ assessment conducted to identify 
the presence of labeled GFP-rASCs. Inguinal lymph nodes, sternum, heart, lung, liver, spleen, 
stomach, intestines, both kidneys, and testes were removed and imaged. Fluorescence was 
quantified and normalized to the fluorescence measured on day 0 for each animal’s arm or thigh. 
Images were converted to a scaled image by applying a threshold of 0.01 scaled counts/second. To 
quantify the fluorescence, an area of interest was selected and the threshold applied using Maestro 
2.10 software (PerkinElmer, Waltham, MA). The viability of the same batch of cells delivered to 
the animals was measured in vitro at each imaging time point using the Cell Titer-Glo Luminescent 
Cell Viability Assay (Promega, Madison, WI).  
3.2.6 Inflammation 
In vivo studies were performed to determine if the degradation by-products generated by 
alginate lyase elicit a delayed hypersensitivity inflammatory response. Male C57 Black 6 mice 
were handled under a protocol approved by the IACUC at Virginia Commonwealth University. 
Prior to surgeries, mice were anesthetized using isoflurane gas. Non-degradable (0 U/g) and 
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degradable (0.22 U/g) alginate microbeads (0.1 ml) without cells were injected subcutaneously on 
the dorsum using a 27 gauge needle [4]. Each animal received one injection subcutaneously above 
the right gastrocnemius (n = 6 for each experimental condition). After 2 weeks each animal 
received another injection above the left gastrocnemius. Animals were euthanized by CO2 
inhalation after 6 weeks and a portion of the leg removed and processed for histology as described 
below.  
After 48 hours of fixation in formalin, samples were dehydrated in a series of 95% and 
100% ethanol and xylene washes. Samples were embedded in paraffin, and cut into 7-μm thick 
sections (Shandon Finesse 325, Thermo Scientific). The sections were stained with haematoxylin 
and eosin, and then imaged with a Leica DMLB microscope (Leica Microsystems, Bannockburn, 
IL). Images were analyzed for the presence of inflammatory cells. 
3.2.7 Statistical Analysis 
The results of the in vitro assays were calculated as the means ± SEM of six independent 
cultures per variable. The results from the in vivo study examining retention of cells were 
calculated as the means ± SEM of 4 animals per variable. Statistically significant differences 
between groups were determined by one-way ANOVA followed by Bonferroni’s modification of 
Student’s t-test. P values ≤ 0.05 were considered significant. All experiments were repeated at 
least twice to ensure validity of results, with the exception of the in vivo studies.  Data presented 
are from representative experiments. 
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3.3. Results 
3.3.1 Effect of Osmolytes 
3.3.1.1 Microbead Diameter 
Microbeads had a spherical morphology that was unchanged by osmolyte type or presence 
of cells (Fig. 3.1A). Inclusion of cells increased microbead diameters by 30% regardless of 
osmolyte. All microbead formulations exhibited an increase in diameter when transferred from the 
crosslinking solution to culture medium, whether or not cells were present. Alginate microbeads 
without cells had the largest increase in diameter upon transfer to culture media (Fig. 3.1B). A 
smaller increase was observed in alginate microbeads incorporating rASCs or MG63 cells (Fig. 
3.1C-D). Microbeads fabricated with glucose as the osmolyte had the smallest diameter. 
Furthermore, glucose maintained diameters below 200 µm in microbeads transferred to culture 
media.  
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Figure 3.1: The diameter of alginate microbeads crosslinked in calcium chloride solutions made 
with different osmolytes. (A) Alginate microbeads incorporating no cells suspended in the 
crosslinking solution and full media, and incorporating rASCs suspended in MSCGM under an 
inverted light microscope (mag. = 10x). (B) Microbeads incorporating no cells. (C) Microbeads 
incorporating rASCs. (D) Microbeads incorporating MG63s. Data were analyzed using one-way 
ANOVA followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. calcium 
chloride, $ vs. sodium chloride, # vs. mannitol, + vs. glucose. 
3.3.1.2 Effects of Osmolytes on ASC Viability 
The type of osmolyte did not impact cell viability (Fig. 3.2A). No differences were noted 
in the ratio of live to dead cells amongst microbead types, nor was there a difference between 7 
and 14 days in culture (Fig. 3.2B).  
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Figure 3.2: Viability of microencapsulated rASCs crosslinked in calcium chloride solutions made 
with different osmolytes (Scale bar = 50 µm). (A) LIVE/DEAD staining of released ASCs, where 
green represents live cells and red represents dead cells and (B) the percent viable cells. Data were 
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p < 
0.05 vs. sodium chloride, # vs. mannitol, a vs. day 7. 
3.3.1.3 Growth Factor Production 
The osmolyte did not impact production of TGFβ2, TGFβ3, IGF-1 and VEGF, either 
secreted into the culture media or retained with the microbeads after treatment with CM for 7 days 
(Table 3.1).  
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Table 3.1. Growth factor secreted in media and retained in the microbeads by microencapsulated 
cells treated with chondrogenic media. 
 Growth Factor in Media/DNA (ng/µg) 
Growth Factor Retained in Microbeads/DNA 
(ng/µg) 
 VEGF IGF-1 TGF-β2 TGF-β3 VEGF IGF-1 TGF-β2 TGF-β3 
NaCl 15  ± 1.6 8 ± 0.5 15 ± 0.8 14 ± 0.8 12 ± 0.9 18.0 ± 1.0 33 ± 2.1 30 ± 1.7 
Mannitol  12 ±  0.7 7 ± 0.5 14 ± 1.0 13 ± 1.0 16 ± 3.0 16.9 ±1.2 29 ± 1.8 28 ± 1.9 
Trehalose 14 ± 1.8 7 ± 0.6 12 ± 1.2 12 + 0.6 13 ± 1.5  15.0 ± 1.4 28 ± 2.3 26 ± 1.6 
Glucose 12 ± 0.8 7 ± 0.4 13 ± 0.8 11 ± 1.1 13 ± 0.8 15.8 ± 1.0 28 ± 1.9 25 ± 2.2 
 
3.3.2 Number of Microbeads per Volume 
Growth factor production was sensitive to microbead number per unit volume.  As the 
number of microbeads increased per well, IGF-1, VEGF, TGFβ2 and TGFβ3 production per cell 
decreased both inside the microbead and in the surrounding media (Fig. 3.3). Compared to beads 
cultured in MSCGM, microbeads cultured in CM produced and retained reduced levels of VEGF.  
The total amount of growth factor produced per well was relatively insensitive to the 
number of microbeads per unit volume (Fig. 3.3).  Compared to microbeads cultured in GM, 
microbeads cultured in CM produced slightly more IGF-1, but this was only statistically higher in 
wells with the lowest number of microbeads (Fig. 3.3E).  Total VEGF levels in the microbeads 
and in the conditioned media was elevated when microbeads were cultured at the highest density 
(Fig. 3.3F).  In contrast, the amounts of TGFβ2 and TGFβ3 were comparable at all microbead 
densities.  
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Figure 3.3: Effect of microbead density per unit volume on growth factor production by 
microencapsulated hASCs. Microbeads were cultured for 7 days in MSCGM or CM, Top row -  
protein levels normalized by DNA: (A) insulin growth factor 1 (IGF-1), (B) vascular endothelial 
growth factor (VEGF), (C) transforming growth factor beta 2 (TGFβ2), and (D) transforming 
growth factor beta 3 (TGFβ3) in conditioned media and retained in the microbead, Bottom row – 
total IGF-1 (E), VEGF (F), TGFβ2 (G), and TGFβ3 (H) in conditioned media and retained in the 
microbead,. Data were analyzed using one-way ANOVA followed by Bonferroni’s modification 
of Student’s t-test. * p < 0.05 vs. 12 GM, # vs. 60 CM, $ vs. 12 CM, and ^ vs. 6 CM. 
3.3.3 Cells per Microbead 
Alginate microbeads encapsulating the smallest number of cells produced the highest IGF-
1, VEGF, TGFβ2 and TGFβ3 level per cell (Fig. 3.4). Control microbeads, which contained 37 
cells per bead, produced similar levels of IGF-1, VEGF, TGFβ2 and TGFβ3 in MSCGM as 
microbeads cultured in CM. However, CM suppressed VEGF secreted into the medium although 
there were no differences in VEGF retention in the microbead. 
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The total amount of growth factor produced per well was relatively insensitive to the 
number of cells per microbead (Fig. 3.4).  Compared to microbeads cultured in GM, cells cultured 
in CM retained more IGF-1 in the microbead, but the number of cells per microbead did not impact 
this result, nor was there an effect on the number of cells on the amount of IGF-1 in the media 
(Fig. 3.4E).  Total VEGF levels in the microbeads and in the media were reduced in CM cultures 
(Fig. 3.4F).  Only in microbeads containing 37 cells was there a statistically relevant increase in 
VEGF compared to other cell densities and this was only evident in the microbead. Cell number 
per bead had only minor effects on TGFβ2 and TGFβ3. 
 
Figure 3.4: Effect of cell number per microbead on growth factor production by microencapsulated 
hASCs.  Protein levels normalized by DNA: (A) insulin growth factor 1 (IGF-1), (B) vascular 
endothelial growth factor (VEGF), (C) transforming growth factor beta 2 (TGFβ2), and (D) 
transforming growth factor beta 3 (TGFβ3) in conditioned media and retained in the microbead, 
Total protein levels of IGF-1 (E), VEGF (F), TGFβ2 (G), and TGFβ3 (H) in conditioned media 
and retained in the microbead,. Data were analyzed using one-way ANOVA followed by 
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Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. 37 GM, # vs. 71 CM, $ vs. 37 CM, 
and ^ vs. 21 CM. 
3.3.4 Effect of Alginate lyase 
 Release of cells from the microbeads varied with the number of microbeads per well (Fig. 
3.5A). At the highest number of microbeads cell release was delayed compared to the other groups. 
These microbeads released 59% of their cells on day 12. The number of cells per microbeads did 
not affect the rate of cell release (Fig. 3.5B).  
 
Figure 3.5: (A) The effect of microbead density per well on cell release from microbeads 
containing 0.06 U/g alginate lyase/alginate over a 12 day period. (B) The effect of number of cells 
per microbead on cell release from microbeads containing 0.06 U/g alginate lyase/alginate.  
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Percent DNA of all cells released. Data were analyzed using one-way ANOVA followed by 
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2. 
3.3.5 Cell Viability  
Cell viability was greatest when microbeads were cultured in GM compared to CM (Table 
3.2).  However, there were no differences in viability as a function of the number of microbeads 
per unit volume amongst the cultures grown in CM.  Similarly, cells grown in CM had reduced 
viability compared to GM, but no differences in cell viability as a function of cells per microbead 
were noted when microbeads were cultured in CM. 
 
Table 3.2: Effects of microbead number per well and number of cells per microbead on cell 
viability. Microbead were cultures for 7 days in MSCGM (GM) or chondrogenic medium (CM), 
* p < 0.05 vs. GM. 
Media GM CM CM CM CM 
Microbeads x 103/well 12 60 12 6 1.2 
% Viability 99 ± 0.2 89 ± 2.4 91 ± 1.4 87 ± 1.8* 82 ± 5.2* 
Cells/Microbead 37 71 37 21 7 
% Viability 98 ± 0.4 91 ± 1.6* 90 ± 0.8* 93 ± 0.7 91 ± 2.9* 
 
3.3.6 Degradable Microbeads and Cell Retention 
Degradable microbeads were able to retain cells at the treatment site for the 14 day test 
period (Fig. 3.6). In contrast, sites treated with cell suspensions showed decreased fluorescence as 
early as day 1. Gastrocnemius muscle injected with microbeads containing 1.75 U enzyme/g 
alginate exhibited decreased fluorescence at day 8 whereas reduced fluorescence as observed in 
the deltoid by day 4.  
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Only the inguinal lymph node had a detectable fluorescence signal. The right inguinal 
lymph nodes for animals receiving the cell suspension had a significantly higher fluorescence 
compared to the left inguinal lymph node and right inguinal lymph nodes of animals in the other 
treatment groups (Fig. 3.7).  
 
47 
 
Figure 3.6: In Vivo localization of rASCs. (A) Fluorescent images indicating the location of 
delivered cells and (B) percent change in the fluorescence from day 0 in the right gastrocnemius, 
(C) fluorescent images indicating the location of delivered cells and (D) percent change in the 
fluorescence from day 0 in the left deltoid of animals receiving a cell suspension (CS), 
microencapsulated cells in 0 U/g, 0.06 U/g, 0.22 U/g, and 1.75 U/g microbeads on days 1, 2, 4, 6, 
8, 10, 12 and 14. Data were analyzed using one-way ANOVA followed by Bonferroni’s 
modification of Student’s t-test. * p < 0.05 vs. day 1 and # vs. day 2. 
 
Figure 3.7: Ex vivo organ assessment (A) Fluorescent images of the inguinal lymph nodes, heart, 
sternum, and lung (B) quantification of the fluorescent signal from both right and left inguinal 
lymph nodes of animals receiving a cell suspension (CS), microencapsulated cells in 0 U/g, 0.06 
U/g, 0.22 U/g, and 1.75 U/g microbeads in the right gastrocnemius and left deltoid on day 14. Data 
were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. 
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* p < 0.05 vs. right inguinal lymph node and # vs. the respective inguinal lymph node in the cell 
suspension group. 
3.3.7 Inflammatory Response to Degradable Alginate Microbeads 
Non-degradable microbeads were still present at 6 weeks and histological sections showed 
no infiltration of white blood cells (Fig. 8A). Degradable microbeads were not present in tissue 
sections at the end of the experiment and two of the 5 animals had an infiltration of foamy 
histiocytes. One animal from each group died during the length of the experiment. However, the 
cause of death was not linked to alginate microbeads or alginate lyase delivered. 
 
Figure 3.8: H&E staining of subcutaneous site of alginate microbead implantation after 6 weeks: 
(A) alginate microbeads (0 U/g), scale bar represents 500 µm; (B) scale bar represents 100 µm, 
arrows indicate alginate microbeads; (C) alginate microbeads incorporating alginate-lyase (0.22 
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U/g), scale bar represents 200 µm, the arrow head indicates the implantation site; and (D) alginate 
microbeads incorporating alginate lyase (0.22 U/g), scale bar represents 20 µm. 
 
3.4. Discussion 
The results of this study confirm that injectable microbeads containing ASCs generated 
using an electrostatic potential will remain viable in vitro and in vivo. They also show that organic 
and inorganic osmolytes can be used as alternatives to glucose in the crosslinking solution without 
negatively impacting cell viability or production of key growth factors, although there are small 
changes in microbead diameter. The microbeads were transferred to culture medium 10 minutes 
after being exposed to the cross-linking solution so any positive effects of using a nutrient osmolyte 
like glucose versus non-nutrient osmolytes like trehalose, mannitol or NaCl was not addressed in 
this study. 
The diameter of the alginate microbeads affects injectability and the mass transfer of 
nutrients to the encapsulated cells. The smallest diameters were observed when using glucose, but 
in all cases diameters were 200 µm or less prior to transfer into culture media. Whether cells were 
present or not, the microbeads increased in diameter once they were transferred from calcium 
crosslinking solution to the respective media. This may have resulted from a change in pH. It is 
known that once anionic polymers like alginate are placed in media with a pH higher than the pKa 
of the polymer’s ionic groups, the swelling ratio increases [39]. A change in the water gradient, 
produced by a low water concentration in the crosslinking solution (75 mM CaCl2) and a higher 
water concentration in the media (1.8 mM Ca2+), may also play a role. In addition, alginate 
hydrogels have been known to swell once they are placed in tissue culture media due to the 
presence of chelators, monovalent ions, and non-crosslinking divalent cations like Mg++, resulting 
in an increase in alginate porosity [40, 41]. Viability of cells in vivo is important to the regenerative 
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success of any cell-based therapy because it affects the ability of the cells to aid in tissue 
regeneration. The viability of rASCs microencapsulated in all four types of crosslinking solutions 
had a relatively high viability and this was at 80% across all groups even at two weeks. This 
confirms our previous observations and suggests that as long as the microencapsulated cells are in 
a nutrient rich environment, the nature of the osmolyte is not a critical factor. Further support for 
this is the fact that the osmolyte did not change the ability of the cells to produce growth factors. 
As a result using any of the osmolytes should be equally acceptable for hASCs. However this may 
change if other cell types are used.  
Our findings indicate that growth factor production is more sensitive to the culture medium 
than to either the number of microbeads per unit volume or the number of cells per microbead. 
The results showed that where the smallest number of microbeads were present there was the 
largest amount of growth factor per cell being produced. This is not surprising as the supply of 
nutrients is greater when cells are competing for a finite resource. Similarly fewer cells per 
microbead correlated with greater production of growth factors. This suggests that a therapeutic 
result may be more effectively achieved using few beads containing fewer cells per bead. 
Assuming diffusivity to be constant, growth factors secretion into the medium would be sensitive 
to the medium, as was the case when microencapsulated rASCs were cultured in CM versus 
MSCGM. 
Unlike growth factor production, alginate-lyase mediated cell release was affected by the 
number of microbeads. As the microbead density increased, the rate of degradation decreased. 
Microbead degradation involves two mechanisms. At early time points, the enzyme’s activity is 
more prominent, leading to cleavage of the glycosidic bonds. At later time points, however, the 
stability of the alginate decreases due to an influx of monovalent ions from the surrounding media 
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and subsequent ion exchange with Ca++. Thus at lower microbead concentrations, there is a greater 
amount of monovalent ions present in each well to displace Ca++ and hence, an earlier release of 
cells [34]. The number of cells per microbead was only important in so for as the cells reduced the 
volume of alginate. Only at the lowest number of cells per microbead, was cell release negligible 
and this may reflect an inability to detect the released cells as much as it reflects the greater alginate 
content. 
The microbeads successfully retain cells at the treatment sites in contrast to cells injected 
as a suspension. As we reported previously [34], microbeads containing 1.75 U alginate lyase per 
gram alginate degraded the most rapidly, and released cells from these microbeads migrated from 
the treatment sites by day 4 in the deltoid muscle and by day 8 from the gastrocnemius. Loss of 
cells from the muscles may have been affected by differences in vasculature or differences in 
loading [42]. In both cases however, even in the fast degrading microbeads, cells were effectively 
retained for up to a week. These results also show that cell retention can be achieved in a controlled 
manner by varying the enzyme content of the microbeads.  
One concern is that the imaging method used in this study is detecting artifact remaining 
following cell death, as has been observed in studies using fluorescent nanoparticles to label cells 
[43]. It is unlikely that the GFP-labelled ASCs became distributed to other tissues, however. In the 
treatment groups where migration was observed, the lymph nodes were the only organs positive 
for the DiR dye used to stain the cells. A significantly higher fluorescence was present in the right 
inguinal lymph node, showing that cells may have migrated to that organ since the microbeads 
were delivered in close proximity to the right lymph node. The lymph nodes belonging to animals 
receiving the cell suspension had the highest fluorescence. Although the other groups had 
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detectable fluorescence additional studies must be done to confirm the presence of DiR labelled 
GFP cells at the treatment site. 
Alginate is a biocompatible hydrogel; however, the biocompatibility of alginate lyase or 
the byproducts of alginate lyase mediated degradation is not known. Our previous results indicate 
that after a single exposure, no inflammation is present, even when alginate-lyase is included [34]. 
Here, we examined whether a delayed hypersensitivity reaction was possible. At 6 weeks after a 
second injection, alginate microbeads were still present whereas alginate microbeads incorporating 
alginate lyase were no longer detectable. Histological sections from animals receiving non-
degradable alginate microbeads had no evidence of macrophages while 2 animals receiving 
degradable alginate microbeads had an infiltration of foamy histiocytes (macrophages with 
abundant cytoplasm), indicating the presence of inflammation. It is possible that the byproducts of 
alginate-lyase mediated degradation may have elicited an inflammatory response earlier in the time 
line of the study that was resolved. This illustrates that the byproducts of alginate lyase mediated 
degradation may elicit a mild chronic inflammatory response but comparatively less than the 
response elicited by sutures [44].  These results are inconclusive with respect to a delayed 
hypersensitivity reaction. 
 
3.5. Conclusions 
This study investigated a number of variables associated with the clinical use of alginate 
microbeads for tissue regeneration applications. Glucose was found to be the optimal osmolyte as 
it relates to the smallest alginate microbead diameter. Both microencapsulated cell viability and 
growth factor production were found to be osmolyte-independent. Only a small number of alginate 
microbeads and a low cell density may be required to achieve the same levels of growth factor 
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production as delivering a high number of alginate microbeads with a higher cell density. The rate 
of cell release can be modulated by the number of microbeads, the number of cells per microbead 
and the concentration of alginate lyase. Clinically, a low microbead density and a low microbead 
cell density can be used to achieve similar growth factor production as higher density groups; 
however the time of cell release may be delayed. Degradable alginate microbeads can be used to 
localize microencapsulated cells at the delivered site. However, alginate microbeads incorporating 
alginate lyase may elicit a mild chronic inflammatory response upon repeated exposures. 
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CHAPTER 4 
 
The Production of Osteogenic and Angiogenic Factors from of 
Microencapsulated ASCs is Species Dependent and can be Modified by the 
Pretreatment of Media used. 
 
Summary 
Cell-based therapies can provide additional cells at an injury site to aid in regeneration 
especially when a large amount of tissue is removed or the host’s stem cells are compromised by 
disease or age. However, present modes of delivering stem cells lead to low viability and cell 
dispersal, limiting the contribution of the cells to the repair process. We previously showed that 
adipose stem cells (ASCs) can be localized in tissues by encapsulating them in injectable alginate 
microbeads generated using an electrostatic potential and Ca++ crosslinking solution containing an 
organic osmolyte.  The microencapsulated cells constitutively produce angiogenic factors but 
when treated with chondrogenic medium, support chondrogenesis in vivo. Here, we investigated 
the effects of osteogenic medium (OM) on encapsulated rat ASCs (rASCs) and determined the 
optimal combination of OM components that will lead to the production of both osteogenic and 
angiogenic factors. Our results showed that microencapsulated rASCs cultured in growth medium 
(GM) produced angiogenic (VEGF, FGF2) and osteogenic (BMP2) factors. OM, which contains 
dexamethasone (d) and ascorbic acid (aa), reduced VEGF in cultures of rASCs, mouse ASCs 
(mASCs) and human ASCs (hASCs), but not in cultures of rabbit ASCs (rbASCs). OM without 
dexamethasone (OM-d), but not OM without ascorbic acid (OM-aa), restored angiogenic factor 
production by rASCs to levels observed in GM. Unlike rASCs, BMP2 levels secreted by rbASCs, 
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mASCs, and hASCs were not affected by treatment media.  In conclusion, microencapsulated 
ASCs can be treated to produce osteogenic and angiogenic factors to aid in the bone repair process, 
but the effects of the media are species specific.  
4.1 Introduction 
Paracrine signaling from multipotent mesenchymal stem cells (MSCs) has a therapeutic 
effect on wound repair.  These cells are involved in the three phases of wound repair – 
inflammation, proliferation, and remodeling, by producing proteins that influence cell migration, 
proliferation, angiogenesis, and survival of surrounding cells [45]. In bone regeneration, MSCs 
contribute by producing osteogenic factors, like bone morphogenetic protein-2 (BMP2) and 
angiogenic factors like fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor 
(VEGF), in addition to modulating inflammation [46].   
 Given the important role MSCs play in the bone repair process, augmenting sites 
of wound repair and fractures at risk for forming non-unions with MSCs would be advantageous, 
especially in cases where the stem cell population is insufficient or otherwise compromised by 
disease, immunodeficiency, smoking and age.  However, to harness the full potential of these 
therapies, the cells must be viable and maintain their phenotype after delivery.  Unfortunately, 
delivery as an injectable suspension or on an implantable scaffold often leads to low cell viability, 
limiting the therapeutic effect of the cells.   
We developed an injectable microbead technology using alginate hydrogels to encapsulate 
cells within 200 µm diameter spheres, thereby protecting the cells from shear during injection and 
providing a high mass to volume ratio, enhancing their mass transfer properties [23, 47].  Alginate 
is a co-block polymer that consists of pure mannuronic acid (M) blocks and pure guluronic acid 
(G) blocks, or alternating MG blocks [24].  The hydrogel is formed when M units form an ionic 
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bond with a divalent cation.  In our system, an alginate-cell suspension is exposed to an 
electrostatic potential of 6kV to generate the microbeads, followed by cross-linking the alginate in 
a Ca++ solution containing glucose as an osmolyte.  The number of cells per microbead is tunable 
and depends on the number of cells in the original suspension.  Using this technology, we have 
shown that the encapsulated cells remain viable in cell culture for at least 3 weeks and in vivo for 
at least 3 months [5].  Moreover, encapsulated adipose stem cells (ASCs) are able to produce 
factors that stimulate angiogenesis in vitro and in vivo, and when pretreated with chondrogenic 
medium, produce factors that support chondrogenesis [37, 48]. 
The goal of the present study was to determine if the microbead technology could be 
adapted for use in bone regeneration strategies.  ASCs are multipotent and have the ability to 
differentiate into osteoblasts when treated with BMP2 or when cultured in osteogenic medium 
(OM) containing dexamethasone , ascorbic acid 2-phosphate, and beta-glycerol phosphate [2, 36].  
It is not known if microencapsulated ASCs differentiate into osteoblasts when cultured in OM or 
if OM affects production of either osteogenic or angiogenic factors.  We previously showed that 
growth factor production by monolayer cultures of ASCs was sensitive to treatment with 
dexamethasone and ascorbic acid 2-phosphate, two of the components of OM [37]. 
Dexamethasone decreased VEGF; ascorbic acid 2-phosphate increased FGF2. However, when the 
ASCs were cultured in chondrogenic medium, removal of dexamethasone resulted in an increase 
in VEGF and removal of ascorbic acid 2-phosphate resulted in a decrease in FGF2. These 
observations led us to hypothesize that treatment with OM would support osteogenic 
differentiation of microencapsulated ASCs and stimulate production of factors associated with 
osteogenesis, including BMP2 and VEGF. Moreover, production of these factors could be tuned 
by manipulating the dexamethasone and ascorbic acid 2-phosphate content of the OM.  
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4.2 Methods 
4.2.1 Adipose Derived Stem Cells 
ASCs were isolated from the inguinal fat pads of 100-125g male Sprague-Dawley rats, 
male New Zealand White rabbits, and C57 Black 6 (C57Bl/6) mice under Institutional Animal 
Care and Use Committee (IACUC) approved protocols at the Georgia Institute of Technology and 
Virginia Commonwealth University as described previously [2, 36].  
The cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured on tissue 
culture polystyrene (TCPS) in mesenchymal stem cell growth medium (GM, Lonza, Walkersville, 
MD) at 37°C and 5% CO2. For the next two days the monolayers were washed with Dulbecco’s 
phosphate buffered saline (DPBS) (Invitrogen) and fed with GM every 24 hours. Thereafter media 
were changed every 48 hours and cells were cultured to confluence. First passage cells were used 
for all studies.  
Human ASCs from three different donors were obtained from Lonza, and cultured to a passage 
where enough cells were present for each study.4.2.2 Microencapsulated Cells 
To form microbeads, ASCs were encapsulated in UV-sterilized medical grade alginate 
(50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC 
BioPolymer) at a concentration of 107 cells/ml. Medical grade alginate was dissolved in 0.9% 
(w/v) saline (Ricca Chemical, Arlington, TX) at a concentration of 40 mg/ml. Microbeads 
incorporating cells were created using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco 
Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle with an inner diameter of 0.12 
mm, and an electrostatic potential of 6 kV. The crosslinking solution contained 50 mM CaCl2, 150 
mM glucose with 15 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] (Sigma 
Aldrich) at pH 7.3 (Sigma Aldrich) [5, 23]. Alginate microbeads were allowed to crosslink for an 
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additional 10 minutes, washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, 
and suspended in the respective culture medium.  
4.2.3 Effect of Microencapsulation on Growth Factor Production  
To investigate the effect of microencapsulation on the ability of ASCs to produce 
angiogenic and osteogenic factors, microencapsulated ASCs derived from Sprague Dawley rats 
(rASCs) were compared to monolayer cultures of rASCs grown on TCPS.  Microbeads containing 
rASCs were cultured for five days in GM.  At that time, one half of the cultures were maintained 
in GM and the other half switched to OM for an additional five days.  rASCs were plated at 5000 
cells/cm2 and grown five days in GM, followed by five days in OM.  In addition, rat osteoblasts 
(ROBs) were plated at 5000 cells/cm2 and were grown for all 10 days in Dulbecco’s modified 
Eagle medium containing 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA) as a positive 
control.  
4.2.4 Effects of Dexamethasone and Ascorbic acid 2-phosphate 
To investigate the contributions of dexamethasone and ascorbic acid 2-phosphate to the 
response of microencapsulated ASCs to OM, microbeads incorporating rASCs (37 
cells/microbead) were cultured in GM for 5 days.  At that time, media were changed and 
microbeads were cultured for an addition 5 days in GM, OM, OM without ascorbic acid 2-
phosphate (OM-aa), OM without dexamethasone (OM-d), or OM without ascorbic acid 2-
phosphate and dexamethasone (OM-aa-d). In order to specifically address the role of 
dexamethasone, rASC microbeads were cultured in GM for 5 days and an additional 5 days in 
GM, GM with dexamethasone (GM+d), OM, or OM-d.  To examine whether effects of 
dexamethasone on growth factor production by microencapsulated ASCs is species specific, 
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microbeads containing ASCs derived from mice, rats, rabbits and humans (37 cells/microbead) 
were cultured in GM for 5 days and an additional 5 days in GM, OM, and OM-d. 
4.2.5 Soluble Factor Quantification 
 Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of 
vascular endothelial growth factor A (VEGF), fibroblast growth factor 2 (FGF2), and bone 
morphogenetic protein 2 (BMP2) (R&D Systems, Minneapolis, MN) in the conditioned media of 
monolayer cultures and microbead cultures.  We also assayed any growth factors retained within 
the microbeads. To do this, beads were collected, uncrosslinked in 82.5 mM sodium citrate, 
lyophilized, resuspended, digested in alginate lyase (1 U/ml) (Sigma Aldrich) for one hour and 
assayed.[37]  
All ELISAs were normalized by the DNA content of the cells. Cells layers were lysed in 
0.05% Triton-X100 (Sigma Aldrich). Cells were collected from the digested microbeads by 
centrifugation and lysed in Triton-X100.  DNA content of the lysates was determined using the 
Quant-iT™ Picogreen® ds DNA Reagent (Invitrogen) according to the manufacturer’s directions.  
4.2.6 RNA Extraction and Real Time PCR 
For these analyses, cells were collected by centrifugation from the digested beads and RNA 
was extracted by adding TRizol ® [Invitrogen] to the resulting cell pellet, which was homogenized 
using a Qiashredder (QIAGEN, Valencia, CA). RNA was extracted using chloroform and 
isopropanol (Sigma Aldrich), and quantified with the Nanodrop Spectrophotometer (Thermo 
Scientific, Waltham, MA). Samples were then converted into cDNA by the reverse transcription 
of 1 µg RNA with random primers (Applied Biosystems, Warrington, UK) and Multiscribe 
Reverse Transcriptase (Applied Biosystems). mRNA levels were measured by real-time PCR 
using the StepOne Plus PCR System (Applied Biosystems). mRNA levels for the following 
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proteins were measured; BMP2 (Bmp2), FGF2 (Fgf2), transforming growth factor beta-1 (Tgfβ1) 
and VEGF-A (Vegfa). In addition the mRNA levels for BMP antagonists, Noggin (Nog) and 
Gremlin 1 (Grem1) were measured. All primers (Table 4.1) were designed using the Beacon 
Designer 7.0 program and then synthesized by the Eurofins MWG Operon (Huntsville, AL). 
mRNA levels were quantified relative to a standard curve of known concentration, and results 
were normalized to the transcript levels of the housekeeping gene, 40S ribosomal protein S18 
(Rps18).  
 
Table 4.1: Primer sequences used for the analysis of mRNA levels. 
Gene  Forward Primer Reverse Primer 
Bmp2 TGT GAG GAT TAG CAG GTC TTT G CTT CCG CTG TTT GTG TTT GG 
Fgf2  Qiagen QuantiTect Primer 00189035 
Grem1 AAG CAC ATC ACC GGC CAA CGG 
ATC AGC GAC AGA CGG GGC 
ATC T 
 Nog GCC AGC ACT ATC TAC ACA TCC CAG CAG CGT CTC GTT CAG 
Rps18 TCG CTA TCA CTG CCA TTA AGG TGT ATT GTC GTG GGT TCT GC 
Tgfβ1 AGCCTGCTTCTTGAGTCC AAGTGGGGTGTTCTTAAATAGG 
Vegfa GGA CAT CTT CCA GGA GTA CC TCC AGG GCT TCA TCA TTG C 
 
 
4.3 Results 
rASCs cultured on TCPS and in alginate microbeads treated with OM had significantly 
lower DNA content compared to groups that received GM treatment (Fig. 4.1A). The DNA content 
of rat osteoblasts was significantly lower than rASCs in monolayer cultured in GM or OM. 
Microencapsulated rASCs receiving treatments with GM or various combinations of OM and its 
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components had similar DNA content. In some experiments, the OM-d group had lower DNA 
compared to OM-aa (Fig. 4.1B) or OM (Fig. 4.1C).  
 
Figure 4.1: A) DNA content of confluent monolayer cultures of rASCs grown in GM and OM on 
tissue culture polystyrene (TCPS). DNA content of rat osteoblasts are shown for comparison.  
DNA content of microencapsulated rASCs (μB) cultured in GM and OM for 5 days. (B) Effect of 
removing ascorbic acid (aa) or dexamethasone (d) from OM on DNA content of microencapsulated 
rASCs.  Microbeads were cultured in GM, OM, OM-aa, OM-d, OM-aa-d for 5 days.  (C) Effect 
of dexamethasone on DNA content of microencapsulated rASCs.  Microbeads were cultured in 
GM, GM+d, OM, or OM-d for 5 days.  Data were analyzed using one-way ANOVA followed by 
Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $ vs. OM, # vs. TCPS. 
Similar VEGF levels were produced by monolayer cultures and microbeads treated with 
GM. Rat osteoblasts produced 3 times less VEGF compared to rASCs cultured in GM. VEGF 
levels were reduced after OM treatment in both monolayer and microencapsulated cultures (Fig. 
2A). A similar reduction in VEGF levels was seen after microencapsulated rASCs were treated 
with OM-aa and GM+d (Figs. 4.2B, 4.2C). However, similar VEGF levels were attained as in GM 
groups once microbeads were treated with either OM-d or OM-aa-d (Figs. 4.2B, 4.2C). OM treated 
microencapsulated rASCs produced significantly less VEGF compared to GM for many 
experiments (Fig. 4.2D). Little or no FGF2 was detected in the conditioned media from all cell 
types cultured on TCPS or microencapsulated rASCs independent of the treatment (Figs. 4.2E – 
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4.2H). There was at least a 100% increase in BMP2 levels produced by microencapsulated rASCs 
cultured in GM or OM compared to their respective monolayer cultures (Fig. 4.2I). The BMP2 
levels were equivalent for all cell types cultured on TCPS and regardless of the treatment (Fig. 
4.2I). OM-aa, OM-d, and OM-aa-d treated groups secreted significantly less BMP2 compared to 
the GM treated group (Fig. 4.2J). However, BMP2 levels produced by microencapsulated rASCs 
treated with OM are similar compared to GM (Fig. 4.2L) despite the fluctuations observed (Figs. 
4.2J, 4.2K). A treatment over control analysis for many experiments demonstrates that BMP2 
levels between GM and OM are not different.  
 
Figure 4.2: (A) VEGF in the conditioned media of monolayer cultures of rASCs and 
microencapsulated ASCs cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts 
grown in their respective media for 5 days are shown for comparison. (B) Effect of removing 
ascorbic acid (aa) or dexamethasone (d) from OM on factor production by microencapsulated 
rASCs after 5 days in GM, OM, OM-aa, OM-d, OM-aa-d for 5 days.  (C) Effect of dexamethasone 
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on factor production by microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5 
days.  (D) Effect of OM v. GM on VEGF, FGF2, and BMP2 in conditioned media of 
microencapsulated rASCs. GM values are indicated by the dashed line at 1.0. (E-H) FGF2 and (I-
L) BMP2 were analyzed as described for VEGF. Data shown in A-C, E-G, and I-K are from a 
representative experiment.  Each data point represents a single independent culture.  Data were 
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 
0.05 vs. GM, $ vs. OM, # vs. TCPS.  Data in D, H and L are treatment/control ratios for N = 6 
separate experiments and were analyzed using the Mann-Whitney test. 
VEGF and FGF2 retained within the microbeads treated with OM were detectable but remained 
significantly lower than GM treated groups (Figs. 3A - 3H). A similar reduction was observed in 
the VEGF and FGF2 levels retained within microbeads treated with OM-aa., and GM+d 
compared to microbeads treated with GM. Removing dexamethasone from OM resulted in 
VEGF and FGF2 levels similar to those produced by GM treated groups (Figs. 3A – 3G). GM+d 
treatment led to a similar reduction in VEGF and FGF2 as observed with OM treatment (Figs. 
3C, 3G). BMP2 levels retained by microbeads cultured in OM, OM-aa, and OM-aa-d were 
similar (Fig. 3J) however, a 3 fold increase was observed in OM-d treated groups compared to 
groups treated with OM (Figs. 3J, 3K). Although significantly higher levels of BMP2 were 
retained within microbeads treated with OM (Fig. 3I), a treatment over control analysis showed 
the BMP2 levels retained within microbeads are not significantly different between GM and OM 
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groups (Fig. 3L).
 
 
Figure 4.3: (A) VEGF retained within the microbeads of microencapsulated rASCs after 5 days of 
culture in GM or OM. (B) Effect of removing ascorbic acid (aa) or dexamethasone (d) from OM 
on factor retention by microencapsulated rASCs after 5 days in GM, OM, OM-aa, OM-d, OM-aa-
d for 5 days.  (C) Effect of dexamethasone on factor retention by microencapsulated rASCs 
cultured in GM, GM+d, OM, or OM-d for 5 days.  (D) Effect of OM v. GM on VEGF, FGF2, and 
BMP2 in retained in rASC microbeads. GM values are indicated by the dashed line at 1.0. (E-H) 
FGF2 and (I-L) BMP2 were analyzed as described for VEGF. Data shown in A-C, E-G, and I-K 
are from a representative experiment.  Each data point represents a single independent culture.  
Data were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s 
t-test. * p< 0.05 vs. GM, $ vs. OM, # vs. TCPS.  Data in D, H and L are treatment/control ratios 
for N = 6 separate experiments and were analyzed using the Mann-Whitney test. 
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OM treatment of cells grown on TCPS and in microbeads caused a decrease in Vegfa expression. 
Rat osteoblasts expressed similar levels of Vegfa as rASCs on TCPS cultured in GM (Fig. 4A). 
Vegfa mRNA levels (Figs. 4A - 4C) decreased after OM, OM-aa, and GM+d treatment and was 
restored when dexamethasone was removed from the media. While OM did not reduce Fgf2 
expression in monolayer ASCs, it did reduce expression in the microencapsulated ASCs (Fig. 4D).  
Deletion of dexamethasone from OM or addition to GM increased expression of this factor (Figs. 
4E, 4F). Tgfb1 expression was also decreased in microencapsulated ASCs but not affected in 
monolayer cultures (Fig. 4G).  Deletion of dexamethasone from OM increased Tgfb1 expression 
but addition of dexamethasone to GM had no effect (Figs. 4H, 4I). 
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Figure 4.4: (A) Vegf expression in monolayer cultures of rASCs and microencapsulated ASCs 
cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts grown in their respective 
media for 5 days are shown for comparison. (B) Effect of removing ascorbic acid (aa) or 
dexamethasone (d) from OM on Vegf expression by microencapsulated rASCs after 5 days in GM, 
OM, OM-aa, OM-d, OM-aa-d for 5 days.  (C) Effect of dexamethasone on expression by 
microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5 days.  (D-F) expression of 
Fgf2 and (G-I) Tgfb1 were analyzed as described for VEGF. Data shown are from a representative 
experiment.  Each data point represents a single independent culture.  Data were analyzed using 
one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $ 
vs. OM, # vs. TCPS.   
Bmp2 mRNA levels of rASCs grown on TCPS increased with OM treatment, however the 
opposite was observed in microencapsulated groups (Fig. 4.5A). Removal of dexamethasone from 
OM reversed the OM inhibition of Bmp2 expression in the microencapsulated cells (Fig. 4.5B) 
but addition of dexamethasone to GM inhibited Bmp2 expression (Fig. 4.5C). Expression of the 
BMP2 antagonist Grem1 was unaffected in monolayer cultures whereas it was blocked in 
microencapsulated ASCs (Fig. 4.5D).  Removal of dexamethasone removed the OM inhibition of 
Grem1 expression but addition of dexamethasone to GM had no effect (Figs. 4.5E, 4.5F). 
Expression of Nog was increased more than 3-fold in monolayer cultures treated with OM but it 
was reduced by 50% in cultures of microencapsulated ASCs (Fig. 4.5G).  Removal of 
dexamethasone from OM restored expression to GM levels (Fig. 4.5H) but addition of 
dexamethasone to GM had no effect. 
67 
 
 
Figure 4.5: (A) Bmp2 expression in monolayer cultures of rASCs and microencapsulated ASCs 
cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts grown in their respective 
media for 5 days are shown for comparison. (B) Effect of removing ascorbic acid (aa) or 
dexamethasone (d) from OM on Bmp2 expression by microencapsulated rASCs after 5 days in 
GM, OM, OM-aa, OM-d, OM-aa-d for 5 days.  (C) Effect of dexamethasone on expression by 
microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5 days.  (D-F) expression of 
Grem1 and (G-I) Nog were analyzed as described for VEGF. Data shown are from a representative 
experiment.  Each data point represents a single independent culture.  Data were analyzed using 
one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $ 
vs. OM, # vs. TCPS.   
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VEGF and BMP2 secreted into the conditioned media were differentially regulated by OM and by 
dexamethasone.  OM reduce secretion of VEGF and BMP2 by microencapsulated rat ASCs; 
VEGF was restored to GM levels by dexamethasone removal but BMP2 was unaffected (Figs. 6A, 
6B). Secretion of neither factor was affected by OM or by OM-d in cultures of microencapsulated 
rabbit ASCs (Figs. 6C, 6D).  VEGF secretion was blocked by OM in cultures of microencapsulated 
mouse ASCs and partially restored by removal of dexamethasone (Fig. 6E), but OM completed 
blocked secretion of BMP2 and dexamethasone removal had no effect on this inhibition (Fig. 6F).  
For all three human donors, OM reduced secretion of VEGF and deletions of dexamethasone 
restored secretion to GM levels but BMP2 in conditioned media was either not detected or was not 
affected by OM or OM-d (Figs. 6G - 6I). Variability was also observed for factors retained within 
the microbeads.  VEGF retained in the rat microbeads was inhibited by OM and restored to GM 
levels by removing dexamethasone from OM (Fig. 6M).  BMP2 in the microbeads was low in 
cultures grown in GM and OM had no effect, but removal of dexamethasone from OM caused a 
marked increase in BMP2 in the microbeads (Fig. 6N).  OM and OM-d had no effect on VEGF or 
BMP2 in microbeads containing rabbit ASCs (Figs. 6O, 6P).  VEGF was reduced by OM in 
microbeads containing mouse ASCs and was increased by removing dexamethasone from the 
medium (Fig. 6Q).  No effects of media were observed in mouse microbead BMP2 (Fig. 6R).  
Microbeads containing human ASCs all exhibited reduced VEGF when cultured in OM, which 
was restored to GM levels by removal of dexamethasone, but no effect of media on BMP2 content 
was observed (Figs. 6S - 6X).  
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Figure 4.6: Comparison of VEGF and BMP2 in the conditioned media microencapsulated ASCs 
and retained within the microbead after 5 days of culture in GM, OM or OM-d. Microbeads 
containing rASCs, New Zealand white rabbit ASCs, C57bl/6 mouse ASCs, or human ASCs from 
three donors were examined.  (A–F) VEGF in conditioned media. (G-L) BMP2 in conditioned 
media. (M-R) VEGF in microbeads. (S-X) BMP2 retained within microbeads. Data shown are 
from a single representative experiment.  Each data point represents 6 independent cultures. Data 
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were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. 
* p< 0.05 vs. GM, $ vs. OM. 
4.4 Discussion 
This study demonstrates that production of growth factors and other regulatory molecules 
by microencapsulated ASCs is sensitive to the culture medium used and is different from 
production by monolayer cultures over the same time period and in the same media.  The effects 
of both culture media and microencapsulation vary with the factor being examined.  In some cases, 
regulation occurs at the expression level.  There is additional regulation due to the differential 
retention of proteins within the alginate bead or released into the conditioned media.  Importantly, 
our results show that deletion or addition of individual media components can have a marked effect 
on expression, retention, and release of both VEGF and BMP2. Finally, our results suggest that 
species differences may exist. Our data indicate that microencapsulation modifies production of 
some, but not all factors. When rASCs were cultured in MSC growth medium, comparable levels 
of VEGF and FGF2 were present in the conditioned media of monolayer cultures and 
microencapsulated cells.  In contrast, the conditioned media of microencapsulated rASCs had 
higher levels of BMP2 than monolayer cultures. Higher production of BMP2 by 
microencapsulated cells may be due to the microenvironment present in the 3D system of the 
microbeads, including cues related to cell shape [49]. MSCs in monolayer culture are flattened and 
spread in contrast to cells within the alginate hydrogel, which are spherical [50].  Other studies 
have shown that cytoskeletal arrangement can have profound effects on BMP2 gene expression 
and protein synthesis [51]. 
Oxygen tension within the microbead environment may also play a role.  Others have 
shown a positive relation between hypoxia and BMP2 production [52, 53]. A study with 
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endothelial cells under hypoxia resulted in a 2-fold to 3-fold increase in Bmp2 expression [52]. 
We did not measure differences in oxygen tension within the bead in the present study. In previous 
work, we showed that microencapsulated ASCs generated angiogenic factors including VEGF and 
FGF2 both in vitro and in vivo [37, 48].  This would suggest that the cells within the beads are in 
a hypoxic environment.  However, in the present study while we observed a marked increase in 
Vegf expression and noted Fgf2 expression, but we did not observe increased VEGF production 
by encapsulated ASCs compared to monolayer ASCs, nor did we detect FGF2 production. 
Moreover, expression and production of VEGF and FGF2 were decreased when the 
microencapsulated ASCs were incubated in OM.  This was not due to a reduction in cell number 
as DNA content of the cultures was not affected by the difference in medium. Osteoblasts in a 
hypoxic microenvironment have been shown to produce VEGF, but osteoblast differentiation does 
not appear to be responsible for the results[53].  Although BMP2 was increased in cultures grown 
in OM, suggesting osteogenic differentiation of the cells, the decrease in VEGF and FGF2 argued 
against the hypothesis that significant differentiation had occurred under the conditions of the 
experiment.   
This led us to consider if specific components of the OM might be responsible. We focused 
on two differentiation cues in OM:  ascorbic acid 2-phosphate and dexamethasone [54, 55]. Our 
results showed that removing ascorbic acid 2-phosphate did not alter any of the parameters tested 
in the study.  In contrast, removal of dexamethasone stimulated expression of Vegfa, Fgf2, Tgfb1, 
and Bmp2 as well as its inhibitors Grem1 and Nog.  There was a corresponding increase in VEGF 
and FGF2, but not of BMP2 in the conditioned media of the microbead cultures.  When we added 
dexamethasone to GM, we observed comparable effects on expression and protein to OM-treated 
microbeads, validating the conclusion that dexamethasone was a key player in modulating 
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production of angiogenic factors, as has been shown by others [56]. Although dexamethasone 
inhibited expression and production of angiogenic factors in our study, Mostafa et al. demonstrated 
the importance of dexamethasone on the differentiation of stem cells along the osteogenic lineage 
and specifically, for the mineralization of cells [57]. It has also been shown that dexamethasone 
induces osteogenesis via Runx2 upregulation [58].  
One explanation for the differences in our study with those reported in the literature is the 
experimental design.  We examined effects on microencapsulated cells, not monolayer cultures as 
has been done previously.  This may have altered the threshold concentration of dexamethasone 
needed to trigger differentiation. The reported dose of dexamethasone in the literature is 10 nM, 
[59] which is similar to the dexamethasone concentration in Lonza OM, suggesting that a different 
optimal dexamethasone concentration may exist for microencapsulated rASCs.   
Time course of exposure is also a consideration.  Whereas Bmp2 expression was reduced 
in microbeads cultured in OM compared to GM, it was increased by removal of dexamethasone 
from OM.  Despite the increase in expression, BMP2 was not increased in the conditioned media 
of OM-d cultures.  However, BMP2 was increased in the microbead itself.  This suggests that 
protein production was stimulated but the rate of BMP2 diffusion through the microbead hydrogel 
was not as efficient as for VEGF or FGF2.  Whether this was due to differential affinities of these 
factors for alginate or to differences in rate of synthesis was not examined.Our data support the 
conclusion that the overall effect of OM is due to interactions among its components.  Removal of 
ascorbic acid 2-phosphate by itself did not modify the parameters we tested, but in cultures grown 
in media without ascorbic acid 2-phosphate and dexamethasone, the deletion of ascorbic acid 2-
phosphate mitigated the effects of dexamethasone depletion.  Expression of Fgf2 in OM-aa-d 
microbeads was double that seen in OM-d and was increased over levels in GM cultures.  In 
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contrast, expression of Tgfb1 was 40% lower in OM-aa-d microbeads compared to OM-d 
microbeads.  Bmp2 and Grem1 in OM-aa-d microbeads were more than 50% lower than OM-d 
microbeads but Nog was unaffected.  Under the conditions of our study, we did not see a 
corresponding effect of ascorbic acid deletion on levels of VEGF, FGF2 or BMP2 in the 
conditioned media, but we did observe a 50% reduction in the amount of BMP2 retained in the 
microbead, supporting our hypothesis that the hydrogel properties are important considerations in 
determining the overall effect of medium composition on outcomes.  Beta-glycerophosphate has 
been shown by others [60] to regulate osteoblastic differentiation of MSCs.  It should be noted that 
we did not modify the beta-glycerophosphate content of the OM, so all of our observations are in 
the context of this important media component being present.   
Our results also showcase potential differences in outcomes dependent on the source of 
ASCs.  Microencapsulated ASCs from New Zealand white rabbits did not exhibit reduced VEGF 
in OM, nor did they show enhanced VEGF when cultured in OM-d. Microencapsulated C57Bl/6 
mouse ASCs did not exhibit increased retention of BMP2 within the alginate hydrogel in OM-d 
media although they did respond similarly to Sprague Dawley rat microbeads to OM-d treatment 
with respect to BMP2 content of the conditioned media.  Moreover, within species variation exists 
as well.  Microbeads containing ASCs from three different human donors had similar responses to 
GM, OM, and OM-d, with one significant exception: production of BMP2.  The findings support 
use of caution in making definite statements concerning complex cell populations typically present 
in ASC preparation. 
4.5 Conclusions 
Microencapsulated rASCs are able to produce osteogenic and angiogenic factors. The 
expression, production, secretion and retention of these factors are dependent on the culture media 
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used and on properties of the alginate hydrogel.  Dexamethasone is a key factor in OM that 
regulates angiogenic factor production. In addition, factor production differs among species as 
well as among individual donors.  Therefore, local factor production by microencapsulated ASCs 
can play an important role in bone regeneration. In the case of clinical applications, pre-screening 
of human donors would be recommended for their ASCs. 
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CHAPTER 5 
The Development of a Degradable Alginate Microbead System for Bone 
Regeneration 
Summary 
Cell-based therapies have potential for tissue regeneration but poor delivery methods lead 
to low viability or dispersal of cells from target sites, limiting clinical utility. Here, we developed 
a degradable and injectable hydrogel to deliver stem cells for bone regeneration. Alginate 
microbeads <200µm are injectable, persist at implantation sites and contain viable cells, but do not 
readily degrade in-vivo. We hypothesized that controlled release of rat adipose-derived stem cells 
(ASCs) from alginate microbeads can be achieved by incorporating alginate-lyase in the hydrogel. 
Microbeads were formed using high electrostatic potential. Controlled degradation was achieved 
through direct combination of alginate lyase and alginate at 4°C. Results showed that microbead 
degradation and cell release depended on the alginate lyase to alginate ratio. Viability of released 
cells ranged from 87% on day 2 to 71% on day 12. Monolayer cultures of released ASCs grown 
in osteogenic medium produced higher levels of osteocalcin and similar levels of other soluble 
factors as ASCs that were neither previously encapsulated nor exposed to alginate lyase. Bmp2, 
Fgf2, and Vegfa mRNA in released cells were also increased. Thus, this delivery system allows 
for controlled release of viable cells and can modulate their downstream osteogenic factor 
production.  
5.1. Introduction 
Approximately 5 to 20% of the total bone fractures that occur yearly fail to heal completely 
resulting in a nonunion [1]. Treatment frequently involves resection of the nonunion tissue and use 
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of grafts augmented with autologous bone marrow. One of the factors contributing to non-union 
is the loss of multipotent stem cells capable of differentiating along the osteoblast lineage [61]. 
Injectable, cell-based therapies could be especially advantageous for these patients since they are 
less invasive than current surgical treatments and could aid in bone regeneration. Adipose-derived 
stem cells (ASCs), which are multipotent [2], are easily isolated, and can be induced to express an 
osteoblastic phenotype [36]. Recent reports indicate that ASCs are not as osteogenic as bone 
marrow stem cells, but their ready availability supports their use as a potential cell source [62].  
One notable disadvantage of cell based therapies is that injected cells tend to disperse to 
tissues other than the intended site [3]. Moreover, those cells that do home to the intended site may 
not remain viable over a sufficient period of time or differentiate into the desired phenotype. This 
is particularly problematic in tissues like fracture non-unions, where vasculature is often not well 
developed. Therefore, the goal of this study was to develop a system of injectable hydrogels that 
would allow ASCs to remain viable at the injury site, maintain their ability to differentiate along 
the osteoblast lineage, and be released after a given time period. 
Alginate hydrogels have gained special attention because of their ability to provide a 
temporary support for a variety of cell types [63-65] while facilitating the transport of nutrients, 
gases and metabolic wastes [66]. Alginate microbeads have been used to deliver insulin secreting 
cells for insulin dependent diabetes [28], parathyroid glands for hypoparathyroidism [29], and stem 
cells for organ repair [30]. Furthermore, alginate hydrogels can be modified to incorporate specific 
biochemical cues [24, 67]. Alginate is a block copolymer that consists of (1-4)-linked-β-D 
mannuronic acid (M units) and α-L-guluronic acid (G units) monomers, where each block may be 
repeating M units (poly (M)) or G units (poly(G)) or a random organization of M and G units 
(poly(MG)) [27]. It is present in the cell walls of brown algae and can also be synthesized by 
77 
 
bacteria. The advantage of alginate compared to synthetic polymers is its ability to form a hydrogel 
under relatively mild pH and temperature, and its ability to be sterilized [27]. Alginate forms a 
hydrogel once it is cross-linked between the G units of neighboring chains with divalent cations 
such as Ca++ or Ba++. 
When ASCs are encapsulated using an electrostatic potential in a calcium crosslinking 
solution containing glucose as an osmolyte, the resulting microbeads contain a tunable number of 
cells in a bead diameter of 200µm . These microbeads were used successfully as a delivery vehicle 
for subcutaneous injection of ASCs in mice and the cells remained viable for two months [4, 5]. 
Mass transfer issues are obviated due their small size and high surface to volume ratio. These 
studies have also shown that encapsulated ASCs can be induced to express a chondrocytic 
phenotype and to produce chondrogenic factors, suggesting that similar approaches will be 
successful for bone regeneration [48, 68]. 
Despite the many advantages of alginate, a central challenge remains – alginate does not 
degrade enzymatically within the human body and non-enzymic breakdown occurs very slowly. 
In vitro, release of cells is achieved by chelating Ca++, thereby breaking the crosslinks between 
chains. There have been attempts to control the rate of degradation of alginate constructs in vivo 
by decreasing the molecular weight through oxidation and γ-irradiation, thus inducing 
hydrolytically labile groups [6].  After six months, these constructs maintained their structure but 
elastic modulus was decreased and cell migration was increased. Another approach involved the 
encapsulation of poly(lactide-coglycolide) (PLGA) particles loaded with alginate lyase [69], an 
enzyme that cleaves the β-1,4-glycosidic linkage between the monosaccharide units of the alginate 
through a β-elimination reaction producing uronate products [26]. Finally another strategy used 
covalent crosslinking with bifunctional groups to degrade alginate constructs [70]. These efforts 
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have been partially successful in larger alginate constructs (4mm), but there are no methods to 
control the degradation of smaller alginate microbeads (200µm – 500µm), which are important for 
injectable applications. 
In the present study, we focused on developing a system of injectable hydrogels to allow 
the cells to remain at the area of injury, and secrete soluble factors that facilitate bone regeneration. 
We hypothesized that controlled degradation of alginate microbeads can be used to control the 
release kinetics of viable cells for regeneration. Our objectives were to (i) develop and optimize a 
method of incorporating alginate lyase in alginate microbeads; (ii) establish controlled degradation 
parameters using medical grade alginate; (iii) determine if alginate lyase-mediated alginate 
degradation has an effect on the viability and phenotype of the released cells; (iv) determine if 
alginate microbeads containing alginate lyase degrade in vivo; and (v) identify if the degradation 
by-products are toxic and elicit an inflammatory response.  
5.2. Methods 
5.2.1 Alginate Degradation  
To test our hypothesis that time controlled degradation can be achieved by the 
incorporation of alginate lyase into alginate microbeads, various ratios of alginate lyase (units [U] 
of enzyme activity) to alginate [g] were combined to form microbeads. Two types of alginates 
were used: “wound healing” grade alginate (55% to 60% mannuronate units) (Protonal® 
LF10/60LS, FMC BioPolymer, Sandvika, Norway) and medical grade alginate (50% mannuronate 
units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC BioPolymer). Low viscosity 
alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a concentration of 
40 mg/ml. Microbeads were created using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco 
Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle with an inner diameter of 
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0.175 mm (0.12 mm for microbeads used in the in vivo study), an electrostatic potential of 6 kV 
and a calcium crosslinking solution. The crosslinking solution contained 75 mM CaCl2, 90 mM 
glucose with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma 
Aldrich) (HEPES-buffered) [70]. Alginate microbeads were allowed to crosslink for an additional 
10 minutes, washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and 
suspended in saline supplemented with calcium chloride (1.8 mM Ca2+).  
Two methods were used to incorporate alginate lyase (28000 U/g, Sigma Aldrich, St. 
Louis, MO) into the microbeads. Initially, the enzyme was first packaged in polylactide-co-
glycolide (PLGA 50:50) (Sigma Aldrich) particles at a w/w ratio of alginate lyase to PLGA of 
1:10. The particles were made using the solid in oil in water method as previously described [69]. 
The PLGA particles were then incorporated into alginate microbeads by encapsulating 1mg PLGA 
particles to 70 mg alginate. Once the beads were made they were suspended in saline with 
physiological levels of calcium (1.8 mM Ca2+) at 370C.  However this approach did not prove to 
be successful in degrading the alginate beads.  
Alternatively, alginate lyase was incorporated into alginate microbeads by combining 
equal volumes of 4% low viscosity, high mannuronate (LVM) alginate and a known concentration 
of alginate lyase solution in 0.9% (w/v) saline. Prior to the combination, both components were 
kept at 4°C. The final 2% (w/v) alginate was mixed at 1000 rpm for one minute. A series of 
degradation experiments were done with various ratios of alginate lyase to alginate to achieve the 
optimal ratios that resulted in controlled degradation over 12 days. The final gradient was 14 U/g 
to 0.35 U/g for experiments assessing alginate degradation in the absence of cells and 1.4 U/g to 
0.09 U/g for experiments assessing degradation in the presence of cells. Prior to assessing 
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degradation in the presence of cells, experiments assessing alginate degradation in mesenchymal 
stem cell growth medium (MSCGM, Lonza Biosciences, Walkersville, MD) were performed. 
Microbead degradation was monitored by measuring the absorbance of the uronate 
products in optically clear 96-well plates (UV-Star® Microplate, Greiner Bio One, Frickenhausen, 
Germany) at 235nm by using a Synergy H4 Hybrid Reader (BioTek, Winooski, VT) [71] every 48 
hours. In addition, the diameter of the microbeads was measured every 48 hours over the 12 day 
period using images taken with a Leica DMIL microscope connected to a Leica DC 300 camera 
(Leica, Solms, Germany) and analyzed with Image-Pro Plus software (version 4.5.1.22, 2002, 
Media Cybernetics, Rockville, MD). The light microscope was used to follow the alginate 
microbead degradation and cell release from the alginate microbeads. At each time point one image 
per field was taken for each group. 
5.2.2 Adipose Derived Stem Cells 
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], under an 
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute 
of Technology. Briefly, the inguinal fat pad was removed and transferred to a container with 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3% 
sterile-filtered L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with 
Hank’s balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) for 30 minutes on a rocker at 37°C. Following 
trypsinization, the supernatant was discarded. Adipose tissue was cut into small pieces and 
incubated in a digestive cocktail containing collagenase type I (365 units/mL) (Sigma Aldrich) and 
dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. After incubation, the oily upper layer 
was removed and the digest was quenched with an equal amount of MSCGM. The cells were 
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separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2. 
For the next two days the monolayers were washed with Dulbecco’s phosphate buffered saline 
(DPBS) (Invitrogen) and fed with MSCGM every 24 hours. Thereafter media were changed every 
48 hours and cells were cultured to confluence. First passaged cells were used for studies. 
ASCs were also isolated from green fluorescent protein (GFP) positive rats (Rat Resource 
and Research Center, Columbia, MO) under IACUC approval and cultured up to passage 6 for the 
cell release studies. 
5.2.3 Cell Release Studies 
To test our hypothesis that controlled release of cells can be achieved through the 
controlled degradation of alginate microbeads, ASCs were encapsulated in various ratios of 
alginate lyase to UV-sterilized medical grade alginate. ASCs were released from the culture plate 
by trypsinization, and collected by centrifugation after rinsing the cell pellet with MSCGM, the 
cells were suspended in the alginate lyase/alginate mixture at a concentration of 25 x 106 cells/ml. 
Alginate microbeads were then formed as previously described. Microencapsulated ASCs and 
GFP-ASCs were suspended in 40µm cell strainers (BD Falcon, Franklin Lakes, NJ) and cultured 
in MSCGM in non-tissue culture treated 6-well plates to limit proliferation of released cells in the 
well. Media were changed every 48 hours and each cell strainer was washed twice with 0.9% (w/v) 
saline to ensure that all the cells released were collected. Additional cells on the plate’s surface 
were collected through trypsinization. 
5.2.3.1 Cell Number 
The number of cells released was counted using a Z1 particle counter (Beckman Coulter, 
Brea, CA). For the groups where the alginate microbeads did not fully degrade by the end of the 
12 day period, 82.5 mM sodium citrate was used to release the remaining cells. All cells were 
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collected, suspended in 0.05% Triton-X100 (Sigma Aldrich) and used to determine the DNA 
content [Quant-iT™ Picogreen® ds DNA Reagent, Invitrogen, CA] and alkaline phosphatase 
specific activity. The percent cell release was calculated as a function of the total number cells in 
the 0 U/g group (control), which reflected any change due to proliferation or cell death over the 
incubation period. The total number of cells microencapsulated in the control group was 
determined by the number of cells released on the 12th day using 82.5 mM sodium citrate. 
To determine if our observations were applicable to other cell types, microbeads were 
prepared containing human osteoblast-like MG63 cells (American Type Culture Collection, 
Rockville, MD). Microbeads were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS; Gibco, Carlsbad, CA) and 1% penicillin-streptomycin.  
5.2.3.2 Alkaline Phosphatase Specific Activity 
To measure alkaline phosphatase specific activity, released cells were suspended in 0.05 
% Triton-X100 and lysed by sonication. Enzyme activity was measured as the ability to convert 
p-nitrophenylphosphate to p-nitrophenol at pH 10.2. This was normalized by the total protein 
content (Pierce Macro BCA Protein Assay kit, Pierce Biotechnology, Rockford, IL) in the cell 
lysate. 
5.2.3.3 Cell Viability 
5.2.3.3.1 LIVE/DEAD Assay 
Viability of cells within microbeads and of cells released from the microbeads (released 
cells) was measured using a LIVE/DEAD Viability kit (Invitrogen). Samples (200µl) were 
collected at each time point (days 0, 2, 4, 6, 8, 10, and 12) for microbeads without alginate- lyase 
and on the days where the greatest cell release occurred for the microbeads incorporating alginate 
lyase. The 200µl aliquots were transferred to a chamber slide and incubated for 30 minutes at 37°C 
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in 0.9% saline containing 4μM ethidium homodimer-1 and 2μM calcein-AM.  Images were 
obtained using a Zeiss LSM 700-405 confocal microscope (Carl Zeiss MicroImaging, Inc., 
Thornwood, NY). Three images were obtained for each well and then red and green cells were 
counted using Image-Pro Plus software (Media Cybernetics) to determine the percent viability. 
5.2.3.3.2 TUNEL Assay 
To determine the number of cells going through apoptosis, the integrity of the cell’s DNA 
was measured using the TiterTACS™ Apoptosis Detection Kit following the manufacturer’s 
protocol (Trevigen, Gaithersburg, MD). At each time point, 300,000 cells from each well were 
used for the assay.  
5.2.4 Phenotype of Released ASCs 
For these experiments ASCs that were never microencapsulated or exposed to alginate 
lyase were compared to ASCs released from microbeads containing either 0 U/g or 0.13 U/g 
alginate lyase. To investigate the osteogenic potential of the released cells, ASCs were collected 
at day 8 from the 0 U/g and 0.13 U/g groups, were plated at 5000 cells/cm2 and cultured in 
MSCGM until confluent. ASCs that were never microencapsulated or exposed to alginate lyase 
were also cultured in MSCGM until confluent. Both cell types were treated with OM for 7 days 
followed by MSCGM for 24 hours. 
5.2.4.1 Alkaline Phosphatase Specific Activity 
Alkaline phosphatase specific activity was measured as described in 5.2.3.2. 
5.2.4.2 Soluble Factor Quantification 
Enzyme-linked immunosorbent assays (ELISA) were used to measure the levels of bone 
morphogenetic protein-2 (BMP2), fibroblast growth factor-2 (FGF2), osteoprotegerin (OPG), and 
vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN) in the conditioned 
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medium. The levels of osteocalcin were measured with a radioimmunoassay kit (Human 
Osteocalcin RIA Kit, Biomedical Technologies, Stoughton, MA). All ELISAs and the 
radioimmunoassay were normalized by the DNA content of the cells.  
5.2.4.3 RNA Extraction and Real Time PCR 
RNA was extracted 8 hours after the last medium change using TRIzol ® [Invitrogen] and 
quantified with the Nanodrop Spectrophotometer (Thermo Scientific, Waltham, MA). Samples 
were then converted into cDNA by the reverse transcription of 1 µg RNA with random primers 
(Applied Biosystems, Warrington, UK) and Multiscribe Reverse Transcriptase (Applied 
Biosystems). The cDNA was analyzed for mRNA levels by real-time PCR using the StepOne Plus 
PCR System (Applied Biosystems). mRNA levels for the following proteins were measured; 
BMP2 (Bmp2), type I collagen (Col1), FGF2 (Fgf2), Osterix (Osx), Runx2 (Runx2), osteocalcin 
(Ocn), and VEGF-A (Vegfa). In addition the mRNA levels for BMP antagonists, Noggin (Nog) 
and Gremlin 1 (Grem1) were measured. All primers (Table 5.1) were designed using the Beacon 
Designer 7.0 program and then synthesized by the Eurofins MWG Operon (Huntsville, AL). The 
mRNA levels were quantified relative to a standard curve of known concentration, and results 
were normalized to the transcript levels of the housekeeping gene, 40S ribosomal protein S18 
(Rps18).  
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Table 5.1. Primer sequences used for the analysis of mRNA levels. 
Gene  Forward Primer Reverse Primer 
Bmp2 TGT GAG GAT TAG CAG GTC TTT G CTT CCG CTG TTT GTG TTT GG 
Col1 CGA GTA TGG AAG CGA AGG AGT GAT AGG TGA TGT TCT GG 
Fgf2  Qiagen QuantiTect Primer 00189035 
Grem1 AAG CAC ATC ACC GGC CAA CGG ATC AGC GAC AGA CGG GGC ATC T 
 Nog GCC AGC ACT ATC TAC ACA TCC CAG CAG CGT CTC GTT CAG 
Ocn Qiagen QuantiTect Primer 01084573 
Osx Qiagen QuantiTect Primer 01083082 
Rps18 TCG CTA TCA CTG CCA TTA AGG TGT ATT GTC GTG GGT TCT GC 
 Runx2 TCC CCA TCC ATC CAT TCC AGA GGC AGA AGT CAG AGG 
Vegfa GGA CAT CTT CCA GGA GTA CC TCC AGG GCT TCA TCA TTG C 
 
5.2.6 Alginate Microbead Degradation In Vivo 
In vivo studies were done to examine if alginate microbeads incorporating alginate lyase 
would degrade and determine if the degradation by-products results in an inflammatory response. 
Male C57 Black 6 mice were handled under a protocol approved by the IACUC at the Georgia 
Institute of Technology. Prior to surgeries, mice were anesthetized using isoflurane gas. Alginate 
microbeads (0.1 ml) with and without alginate lyase (1.75 U/ml and 0 U/ml) but without cells were 
injected subcutaneously in the dorsal side using a 16 gauge needle [4]. Each animal received 1 
injection subcutaneously (n = 6 for each experimental condition). Animals were euthanized by 
CO2 inhalation after 2 weeks and a portion of the skin removed and processed for histology as 
described below. 
5.2.6.1 Histology 
After 48 h of fixation in formalin, samples were dehydrated in a series of 95% and 100% 
ethanol and xylene washes. Samples were embedded in paraffin, and cut into 8-μm thick sections 
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(Shandon Finesse 325, Thermo Scientific). The sections were stained with haematoxylin and eosin, 
and then imaged with a Leica DMLB microscope (Leica Microsystems, Bannockburn, IL).  
5.2.7 Statistical Analysis of Data 
The results of the quantitative and morphometric analyses were calculated as the means ± 
SEM of six independent cultures per variable. Statistically significant differences between groups 
were determined by one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. 
P values ≤ 0.05 were considered significant. All experiments were repeated at least twice to ensure 
validity of results.  Data presented are from representative experiments. 
5.3 Results 
5.1 Controlled Degradation of Alginate Microbeads 
Controlled degradation of alginate microbeads made from both “wound healing” (Fig. 5.1) 
and medical grade (Fig. 5.2) alginate was a function of alginate lyase concentration. For both 
alginate types, as the ratio of alginate lyase to alginate increased, the time required for total 
degradation of the alginate microbeads decreased (Figs. 5.1A and 5.2A). Complete degradation 
was not observed in microbeads produced using 0.7 U/g in either alginate formulation over the 12 
day time course. Degradation of the wound healing grade alginate (28 U/g) occurred within 4 days 
(Fig. 5.1B) whereas degradation of the medical grade alginate (14 U/g) required 6 days (Fig. 5.2B).  
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Figure 5.1: Degradation of alginate (wound healing grade) microbeads with different formulations 
of alginate lyase (U): alginate (g). (A) Visualization of alginate microbead degradation under an 
inverted light microscope (mag. = 10x), (B) absorbance of uronate products, and (C) diameter of 
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beads as they degrade over the 12 day period. Data were analyzed using one-way ANOVA 
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 0. 
Microbead diameter changed overtime in an enzyme-dependent manner that was 
formulation specific. Newly generated microbeads had an average diameter of 400µm when placed 
in the degradation solution (saline with 1.8mM Ca2+). Incorporation of 28 U/g alginate-lyase 
caused wound healing grade alginate bead diameters to decrease by >100µm within 2 days. In 
contrast microbeads containing 0.7 U/g did not decrease significantly until day 12. There were no 
changes in diameter in the absence of enzyme (Fig. 5.1C). Similarly, medical grade alginate beads 
did not change size in the absence of enzyme (Fig. 5.2C). However, diameters increased by 100µm 
in the presence of alginate lyase and this effect occurred more rapidly at higher enzyme 
concentrations. 
Degradation of the medical grade alginate microbeads with no cells in MSCGM (data not 
shown) occurred faster compared to the same microbeads suspended in saline supplemented with 
physiological levels of calcium (1.8 mM Ca2+) (Fig. 5.2D). 
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Figure 5.2: Degradation of alginate (medical grade) microbeads with different formulations of 
alginate lyase (U): alginate (g). (A) Visualization of alginate microbead degradation under an 
inverted light microscope (mag. = 10x), (B) absorbance of uronate products, (C) diameter of beads, 
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and (D) diameter of beads in MSCGM as they degrade over the 12 day period, Data were analyzed 
using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 v. 
day 0. 
5.3.2 Release of Cells  
Cell release kinetics varied as a function of alginate lyase content (Fig. 5.3A). Medical 
grade alginate microbeads with the highest concentration of alginate lyase (1.4 U/g) released the 
cells in the shortest period of time (2 days) (Fig. 5.3B). A similar result was seen in the percent 
release where the highest percentage of cells (63%) was released on day 2 from the 1.4 U/g 
microbeads (Fig. 5.3C). DNA content of the released cells confirmed these observations (Fig. 
5.3D). Released cells had measureable alkaline phosphatase specific activity (Fig. 5.3F). The 
highest levels of enzyme activity were seen in cells that were encapsulated in beads with alginate 
lyase content varying from 0.09 to 0.24 U/g.  Similar cell release kinetics were observed using 
GFP-ASCs (Figs. 5.4A and 5.4B), and confirmed by measuring fluorescence (Fig. 5.4C).  Release 
of MG63 cells exhibited comparable kinetics (Figs. 5.4D and 5.4E).  Unlike the ASCs, however, 
alkaline phosphatase specific activity of the released MG63 cells was low and did not vary with 
alginate lyase content of the microbeads (Fig. 5.4F). 
91 
 
 
Figure 5.3: Release of ASCs from alginate (medical grade) microbeads with different formulations 
of alginate lyase (U): alginate (g) over a 12 day period. (A) Visualization of the released ASCs 
from alginate microbeads under an inverted light microscope (mag. = 10x), (B) the number of 
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released ASCs, (C) percent cell release, (D) total DNA content of the released cells, and (E) total 
alkaline phosphatase in the cell lysate. Data were analyzed using one-way ANOVA followed by 
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2. 
 
Figure 5.4: Release of GFP-conjugated ASCs and MG63 osteoblast-like cells from alginate 
(medical grade) microbeads with different formulations of alginate lyase (U): alginate (g) over 12 
days. Top row – GFP-ASCs: (A) the number of released cells, (B) total DNA content, and (C) 
fluorescence. Bottom row – MG63 cells: (D) the number of released cells, (E) total DNA content, 
and (F) total alkaline phosphatase in the cell lysate. Data were analyzed using one-way ANOVA 
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2. 
5.3.3 Effect of Alginate lyase Mediated Degradation on Viability of Released Cells 
Live/dead staining demonstrated that ASCs microencapsulated in alginate without alginate 
lyase remained viable throughout the culture period (Fig. 5.5A). On day 2, 64% of the cells were 
viable and on day 12, 79% were viable (Fig. 5.5B). The cells released from the microbeads 
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remained viable throughout the 12 days (Fig. 5.6A), ranging from 87% on day 2 to 71% on day 12 
(Fig. 5.6B). As the cells were released they were not in the process of apoptosis (Fig. 5.6C).  
 
Figure 5.5: Viability of ASCs in microbeads without alginate lyase. (A) Live/dead staining of 
ASCs within the 0 U/g alginate (medical grade) microbeads (Scale bar = 50 µm) on days 2, 4, 6, 
8, 10, and 12, where green represents live cells and red represents dead cells, and (B) the percent 
viable cells. Data were analyzed using one-way ANOVA followed by Bonferroni’s modification 
of Student’s t-test. * p < 0.05 vs. day 2. 
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Figure 5.6: Viability of  ASCs released from alginate (medical grade) microbeads made with 
different formulations of alginate lyase (U): alginate (g) (Scale bar = 50 µm) (A) Live/dead staining 
of released ASCs, where green represents live cells and red represents dead cells, (B) the percent 
viable cells, and (C) TUNEL assay of released  ASCs (the horizontal bar represents the positive 
control generated) at the respective times; 1.4 U/g on day 2, 0.35 U/g on day 4, 0.24 U/g on days 
4 and 6, 0.18 U/g on day 8, 0.13 U/g on day 10, and 0.09 U/g on days 10 and day 12. Data were 
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p < 
0.05 vs. day 2. 
5.3.4 Effect of Alginate Lyase Mediated Degradation on Cell Phenotype 
Microencapsulation in alginate microbeads containing alginate lyase did not alter the 
osteoblast differentiation potential of ASCs.  When compared to ASCs that were never 
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encapsulated, the released cells exhibited lower DNA content following culture for 7 days in OM 
but there were no differences due to incorporation of alginate lyase in the microbeads (Fig. 5.7A).  
Alkaline phosphatase specific activity of the released cells was comparable to that of the never 
encapsulated ASCs (Fig. 5.7B).  In contrast, ASCs released from the microbeads produced higher 
levels of osteocalcin than the never-encapsulated cells, but again, no difference was observed as a 
function of alginate lyase content (Fig. 5.7C). Osteoprotegerin content of the conditioned media 
was comparable for never-encapsulated ASCs and ASCs released from microbeads containing 
0.13 U/g enzyme, whereas cells released from the control microbeads exhibited lower production 
of this protein (Fig. 5.7D).  None of the ASCs produced detectable VEGF following 7 days culture 
in OM, although all ASCs produced FGF2 (Figs. 5.7E, and 5.7F).   
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Figure 5.7: The osteogenic potential of ASCs released from alginate microbeads. ASCs that were 
not encapsulated (monolayer cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13 
U/g alginate (medical grade) microbeads were cultured in osteogenic medium for 7 days, followed 
by MSCGM for 24 hours. (A) DNA content, (B) alkaline phosphatase specific activity in the cell 
lysate, and levels of the following proteins in the conditioned media: (C) osteocalcin, (D) 
osteoprotegerin, (E) vascular endothelial growth factor (VEGF), and (F) fibroblast growth factor 
2 (FGF2). Data were analyzed using one-way ANOVA followed by Bonferroni’s modification of 
Student’s t-test. * p< 0.05 vs. M. 
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mRNA levels were more sensitive to whether the ASCs had been microencapsulated and 
the type of microbead.  Runx2 (Fig. 5.8A), Osx (Fig. 5.8B), and Col1 (Fig. 5.8C) mRNAs were 
comparable in all ASCs.  Bmp2 levels were elevated in cells released from the microbeads and 
this effect was even greater in cells released from microbeads containing alginate lyase (Fig. 5.8D).  
mRNAs for the BMP inhibitors Gremlin-1 and Noggin were also increased in ASCs released from 
microencapsulated cells.  Whereas Grem1 was highest in cells from microbeads containing 
enzyme (Fig. 5.8E), Nog was elevated to a comparable extent in cells that had been 
microencapsulated in both types of microbeads (Fig. 5.8F).  Vegf was increased in a comparable 
manner to Nog (Fig. 5.8G) and Fgf2 was increased in a comparable manner to Grem1 (Fig. 5.8H).  
Osteocalcin mRNA was insensitive to the prior experience of the ASCs (Fig. 5.8I). 
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Figure 5.8: mRNA expression in ASCs released from alginate microbeads.  ASCs that were not 
encapsulated (monolayer cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13 
U/g alginate (medical grade) microbeads were cultured for 7 days in osteogenic medium, followed 
by MSCGM for 8 hours. mRNA’s for (A) runt-related transcription factor 2 (Runx2), (B) osterix 
(Osx), (C) type 1 collagen (Col1), (D) bone morphogenetic protein 2 (Bmp2), (E) Gremlin 1 
(Grem1), (F) noggin (Nog), (G) vascular endothelial growth factor (Vegfa), (H) fibroblast growth 
factor 2 (Fgf2), and osteocalcin (OCN) were measured. Data were analyzed using one-way 
ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. M. 
5.3.5 Alginate Microbeads without Cells Incorporating Alginate Lyase Degrade In Vivo 
After two weeks of implantation, microbeads without alginate lyase were present in the 
tissue of all animals (Fig. 5.9A). There was no apparent immune response (Fig. 5.9B) and the size 
of the beads was not reduced. In contrast, beads that contained alginate lyase were not present 
(Figs. 5.9C and 5.9D). There was no immune cell infiltrate in response to the degradation products.  
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Figure 5.9: H&E staining of subcutaneous site of alginate microbead implantation after 2 weeks: 
(A) alginate microbeads (0 U/g), scale bar represents 500 µm; (B) scale bar represents 200 µm, 
arrows indicate alginate microbeads; (C) alginate microbeads incorporating alginate lyase (1.75 
U/g), scale bar represents 500 µm, the arrow head indicates the implantation site; and (D) alginate 
microbeads incorporating alginate lyase (1.75 U/g), scale bar represents 200 µm. The outlined 
black box represents the area magnified 4 times on the right. 
5.4. Discussion 
Alginate hydrogels used to deliver stem cells must be degradable in vivo to allow for the 
release of cells, thus facilitating tissue regeneration. Moreover, the rate of degradation must be 
controllable in order to fit the clinical application. In order to achieve controlled degradation, our 
first approach incorporated PLGA particles loaded with alginate lyase in alginate microbeads, as 
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suggested by Ashton et al. [69]. However this approach did not result in degradation, for a number 
of reasons.  The loading efficiency of the PLGA particles in the microbeads was low, and the 
amount of released enzyme was insufficient to degrade the alginate. The 4 mm diameter constructs 
described by Ashton et al. were not only significantly larger than the microbeads used in the 
present study, but they were fabricated with 50% less alginate, which leads to lower guluronate 
content resulting in a lower cross-linking density. Hydrogel structures with lower mechanical 
stability and glycosidc bonds may degrade easily with PLGA loaded with alginate lyase.  
Moreover, the high electrostatic potential used to generate the microbeads used in the present study 
causes formation of an alginate-rich shell, which may further limit degradation. 
The second approach demonstrated that controlled degradation can be achieved by the 
incorporation of alginate lyase during microbead production using an electrostatic potential. The 
effects of the alginate lyase are concentration dependent. As the amount of incorporated enzyme 
is increased, the rate of microbead degradation is increased.  This correlation between enzyme 
content and alginate degradation was found with two different alginate formulations used in 
medical applications but there were some differences.  Wound healing grade alginate required 
greater units of alginate lyase to achieve degradation within the 12 day period.  In contrast, medical 
grade alginate degraded over a longer period of time and the diameter of the microbeads increased.  
Despite both types of alginate having similar ratios of M units to G units, differences in purity as 
well as alginate chain length may have played a role in the degradation rate [70].  The presence of 
polyphenols in the wound healing alginate does not appear to be responsible, however, since 
polyphenols have been shown to reduce the activity of alginate lyase in aerobic degradation [72, 
73]. 
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Degradation of alginate microbeads via alginate lyase occurs by two mechanisms; 
enzymatic cleavage and ion exchange. In the first few days, degradation is primarily due to 
enzymic cleavage of the glycosidic bonds between the M units. In our system, this was evidenced 
by the production of uronate products in the first four days of incubation. Once the glycosidic 
bonds are broken, the Ca++ ion crosslinks become more susceptible to ion exchange. The alginate 
structure disintegrates as a result of the out flux of Ca++ ions, which are replaced by monovalent 
ions resulting in decreased cross-linking density and, thus, a weakened hydrogel structure 
associated with an increase in pore size [74]. This two part mechanism likely contributed to the 
changes observed in microbead diameter over the 12 day period. The reduced crosslinking density 
coupled with the inward diffusion of other molecules resulted in the swelling observed in medical 
grade alginate microbeads. It is possible that a similar process takes place with microbeads 
produced using wound healing grade alginate, but it is more likely that the rapid cleavage of 
glycosidic bonds caused erosion of the surface of the microbead resulting in a decreased diameter.  
The controlled release of cells was illustrated with various cell types demonstrating the 
versatility of the delivery system. For all three cell types, 1.4 U/g alginate lyase released most of 
the cells on day 2, while 0.09 U/g caused a gradual release of cells up to day 12. Alginate 
degradation in the absence of cells occurred more slowly. The ratio of alginate lyase to alginate 
was adjusted to account for the difference in degradation rates in the presence of cells. This 
difference is due to the reduced alginate content in each microbead. Mammalian cells do not 
possess alginate lyase, ruling out the possibility that native cellular enzymes contributed to 
microbead degradation.  Additionally, the cells begin to leave the microbeads before total 
degradation occurs as observed with 0.35 U/g group where the majority of the cells were released 
102 
 
on day 4, but without cells the total degradation did not occur in 12 days. Also in the presence of 
the cells and as time increases, alginate has been shown to decrease in gel strength [74]. 
The viability of cells post-injection is critical to the success of injectable cell-based 
therapies. Injection of stem cells is known to result in low viability ranging from 1% to 32% 
because of the harsh environment at the injury site and the mechanical disruption of the cell 
membrane by extensional flow during ejection from the needle [47]. Delivering cells in crosslinked 
alginate by injection has been shown to improve cell viability because of its protective effects 
during ejection via “plug flow”.  This plug flow occurs when the hydrogel near the wall acts as a 
lubricant, protecting the rest of the hydrogel by allowing it to stay intact and move through the 
needle [47]. 
Once the cells are injected, the alginate can provide further protection while retaining them 
at the injury site.  Our results indicate that cells encapsulated in the microbead formulations tested 
in this study are viable in the microbead environment, indicating favorable mass transfer of 
nutrients.  The small increase in the number of viable cells noted in microbeads produced without 
enzyme may have been due to proliferation or to retention of secreted factors within the microbead 
[48] or to limited apoptosis.  Moreover, inclusion of alginate lyase in the alginate did not have a 
negative impact on viability of ASCs released from the microbeads.  Indeed, viability of cells 
released from microbeads containing alginate lyase was greater than from microbeads without 
enzyme.  This suggests that the weakened structure of the alginate microbead due to cleavage of 
glycosidic bonds may have improved nutrient transfer.  
Importantly, ASCs released from the microbeads did not exhibit major differences from 
cells that had never been microencapsulated, at least as a function of growth in osteogenic medium.  
At the time of release, cellular alkaline phosphatase specific activity was comparable for all 
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formulations of microbead.  Released cells cultured in monolayer to confluence and then for 7 
days in osteogenic medium had comparable alkaline phosphatase activity to ASCs that had never 
been previously microencapsulated.  Similarly, mRNA levels for the osteogenic transcription 
factors Runx2 and Osx were not different compared to the monolayer cells, nor were mRNA levels 
for Col1.  
Our results also suggest that microencapsulation may enhance the osteogenic potential of 
the ASCs with respect to their ability to produce paracrine factors that stimulate bone formation.  
The released ASCs exhibited reduced DNA content and increased osteocalcin production 
compared to the never-encapsulated ASCs after 7 days in OM.  This was correlated with increased 
levels of Bmp2 mRNA, suggesting that BMP2 might act as an autocrine/paracrine regulator of the 
microencapsulated cells.  Interestingly, expression of Bmp2 was accompanied by expression of its 
inhibitors, Grem1 and Nog, but in a differential manner.  The significance of this is not known at 
this time, but other studies have shown that these proteins are regulated independently [75]. 
There was not complete convergence between mRNA levels at 8 hours post-treatment with 
osteogenic medium and protein levels at 24 hours for a number of factors, including osteocalcin, 
VEGF and FGF2, which may reflect normal cellular transcription and translational controls.  
Interestingly, mRNA expression was more sensitive to differences in microbead formulation.  
Cells encapsulated in alginate containing alginate lyase had greater expression of Bmp2, Grem1 
and Fgf2 than cells that had been encapsulated in alginate without enzyme.  Similarly, for some 
mRNAs, having the experience of encapsulation caused greater expression than seen in ASCs that 
had not been encapsulated, even though the same starting population of ASCs was used for these 
experiments.  Previous research has shown that glucocorticoids can decrease production of 
angiogenic factors [56], suggesting that the dexamethasone present in osteogenic medium may 
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have inhibited VEGF production by the cells.  The fact that Vegf mRNA was not affected and that 
the ASCs produced both Fgf2 mRNA and FGF2 protein argues against this, however. 
It is important that the results gathered in vitro can be obtained in vivo to ensure that the 
delivery system is capable of working. Therefore alginate microbeads without cells (0 U/g and 
1.75 U/g) were placed subcutaneously to determine if degradation would occur and whether or not 
the by-products of alginate lyase mediated degradation would elicit an inflammatory response. At 
the end of two weeks the alginate microbeads incorporating alginate lyase were not present thus 
showing that degradation took place while in the control group alginate microbeads were present 
in all the samples. The histological analysis of the skin shows that there was no leukocyte 
infiltration thus indicating no inflammatory response. 
5.5. Conclusions 
In conclusion, we have developed a degradable and injectable delivery system for stem 
cells where the time of cell release can be modulated for specific applications. The controlled 
degradation was achieved through the incorporation of alginate lyase into alginate microbeads. 
This system has shown that it can be used with multiple cell types. The cells released from the 
microbeads remained viable and maintained their ASC phenotype with respect to growth in 
osteogenic medium. Importantly, the results also show that mRNA expression of released cells is 
more sensitive to microbead formulation than protein production at the time points assayed. The 
released cells express higher levels of mRNAs associated with paracrine regulation of 
osteogenesis, suggesting they may positively impact bone formation in vivo. These 
microencapsulated cells can be directly injected to the site of injury. Therefore, in cases where 
surgery is usually required for fractures or non-unions, this stem cell delivery method can be used, 
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allowing controlled release of cells and the production of factors thus enhancing tissue 
regeneration. 
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CHAPTER 6 
 
Microencapsulated Rabbit ASCs supported Chondrogenesis in a Rabbit 
Auricular Defect Model 
 
Summary 
Cell-based tissue engineering can promote cartilage tissue regeneration, but cell retention 
in the implant site post-delivery is problematic.  Alginate microbeads containing adipose stem cells 
(ASCs) pretreated with chondrogenic media (CM) have been used successfully to regenerate 
hyaline cartilage in critical size defects in rat xyphoid suggesting that they may be used to treat 
defects in elastic cartilages like the ear.  To test this, we used microbeads containing rabbit (rb) 
ASCs in critical size defects in New Zealand White rabbit ear cartilage.  Low viscosity, high 
mannuronate medical grade alginate microbeads were generated using a high electrostatic potential 
and a calcium crosslinking solution containing glucose. rbASCs were isolated from inguinal fat 
pads of male New Zealand White rabbits and their multipotency validated. Microencapsulated 
rbASCs cultured in chondrogenic media expressed mRNAs for aggrecan, type II collagen, and 
type X collagen. Microbeads were implanted in 3mm defects created using a trephine in the mid-
cartilage located in the ear of each 6 skeletally mature male rabbits (empty defect; microbeads 
without cells; microbeads with cells; degradable microbeads with cells; and autograft). At 12 
weeks post-implantation, cartilage regeneration was assessed by microCT and histology. 
Microencapsulated rbASCs induced cartilage regeneration as well as formation of bone-like tissue 
in the defects. Elastin, the hallmark of auricular cartilage, was not evident in the neocartilage. This 
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delivery system offers the potential for regeneration of auricular cartilage but factors that induce 
elastin and consideration of the vascularity of the treatment site must be considered. 
6.1 Introduction 
Cartilage replacement is one of the top five cosmetic surgical procedures performed each 
year involving the ear and nose, as well as congenital birth defects in the United States [1].  
Cartilage is difficult to regenerate due to its avascular nature making any repair or replacement of 
this tissue slow or challenging to achieve. Therapies that repair elastic cartilage include 
implantation of cell-laden scaffolds [76] and reshaping cartilage harvested from another site within 
the body [1], but these approaches frequently do not lead to complete cartilage regeneration.  
Moreover, donor site morbidity and lack of available tissue in the case of grafting, and cell 
migration compounded with low cell viability in the case of tissue engineering techniques, limit 
success [77, 78].   
A more focused approach using a cell-based therapy that would maintain the viability, 
retention, and phenotype of the cells once implanted should improve tissue regeneration.  We 
previously showed that alginate microbeads containing adipose stem cells (ASCs) pretreated with 
chondrogenic media could be used successfully to regenerate hyaline cartilage in critical size 
defects in the rat xyphoid [48].  This suggested that a similar approach could be used to treat critical 
size defects in elastic cartilages like the ear.  
Alginate is found in seaweed and is a block copolymer that contains blocks of guluronic 
acid, mannuronic acid, or alternating guluronic-mannuronic acid residues [24]. This biopolymer 
instantaneously forms a hydrogel once it comes in contact with calcium forming an ionic bond 
between guluronic acid and Ca++. The material is currently used in biomedical engineering for 
drug delivery, regenerative medicine, and wound healing [79, 80]. Using a microencapsulator to 
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apply an electrostatic charge in combination with a calcium crosslinking solution containing 
glucose, cells can be incorporated into alginate microbeads that are ≤200 µm in diameter, with cell 
viability greater than 85% in vitro after 2 weeks [81].  Moreover, cells within the beads are viable 
after 3 months in vivo [4]. The hydrogel system provides small diffusion distances allowing the 
exchange of nutrients, wastes and secreted factors.  
Despite the biocompatibility of alginate, the polymer does not degrade in vivo. Alginate 
may persist up to six months at the delivery site, thus preventing the release of cells and secreted 
factors [6].  Recently, we showed that controlled cell release from alginate microbeads can be 
achieved by incorporating alginate lyase [34]. This enzyme acts through a β-elimination 
mechanism to cleave the glycosidic bonds between mannuronate residues [26]. Controlling the 
rate of release by varying the rate of microbead degradation allows the encapsulated cells to aid 
tissue regeneration in addition to the secretion of factors, which affects cell signaling and induces 
endogenous progenitor recruitment to facilitate tissue repair [81].  
In this study, we developed an auricular cartilage critical size defect model in adult male 
New Zealand White rabbits and used it to examine the utility of the microbead technology for 
regenerating elastic cartilage.  We hypothesized that the controlled release of rbASCs and secreted 
factors will lead to induction of cartilage in an auricular critical size defect.   
 
6.2. Methods 
6.2.1 Adipose Derived Stem Cells 
rbASCs were isolated from New Zealand White rabbits rats (n = 2) [2, 36], under an 
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute 
of Technology. Briefly, the inguinal fat pad was removed and transferred to a container with 
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Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented with 3% sterile-filtered 
L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with Hank’s 
balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) for 30 minutes on a rocker at 37°C. Following 
trypsinization, the supernatant was discarded. Adipose tissue was cut into small pieces and 
incubated in a digestive cocktail containing collagenase type I (365 units/mL) (Sigma Aldrich) and 
dispase (3 units/mL) (Gibco) for four hours. After incubation, the oily upper layer was removed 
and the digest was quenched with an equal amount of MSCGM. The cells were separated, plated 
in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2. For the next two 
days the monolayers were washed with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen) 
and fed with MSCGM every 24 hours. Thereafter media were changed every 48 hours and cells 
were cultured to confluence. First passaged cells were used for the phenotype studies. 
6.2.2 Phenotype of rbASCs 
To investigate the multipotency of rbASCs, cells were plated at 5000 cells/cm2 and cultured 
in MSCGM until confluent. rbASCs were treated with MSCGM, osteogenic differentiation 
medium (OM, Lonza), chondrogenic differentiation medium (CM) and adipogenic differentiation 
medium (AM, Lonza) for 18 days. The CM was made with high glucose DMEM (4.5 g/L glucose), 
110 mg/L sodium pyruvate (Sigma Aldrich), 50 µg/mL ascorbic acid 2-phosphate (Sigma 
Aldrich), 10 nм dexamethasone (Sigma Aldrich), 1% ITS+ (Sigma Aldrich), 40 µg/mL proline 
(Sigma Aldrich), 100 ng/mL of the recombinant human bone morphogenetic protein 6 (PeproTech, 
Rocky Hill, NJ), and 10 ng/mL recombinant human transforming growth factor beta-1 (R&D 
Systems, Minneapolis, MN). 
 
110 
 
6.2.2.1 RNA Extraction and Real Time PCR 
RNA was extracted 8 hours after the last medium change using TRIzol ® [Invitrogen] and 
quantified with the Nanodrop Spectrophotometer (Thermo Scientific, Waltham, MA). Samples 
were then converted into cDNA by the reverse transcription of 1 µg RNA with random primers 
(Applied Biosystems, Warrington, UK) and Multiscribe Reverse Transcriptase (Applied 
Biosystems). The cDNA was analyzed for mRNA levels by real-time PCR using the StepOne Plus 
PCR System (Applied Biosystems). mRNA levels for the following proteins were measured; 
collagen type II (COL2), collagen type X (COL10), runt-related transcription factor 2 (RUNX2), 
peroxisome proliferator-activated receptor gamma (PPAR-γ), aggrecan (ACAN), leptin receptor 
(LEPR), and osteocalcin (bone gamma-carboxyglutamate protein, BGLAP). All primers (Table 
6.1) were designed using the NCBI program and then synthesized by Integrated DNA 
Technologies (IDT). The mRNA levels were quantified relative to a standard curve of known 
concentration, and results were normalized to the transcript levels of the housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
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Table 6.1. Primer sequences used for the analysis of mRNA levels 
Gene Forward Primer Reverse Primer 
ACAN 
GGA GCA GGA GTT TGT CAA CAA CAA 
C 
CCA GTT CTC AAA TTG TAG 
GGG GTG T 
COL2 
AGA AGA ACT GGT GGA GCA GCA AGA 
G 
AGG CTG CTG TCT CCA TAG 
CTG AAG 
COL10 GTT CAT GGA GTG TTC TAC GCT GAG 
ACC TTG TTC TCC TCT CAC 
TGG 
GAPDH CAGTTTCCATCCCAGACCCC 
TGCTGTCGAGACTTTATTGA
TGGT 
LEPR 
GTTGGCCTTAAGGTCCATCTTTTATATG
TTCTGCCT 
GCTGCTGGCACAGGCACAT
GAC 
OCN CCTCACTCTTGTCGCCCTGCTG 
CTCCCTCTTGGACACGAAG
GCTGAG 
PPAR-γ 
CAG CAT CTC TGC TCC ACA CTA TGA 
A 
AGG TTC CAC TTT GAT TGC 
ACT TTG A 
RUNX2  CATGTCCCTCGGTATGTCCG 
ACTCTGGCTTTGGGAAGAG
C 
 
6.2.2.2 Histological Stains 
Multipotency of rbASCs was also demonstrated via the use of histological stains of 
cultured cells. P1 rbASCs were plated at 5000 cells/cm2 in 6-well plates. At confluence, cells were 
treated with MSCGM, OM, and AM for 14 days. Cells differentiated along the osteogenic lineages 
were stained with alkaline phosphatase and Alizarin Red. Cells differentiated along the adipogenic 
lineage were stained with Oil Red-O. Cell differentiation along the chondrogenic lineage was 
performed using pellet culture. Briefly, 150,000 cells were spun at 5000 RPM for 10 minutes in a 
15 mL conical tube.  Pellets were cultured for 14 days in CM.  The pellet was embedded in paraffin 
and sections were stained with Alcian Blue. All stains were compared to an equivalent sample 
cultured in MSCGM as the control. In addition, sections were examined for the presence of elastin 
as described below for histologic analysis of regenerated ear cartilage. 
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6.2.3 Microencapsulated Cells 
Low viscosity medical grade alginate (50% mannuronate units) (PRONOVA™ UP LVM, 
ultrapure sodium alginates, FMC BioPolymer) was dissolved in 0.9% (w/v) saline (Ricca 
Chemical) at a concentration of 40 mg/ml. Microbeads were created using a Nisco Encapsulator 
VAR V1 LIN-0043 (Nisco Engineering AG) at a 5 ml/hr flow rate, nozzle with an inner diameter 
of 0.12 mm, an electrostatic potential of 6 kV and a calcium crosslinking solution. The crosslinking 
solution contained 75 mM CaCl2, 90 mM glucose with 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPES-buffered) [70]. Alginate 
microbeads were allowed to crosslink for an additional 10 minutes, washed with 0.9% (w/v) saline 
(Ricca Chemical) to remove the excess Ca++, and suspended in saline supplemented with calcium 
chloride (1.8 mM Ca++) at 370C.   
Degradable alginate microbeads were made by incorporating alginate lyase in the 
microbeads following the methods described in Leslie et al. [34]. Briefly, equal volumes of 4% 
alginate and a known concentration of alginate lyase solution combined in 0.9% (w/v) saline. At 
confluence, rbASCs were treated with CM for 7 days.  The cells were released from the culture 
plate by trypsinization and collected by centrifugation after rinsing the cell pellet with MSCGM. 
The cells were then suspended in the alginate lyase/alginate mixture at a concentration of 10 x 106 
cells/ml. Non-degradable microbeads incorporating rbASCs were made similarly with the 
exception of adding alginate lyase.  Alginate microbeads were then formed as previously described 
and suspended in MSCGM for 24 h. 
6.2.3 Phenotype of Microencapsulated rbASCs 
To investigate whether or not microencapsulation affects the chondrogenic effects of CM, 
microencapsulated rbASCs (10 x 106 cells/ml) were treated with MSCGM for 3 days then CM or 
MSCGM for 7 days. 
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6.2.3.1 Soluble Factor Quantification 
Enzyme-linked immunosorbent assays (ELISA) were used to measure the levels of 
vascular endothelial growth factor A (VEGF), transforming growth factor beta 2 (TGFβ2), bone 
morphogenetic protein 2 (BMP2) and transforming growth factor beta 3 (TGFβ3) (R&D Systems, 
Minneapolis, MN) in the conditioned medium and retained in the microbeads. To measure growth 
factor retention within microbeads, beads were collected, uncrosslinked in 82.5mM sodium citrate, 
lyophilized and resuspended and digested in alginate lyase (1U/ml) (Sigma Aldrich) for one hour 
and measured with ELISAs. All ELISAs were normalized by the DNA content of the cells. 
6.2.3.2 DNA Quantification 
The digested microbeads were used to determine the DNA content (Quant-iT™ 
Picogreen® ds DNA Reagent, Invitrogen) of the microencapsulated cells.  
6.2.3.2 mRNA Levels 
ACAN, COL2, and COL10 mRNA levels were measured as previously described in 
section 6.2.2.1 and normalized by GAPDH. 
6.2.4 Cartilage Ear Defect In Vivo 
6.2.4.1 Rabbit Auricular Cartilage Defect Surgery 
All surgical procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Georgia Institute of Technology. Male New Zealand white rabbits (2 
– 3 kg, n = 6) were induced with a ketamine and xylazine intramuscular injection; anesthesia was 
maintained with inhaled isofluorane gas. Each animal was placed prone on the operating table and 
a 6 cm incision was made extending from the tragus to the mid-helix. A flap was created both 
anteriorly and posteriorly by elevating the perichondrium from the auricular cartilage. To create a 
full thickness defect, a dermal biopsy punch (Miltex Inc., Plainsboro, New Jersey) was used. In 
each ear, defects were made by placing a surgical stainless steel ruler in the posterior flap for 
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support and a dermal biopsy punch was used to create a full thickness cartilage defect. The skin 
incision was closed using 5-0 PDS (polydiaxanone) suture (Ethicon, Somerville, NJ) using a 
simple running technique.  
6.2.4.2 Determining Critical Cartilage defect size 
Prior to assessing the ability of microencapsulated rbASCs (n = 3) to initiate cartilage 
regeneration, a rabbit auricular cartilage critical size defect model was developed. Cylindrical full 
thickness defects were created using 1, 3 and 4 mm dermal biopsy punches (Miltex Inc). The 
defects were separated by 1 mm. In one ear of each animal, the autograft for the respective defect 
size was used to fill the defect to compare healing. After six weeks, the defects were examined for 
the degree of healing using equilibrium partitioning of an ionic contrast agent microCT (EPIC-
microCT) (Scanco Medical) [82, 83]. 
6.2.4.3 Implantation of Microencapsulated rbASCs 
The protocol used to assess the ability of the microencapsulated rbASCs to regenerate 
auricular cartilage is shown in Figure 6.1. rbASCs were cultured in CM for 7 days and 
microencapsulated in low viscosity, high mannuronate alginate microbeads as described above. 
Five 3 mm defects were made in each ear. Four defects were separated by 1.5 cm and a fifth defect 
(autograft) was created medially 1.25 cm away from the most superior defect. A 4 mm x 4 mm 
piece of SepraFilm ® (Genzyme Corporation, MA) was placed posteriorly to each defect. Each 
defect was filled with the respective treatment as outlined in the experimental schematic (Fig. 6.1). 
The five treatments in each ear included empty defect, non-degradable alginate microbeads 
containing rbASCs, non-degradable alginate microbeads, degradable alginate microbeads 
containing rbASCs, and an autograft.  Each defect with a microbead treatment received 100 µl of 
microbeads (approximately 2500 microbeads). Each defect was sealed with a 4 mm x 4 mm piece 
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of SepraFilm.  After 12 weeks the posterior skin was removed and the defects were recovered.  A 
total of 6 rabbits were used with each ear receiving the procedure, resulting in a total of 12 samples 
per group. 
   
Figure 6.1. Schematic outlining the experimental method. rbASCs that were previously treated 
with chondrogenic media for 7 days were microencapsulated and delivered to the appropriated 
defect site: 1. empty, 2. non-degradable microbeads incorporating rbASCs, 3. non-degradable 
microbeads without rbASCs, 4. degradable microbeads incorporating rbASCs, and 5. autograft. 
After 12 weeks the defects were harvested and analyzed via microCT and histology. 
 
6.2.4.4 Epic MicroCT to Assess Neocartilage Formation 
To assess the degree of healing in each defect, contrast-enhanced microCT analysis 
technique based on equilibrium partitioning of an ionic contrast agent (EPIC-microCT) was used 
[82]. Using this method we quantified the tissue volume and density within each defect. Once the 
defects were harvested they were placed in 10% neutral buffered formalin (VWR) for 24 h and 
transferred to 40% Hexabrix and 60% phosphate buffered saline incubated for 12 h at 370C. All 
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samples were scanned in air using a µCT 40 (Scanco Medical) at 45 kVp, 200 µA, 600 ms 
integration time, and a voxel size of 35 µm. Images were processed using the accompanying 
Scanco Medical software. A constant volume of interest representing the absolute volume centered 
at the defect cavity was used for the analysis of each sample. The diameter of the volume of interest 
was 3 mm by 3 mm. To observe three-dimensional distribution of sulfated glycosaminoglycan 
(GAG) in the tissue, color images were based on the X-ray attenuation. Low X-ray attenuation 
(green and blue) corresponded to regions of high proteoglycan concentration and high X-ray 
attenuation (red and yellow) indicated regions of low proteoglycan concentration. 
6.2.4.5 Histology 
After 48 h of fixation in neutral buffered formalin, samples were dehydrated in a series of 
95% and 100% ethanol and xylene washes. Samples were embedded in paraffin, and cut into 8 μm 
thick sections (Shandon Finesse 325, Thermo Scientific). The sections were stained with 
haematoxylin and eosin, safranin O, or Masson’s trichrome and then imaged with a Zeiss 
Observer.Z1 axio microscope (Leica Microsystems, Bannockburn, IL).  
In addition, we examined the tissues for the presence of elastin using ab150667 Modified 
Verhoeff’s stain kit (Abcam, Cambridge, UK).  Deparaffinized, hydrated sections were incubated 
for 15 minutes in elastic stain containing haematoxylin solution, ferric chloride, and Lugol’s iodine 
solution. After rinsing in tap water, the sections were dipped 20 times in a differentiating solution, 
rinsed and incubated in sodium thiosulfate solution for 1 minute.  After rinsing in tap water, they 
were stained using van Gieson’s solution for 2-5 minutes, rinsed twice in 95% alcohol, dehydrated 
in absolute alcohol, cleared and mounted.  This method stains elastic fibers black to blue/black, 
nuclei are blue to black, collagen is red, and muscle and other tissues are yellow. 
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6.2.4.6 Histomorphometric Analysis 
To analyze the ability of the microencapsulated rbASCs to induce cartilage regeneration, 
the area of the new cartilage and the defect width were measured using IMAGE J software (NIH, 
Bethesda, MD). The area of new cartilage was identified by a color change in the H&E staining - 
mature cartilage (dark purple) to newly formed cartilage (light purple). Percent healing was 
defined as the summation of all cartilage or bone-like tissue within the borders of the defect divided 
by the width of the original defect. 
6.2.5 Statistical Analysis 
Data are presented as the mean with standard error.  Statistically significant differences 
between groups were determined by one-way ANOVA followed by Bonferroni’s modification of 
Student’s t-test. P values ≤ 0.05 were considered significant. 
 
 
6.3. Results 
6.3.1 Multipotentiality of rbASCs 
Gene expression was sensitive to the culture media in which the rbASCs were cultured. 
rbASCs treated with CM for 18 days had higher mRNAs for COL2, ACAN, and COL10 than cells 
cultured in GM (Figs. 6.2A,B,C), but did not produce elastin (data not shown).  Similarly, rbASCs 
in OM had significantly higher mRNAs for RUNX2 and BGLAP compared to rbASCs treated 
with GM for the same period (Figs. 6.2D and 6.2E). Cells cultured in AM had significantly higher 
mRNAs for LEPR and similar levels of mRNA for PPAR-γ compared to those treated with GM 
(Figs. 6.2F and 6.2G).  
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Gene expression was confirmed by histologic staining of the cultures.  rbASCs cultured as 
a pellet in CM for two weeks showed a higher presence of proteoglycans with Alcian Blue staining 
than cells in GM (Fig. 6.2H). rbASCs cultured in OM for two weeks had greater calcium deposition 
and alkaline phosphatase staining than cells in GM (Fig. 6.2I), while rbASCs treated with AM had 
a greater presence of oil droplets with Oil Red O staining (Fig. 6.2J).  
 
Figure 6.2: Multipotency of rbASCs. mRNA levels for COL2, ACAN, COL10, RUNX2, BGLAP, 
PPAR-γ, and LEPR (A-G); Alcian Blue staining of a 3D culture of rbASCs cultured in MSCGM 
and CM (H); alkaline phosphatase (ALP) and Alizarin Red staining of rbASCs cultures in 
MSCGM or OM (I); and Oil Red-O staining of monolayer cultures cultured in MSCGM or AM 
(J). Magnification 10x.  
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6.3.2 Chondrogenic Phenotype of Microencapsulated rbASCs 
Microencapsulated rbASCs exhibited chondrogenic differentiation when cultured in CM. 
mRNAs for ACAN, COL2, and COL10 were increased compared to microencapsulated cells 
cultured in GM (Figs. 6.3A,B,C). Levels of TGFβ2 and TGFβ3 in the conditioned media and 
retained within alginate microbeads were significantly higher than in GM cultures (Figs. 
6.3D,E,F,G). BMP2 levels were comparable when microbeads were cultured in CM or GM 
(Figs. 6.3H,I). VEGF levels in the conditioned media of microbeads cultured in CM were 
significantly lower compared to GM cultures, but there was no difference in the amount of 
VEGF retained within the microbeads (Figs. 6.3J, K).  
 
Figure 6.3. Phenotype of rbASCs after microencapsulation. mRNA levels for ACAN, COL2, and 
COL10 (A-C); and production of TGFβ2, TGFβ3, BMP2, and VEGF by microencapsulated 
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rbASCs treated with MSCGM and CM for 7 days. Data were analyzed using one-way ANOVA 
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. MSCGM. 
6.3.3 Determination of Rabbit Auricular Cartilage Critical Size Defect  
After six weeks, empty defects of 1 mm, 3 mm, and 4 mm in diameter did not regenerate, 
as shown in the histological sections (Figs. 6.4A,B,C). A similar result was observed in the 
microCT images of 1 mm and 3 mm diameter empty defects (Figs. 6.4A,B). Neocartilage was not 
observed at the margins of the autograft and defect suggesting the autograft did not integrate with 
the adjacent cartilage tissue (Figs. 6.4D,E,F). MicroCT confirmed the presence of cartilage in the 
autografted defect sites.  Based on these results, all subsequent surgeries were performed using a 
3 mm defect. 
 
Figure 6.4. Critical size defect in auricular cartilage. H&E staining and microCT images of empty 
defects (A, B, C) and the corresponding autografts of 1, 3, and 4 mm in diameter (D,E,F). 
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6.3.4 EPIC-microCT Analysis 
Analysis of the defect sites at 12 weeks post-surgery showed that sites receiving autograft 
had a significantly greater total volume of tissue compared to all other groups (Fig. 6.5A).  The 
average attenuation of the defect site was significantly greater when defects were treated with 
degradable microbeads containing rbASCs compared to all other groups (Fig. 6.5B).  Empty 
microbeads and autograft had similar levels of attenuation, and were significantly higher than 
empty defects. Representative images of the defect locations and attenuation maps are shown in 
Figures 6.5C and 6.5D respectively. 
 
Figure 6.5. MicroCT analysis of tissue in defects at 12 weeks post-surgery: tissue volume within 
the defect site (A), average attenuation of the defect site (B), 3D images of ear with defect location 
(C); and attenuation map of defects (D). Data were analyzed using one-way ANOVA followed by 
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. empty defect, $ vs. µBs with rbASCs, 
^ vs. degradable µBs with rbASCs. 
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6.3.5 Histomorphometric Analysis of Cartilage Ear Defects 
Histological analysis showed the infiltration of fibrous tissue after 12 weeks in empty 
defects (Fig. 6.6A). In contrast, autografts had the appearance of normal auricular cartilage but as 
noted above, it was not integrated with the margins of the defect (Fig. 6.6B).  Autografts did not 
lead to either partial or complete healing. While the autograft maintained the structural properties 
of cartilage, there was no reintegration of the autograft with the defect tissue.  Empty microbeads 
were still observed in the defect site surrounded by fibrous connective tissue (Figs. 6.6C,D). Non-
degradable alginate microbeads incorporating rbASCs initiated cartilage regeneration, and in one 
case resulted in complete regeneration of the cartilage within the defect (Fig. 6.6E). Large areas of 
newly formed cartilage were observed in these samples.  
 
Figure 6.6. Defects after 12 weeks. H&E staining of:  A – empty defect, B - autograft, C - non-
degradable microbeads without cells, and D - magnified view of microbeads in C. E - H - Defects 
incorporating non-degradable microbeads containing rbASCs. Defects treated with non-
degradable microbeads containing rbASCs exhibited: newly generated cartilage, cartilage 
interwoven with calcified tissue and immature bone-like tissue. Sections of one defect stained with 
H&E (F), Safranin O (G), and Masson’s trichrome (H).  Black arrows point to the newly formed 
cartilage and yellow arrows point to the original cartilage. 
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Degradable alginate microbeads containing rbASCs produced a different tissue response.  
Bone-like tissue adjacent to the defect margins was evident in H&E stained sections of the defect 
sites (Fig. 6.7F). This region also positively stained with safranin O, indicating cartilage was 
present as well (Fig. 6.7G).  Masson’s trichrome staining of these samples confirmed that immature 
bone-like tissue was present (Fig. 6.7H).  
 
Figure 6.7. Defects filled with degradable microbeads incorporating rbASCs. Histological stains 
of different regions of the same defect: H&E (A), Safranin O (B), Masson’s trichrome (C). Inset 
on left shows a magnified version of newly formed bone (Magnification 40x). Green arrows point 
to newly formed bone/calcified tissues. Radiographic image of defect with calcified tissue and the 
corresponding H&E staining (D). 
 
There was no evidence of elastin in the neocartilage formed within the defect sites (Fig. 
6.8). Normal chondrocytes in the auricular cartilage adjacent to the defect exhibited the 
characteristic pericellular staining indicative of elastic fibers (Fig. 6.8A).  However, chondrocytes 
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in the neocartilage in the defect sites showed mainly collagen in the extracellular matrix (Figs. 
6.8B,C,D). 
 
Figure 6.8. Normal chondrocytes have pericellular elastic fibers (A) while cells in the sites 
implanted with nondegradable microbeads containing rbASCs are surrounded mainly by collagen 
(B-D). Staining with Modified Verhoeff’s elastic stain; images taken at 40x magnification. Elastic 
fibers are stained black to blue/black, nuclei stained blue to black, collagen stained red, and any 
muscle and other tissue stained yellow. 
 
Histomorphometry demonstrated that the defects that received non-degradable alginate 
microbeads with rbASCs had the greatest area of new cartilage (Fig. 6.9A, Fig. 6.6E). In contrast, 
the empty defects had significantly less cartilage than all other groups (Fig. 6.9A). New immature 
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bone-like tissue was also evident in all defects (Fig. 6.9B, Fig. 6.7C), but the area of new bone was 
small and to a comparable extent in all defect sites.  This tissue was observed in microCTs of the 
tissue (Fig. 6.7D), indicating that it was mineralized.   
 
Figure 6.9. Histomorphometric analysis of the area of new cartilage (A); area of immature bone-
like tissue (B); percent healing with new cartilage (C); and percent healing with immature bone-
like tissue (D). Data were analyzed using one-way ANOVA followed by Bonferroni’s 
modification of Student’s t-test. * p < 0.05 vs. empty defect, $ vs. µBs with rbASCs, ^ vs. 
degradable µBs with rbASCs. 
 
Histology showed that neocartilage and bone like tissue were present both inside and 
outside the defect region.  When examining only the cartilage and bone-like tissue within the 
defect, percent healing of new cartilage for both degradable and non-degradable microbeads with 
rbASCs were increased compared to other groups, but not significantly (Fig. 6.9C). The percent 
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healing of immature bone-like tissue found in all defects was comparable regardless of treatment 
(Fig. 6.9D). 
There was considerable variation in tissue response among animals in the same treatment 
group (Table 6.2).  Empty defects only exhibited cartilage in 1 of 6 rabbit ears but immature bone 
like tissue was present in 4 of the 6.  One of these had both cartilage and bone in the defect tissue.  
When defects were treated with non-degradable microbeads containing rbASCs, 7 of 11 rabbit ears 
had cartilage and 7 of 11 had immature bone.  All rabbit ears had either cartilage or bone, but only 
3 had both cartilage and bone.  Defects treated with microbeads that did not contain cells also had 
cartilage (4/10) and bone like tissue (6/10).  Seven of the rabbit ears had either cartilage or bone 
but only 3 had both types of tissue within the defect site.  In sites treated with degradable 
microbeads containing rbASCs, 4 of 8 rabbit ears had cartilage and 6 of 8 rabbit ears had bone.  
Seven of the 8 rabbit ears had either cartilage or bone but only 4 had both.  In defects treated with 
autograft, 4 of 11 animals had neocartilage, 7 of 11 had bone-like tissue; nine of the rabbit ears 
had either neocartilage or bone but only 2 had both tissues in the defect site. 
 
Table 6.2.  Induction of cartilage and/or immature bone by microencapsulated rbASCs. Data are 
the number of samples with new tissue in the defect site v. the number of total sites in a given 
group. 
 
Defect Cartilage 
Bone-like 
Tissue 
Cartilage or 
Bone-like 
Tissue 
Cartilage and Bone-
like Tissue 
Empty 1/6 4/6 4/6 1/6 
uBs with ASCs 7/11 7/11 11/11 3/11 
uBs without ASCs 4/10 6/10 7/10 3/10 
Deg. uBs with ASCs 4/8 6/8 7/8 4/8 
Autograft 4/11 7/11 9/11 2/11 
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There was no evidence of inflammation in any of the treatment sites.  Alginate lyase 
enzyme and the byproducts of alginate lyase mediated degradation did not lead to the infiltration 
of leukocytes. Similarly, defects that received only alginate microbeads with and without rbASCs 
did not exhibit an inflammatory response after 12 weeks. 
 
6.4. Discussion  
 The therapy presented in this work packaged ASCs into injectable alginate microbeads that 
are 200 µm in diameter and tested their ability to support cartilage regeneration in critical size 
auricular cartilage defects.  The results indicate that neocartilage formation can be achieved but 
the chondrogenic regimen used to pretreat the ASCs led to a phenotype more typical of 
commitment to an osteochondral lineage than to an elastic cartilage lineage. Moreover, 
characteristics of the rabbit ear model, particularly the vasculature in the overlying skin, may have 
contributed to the formation of immature bone in the regenerated tissues. 
rbASCs have been used in tissue regeneration models for bone, cartilage, and cornea, but 
it has not been explicitly demonstrated that these stem cells are multipotent [84-86]. Our results 
show that, like rat and human ASCs [2, 87], rbASCs are multipotent and are able to differentiate 
along osteogenic, adipogenic, and chondrogenic lineages.  Expression of mRNAs for phenotypic 
marker proteins was significantly higher in the respective differentiation media compared to 
control cultures. Additionally, all histological stains confirmed that rbASCs are able to 
differentiate along all three lineages.  
Microencapsulated rbASCs maintained their chondrocyte phenotype after encapsulation.  
They expressed mRNAs for aggrecan (ACAN) and type 2 collagen (COL2), both of which are 
extracellular matrix proteins found in hyaline cartilage.  They also expressed mRNAs for type X 
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collagen, which is typically found in hypertrophic growth plate chondrocytes, suggesting that these 
cells primed the regenerating tissue to support endochondral bone formation.  The 
microencapsulated rbASCs secreted TGFβ2 and TGFβ3, both of which are associated with 
chondrogenesis [88], indicating that their presence in the defect sites may have contributed to 
neocartilage formation.  The CM-treated rbASCs also secreted BMP2, an osteogenic factor, but 
not to a greater extent than the GM treated cells.  Moreover, treatment with CM lead to a marked 
reduction in VEGF secretion.  Taken together, these data suggest a complex cocktail of factors 
was generated by CM treatment that caused an endochondral lineage commitment while at the 
same time, reducing the vasculogenesis in the repair tissue generally associated with ossification.  
We selected the rabbit ear as a model to test the effectiveness of the microbeads in 
regenerating cartilage based on published reports using this method [89, 90].We were able to 
define criteria for a critical size defect in the rabbit ear cartilage.  Based on our findings, the 3 mm 
defect was chosen due to its size for microbead implantation and ease of manipulation during 
surgery.  
However, our results using multiple end points indicate that there are limitations that must 
be taken into consideration in future study designs.  It should be noted that although autografts 
maintained the structural properties of cartilage, there was no reintegration of the autograft with 
the cartilage bed. In addition immature bone like tissue was present in all of the treatment groups.  
This was unexpected, given that the rbASCs were pretreated with CM and produced factors 
associated with chondrogenesis. The CM-treated rbASCs did not produce elastin, the hallmark of 
elastic ear cartilage, suggesting that they had not fully differentiated along an auricular 
chondrocyte lineage prior to implantation. Our results indicate that factors present in the 
surrounding tissue were insufficient to support auricular chondrocyte differentiation of the 
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implanted microencapsulated cells, at least over the time frame of the study. Moreover, the tissue 
overlaying the auricular cartilage is highly vascularized and bleeding during microbead placement 
may negatively impact chondrogenesis. These results are consistent with other reports of bone 
formation in auricular cartilage defects from tissue engineered constructs [91].   
Even with these limitations, our results show that the formatting of the rbASCs contributed 
to the degree of chondrogenesis that was observed in the defects.  The greatest amount of 
neocartilage was generated in sites implanted with non-degradable microbeads containing CM-
treated rbASCs.  These cells not only secreted higher levels of TGFβ2 and TGFβ3 than GM-treated 
rbASCs, but they retained these factors within the microbead itself.  Moreover, VEGF secretion 
was markedly reduced.  This suggests that secreted factors remained in a concentrated area within 
the defect leading to the induction of new cartilage and suppression of vasculogenesis. The 
neocartilage was present in small islands of tissue within the defect, and in one case, nearly 
spanned the full width of the defect. Although we expected to see the microbeads remaining in the 
tissue after 12 weeks, they were no longer present in most samples, possibly due to enzyme activity 
from neighboring defects containing degradable microbeads.  
Degradable microbeads containing rbASCs also supported neocartilage formation, but to a 
lesser extent than the non-degradable beads containing rbASCs.  However, production of bone-
like tissue was highest in this group.  Highly attenuated tissue on microCT corresponded to 
immature bone-like tissue based on Masson’s trichrome stained sections [92]. One possibility is 
that the CM-treated rbASCs released from these microbeads had a more hypertrophic chondrocyte 
phenotype than those retained in a rounded hyaline cartilage cell shape within the non-degradable 
microbeads, and as such supported endochondral ossification within the defect. The degradable 
microbeads were designed to release cells approximately 4 to 6 days post-implantation [34].  In 
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contrast, the retention of cells within the non-degradable microbeads may have allowed the defect 
site to have more exposure to the chondrogenic factors, thereby affecting chondrogenic 
differentiation of surrounding cells.   
 
6.5. Conclusions 
Cell-based therapy will be beneficial to patients in need of cartilage regeneration for 
craniomaxillofacial problems. Multipotent rbASCs formatted in alginate microbeads 200 
micrometers in diameter can be delivered to auricular cartilage defects to stimulate 
chondrogenesis.  Our results using a rabbit auricular cartilage critical size defect model suggest 
that it may be necessary to specifically induce rbASCs along an auricular cartilage cell lineage to 
ensure elastic cartilage formation without new bone formation in a well vascularized site.  
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CHAPTER 7 
 
7.1 Discussion 
Approximately 5-20% of fractures end in non-union due to the lack of growth factors and 
stem cells to aid in regeneration and repair. In some cases, the defect gap is too large for the body 
to heal on its own with bone [1]. Bone regeneration requires three important factors – cellular 
components, growth and differentiating factors, and a scaffold matrix. Cellular components from 
either exogenous cell sources or the local environment can give rise to new structural tissue. 
Growth and differentiating factors can guide the development of cellular components. Both factors 
can be provided exogenously using purified proteins or implanted cells secreting proteins and 
endogenously from extracellular matrix deposits generated by resident tissue cells. Where there is 
insufficient endogenous matrix to provide a substrate for cellular attachment, proliferation and 
differentiation, it is also necessary to provide a scaffolding structure [16].      
Three approaches have been applied to the tissue engineering of bone: (1) matrix-based 
therapies, (2) factor-based therapies, and (3) cell-based therapies [16]. Matrix-based therapies use 
an implant to provide structure and stability. This approach depends on the recruitment of 
endogenous osteoprogenitors to repair the fracture. The implant’s surface aids in the regeneration 
process by initiating MSC differentiation. Commonly used implants are constructed from titanium, 
ceramics or hydroxyapatite. These implants tend to be porous and facilitate ingrowth of bone into 
the pores however, the lack of their ability to induce bone formation limits their use significantly. 
Although hydroxyapatite has been proven to be a good support for cell and matrix interactions in 
bone formation, it requires many years before complete resorption occurs. In contrast, factor-based 
therapies supply osteoinductive stimuli, which otherwise may not be present or insufficient. 
Delivering growth factors has been successful in forming bone but is limited by the difficulty in 
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translating results from rodent models to larger animals. In addition, the optimal method to deliver 
and present these factors remains a challenge.  
Cell-based therapies use the approach of delivering cells directly to the defect site. It is 
challenging to determine which factors are needed in any injury site. The cell-based approach does 
not rely on endogenous stem cells to produce new bone or growth factors; instead these factors are 
produced by the cells that are delivered, thereby compensating for the growth factor deficiency 
[16]. Cell-based therapies are particularly advantageous where the host tissue beds are 
compromised and in cases where the patients suffer from severe trauma or diabetes or patients 
with a limited number of osteoprogenitor cells because of age or osteoporosis.  
Cell-based therapies may employ various cell types, including unfractionated bone 
marrow, purified and cultured expanded MSCs, differentiated osteoblasts or chondrocytes, or cells 
modified genetically to produce factors like rhBMP.  Fresh bone marrow aspirates contain 
osteogenic precursors, however a significant amount of bone marrow is required to acquire 
sufficient cells thus making it an impractical source for large defects.  An alternative source is 
autologous MSCs that have been expanded ex vivo. MSCs that have been differentiated along the 
osteogenic or chondrogenic lineage may also be used. Studies with pre-differentiated osteoblasts 
combined with an implant have shown the production of significantly more bone.  The last type of 
cells are used for the delivery vehicle of genetic material coding for BMP2 [16].  
The cell-based therapy developed in this thesis is a combination of applying the factor-
based and cell-based approach. The factor-based approach is demonstrated by the growth factors 
secreted by microencapsulated ASCs once they were cultured in MSCGM or differentiation media. 
In our application, the matrix, alginate, was primarily used for localizing the cells rather than to 
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provide an attachment substrate for the cells. However, others have modified the polymer to 
provide attachment sites as well as bioactive ligands [93, 94].  
Alginate microbeads are used as a mode of cell delivery in a number of fields and has great 
potential for tissue regeneration. Our approach has differed from previous work by generating 
microbeads that are less than 200 m in diameter, thereby ensuring adequate mass transport to 
retain cell viability.  Using this technology as my base, I have shown that these microencapsulated 
cells are able to produce growth factors that will aid in tissue regeneration, thus displaying their 
therapeutic potential. I have developed a method to control the release of cells from alginate 
microbeads using alginate lyase. Furthermore when placed in vivo I have demonstrated that 
degradable and non-degradable microbeads localize cells at the delivered site.  
To investigate the ability of the microbead cell delivery system to facilitate tissue 
regeneration, we used a rabbit ear cartilage critical size defect model using rbASCs. Delivery of 
CM-treated rbASCs in alginate microbeads supported chondrogenesis, particularly when 
nonresorbable microbeads were used. Immature bone-like tissue was present in most of the 
treatment sites, but this was especially the case in sites treated with degradable microbeads.  This 
may have been due to higher VEGF levels secreted by rbASCs or the presence of many veins at 
the site. Therefore to fully achieve elastic cartilage regeneration rbASCs may require a specific 
culture regime that would prevent the cells from going along an endochondral ossification 
pathway. In addition, another animal model could be used to assess the ability of 
microencapsulated rbASCs to regenerated elastic cartilage.  
Many human trials investigating the use of stem cells have not been completed or were 
unable to assess the full potential of the use of stem cells partly due to the loss of cells after 
delivery.  Alginate microbeads are known to localize cells and therefore may enable the completion 
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of human clinical studies assessing the effect of cell-based therapies on musculoskeletal defects. 
The delivery system could be adapted for any other tissue once the appropriate cells are 
microencapsulated. Microencapsulated cells are great for the production angiogenic factors 
namely VEGF and FGF because of the minimally hypoxic microbead environment. Therefore, 
microencapsulated stem cells would be effective in delivering angiogenic factors where 
angiogenesis is needed. Angiogenesis is critical to wound healing, therefore microbeads could be 
used in wounds that are difficult to heal. Microencapsulated ASCs in the muscle resulted in the 
formation of adipose tissue and therefore could be useful in clinical settings where a void space is 
remaining after a surgical procedure. Additional applications of the alginate microbead system 
could be the delivery of any pharmaceutical products, even nanoparticles to aid in other treatments 
since the degradation kinetics are controllable. 
This delivery system enables the use of cell-based personalized medicine by 
microencapsulating patient’s cells. This approach reduces the possibility for immune rejection. We 
have also shown that only a few number of microbeads would be needed containing a small number 
of cells which is particularly advantageous for patients with a small number of available stem cells. 
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APPENDIX A 
 
Osteoinductive Nature of Microencapsulated ASCs 
 
Summary 
Bone regeneration can be aided by bone graft substitutes due to their osteoconductive 
properties. Some of the current bone graft substitutes are not osteoinductive. We have developed 
a system of degradable and injectable alginate microbeads to deliver stem cells. ASCs secrete 
osteogenic and angiogenic growth factors. ASCs treated with OM or OM-d have shown osteoblast 
like properties. Therefore, we investigated the ability of microencapsulated ASCs derived from 
different species to induce ectopic bone in different models. All ASCs were pretreated with 
MSCGM or OM or OM-d. Microencapsulated ASCs were not osteoinductive. However, we 
observed the formation of additional adipose tissue indicating that the ASCs delivered supported 
adipogenesis. 
A.1 Introduction 
The gold standard for bone repair is an autologous source of bone. Autografts have 
osteogenic properties and provide structural support for new bone growth, however it is not 
osteoinductive. Autografts can be used from the patient’s iliac crest but at least 25% of the patients 
still report the experience of pain two years after the procedure. In addition, autografts are 
associated with donor site morbidity. An alternative approach for bone formation is growth factors. 
BMP2 and BMP7 are Food and Drug Administration (FDA) approved growth factors for bone. 
These two members of the BMP2 family achieve bone formation by initiating a cascade of events 
resulting in the cells secreting extracellular matrix that is characteristic of bone. Osteopromotive 
growth factors such as VEGF and FGF aid in bone formation once the process begins and leads to 
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better healing, but by themselves are not osteoinductive. Growth factors can be derived from living 
tissue – human or bovine bone, recombinant proteins or gene therapy [95]. To harness the 
effectiveness of growth factors the dose, delivery method and release kinetics must be optimized.  
Biomaterials induce bone in ectopic sites by initiating a cascade of events resulting in 
MSCs undergoing osteogenic differentiation [96]. The roughness, porosity or the chemical 
components of the biomaterial are responsible for initiating the cascade of events. The presence of 
calcium phosphate has been shown to play an important role in inducing bone [97, 98]. The bone 
may form by intramembranous ossification or endochondral ossification if BMP2 is present [97, 
99, 100]. The cascade of events involve the chemotaxis of undifferentiated MSCs followed by cell 
proliferation. The next steps only occur in the presence of BMP2 - cells are differentiated into 
chondrocytes with cartilaginous extracellular matrix; chondrocytes go through maturation, 
hypertrophy and calcification; blood vessel and osteoprogenitor infiltration, cartilage removal, 
osteoid apposition and bone matrix production; bone marrow formation and bone remodeling [83]. 
ASCs are multipotent and upon induction with differentiation media, secrete osteogenic 
growth factors including BMP2. Therefore ASCs could be used a source of growth factors for 
orthopedic tissue engineering. However, ASCs delivered as a suspension will not remain in the 
site of delivery. Providing a reliable delivery system, ASCs could be delivered to the site of interest 
and aid in the regeneration process by secreting osteogenic factors.  
ASCs can be microencapsulated into alginate microbeads as a mode of delivery. 
Microencapsulated ASCs remain viable for as long as three weeks. ASCs derived from mice, rats 
and rabbits have shown the production of VEGF and BMP2 with and without induction media. 
OM treatment with microencapsulated rASCs and mASCs display a reduction in VEGF, however 
VEGF production is regained once dexamethasone is removed from OM. rbASCs produced higher 
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amounts of VEGF than ASCs from mice or rats. Given the osteopromotive nature of VEGF we 
first investigated the ability of microencapsulated rbASCs to induce ectopic bone in male New 
Zealand white rabbits. We also investigated the ability of microencapsulated ASCs derived from 
mice and rats to induce ectopic bone in athymic nude mice (an American Society of the 
Interanational Association for Testing and Materials (ASTM) model) [101]. 
A.2. Methods 
A.2.1 Adipose Derived Stem Cells 
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], a male New 
Zealand rabbit, male C57 Black 6 mice (n=6) under an Institutional Animal Care and Use 
Committee (IACUC) approved protocol at the Virginia Commonwealth University. Briefly, the 
inguinal fat pad was removed and transferred to a container with Dulbecco’s modified Eagle 
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3% sterile-filtered L-glutamine-
penicillin-streptomycin (P/S). The tissue was washed three times with Hank’s balanced salt 
solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–ethylenediaminetetraacetic acid 
(EDTA) for 30 minutes on a rocker at 37°C. Following trypsinization, the supernatant was 
discarded. Adipose tissue was cut into small pieces and incubated in a digestive cocktail containing 
collagenase type I (365 units/mL) (Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad, 
CA) for four hours. After incubation, the oily upper layer was removed and the digest was 
quenched with an equal amount of MSCGM. The cells were separated, plated in T-175 flasks at 
5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2. For the next two days the 
monolayers were washed with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen) and fed 
with MSCGM every 24 hours. Thereafter media were changed every 48 hours and cells were 
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cultured to confluence. ASCs were then cultured in either MSCGM, OM or OM without 
dexamethasone for an additional seven days before microencapsulation. 
A.2.2 Microencapsulated Cells 
To form microencapsulated cells, rASCs were encapsulated in UV-sterilized medical grade 
alginate (50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC 
BioPolymer) at a concentration of 10 x 106 cells/ml and crosslinked in a calcium solution. Medical 
grade alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a 
concentration of 40 mg/ml. Microbeads incorporating cells were created using a Nisco 
Encapsulator VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow 
rate, nozzle with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a calcium 
crosslinking solution. The crosslinking solution contained 50 mM CaCl2, 150 mM osmolyte with 
15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPES-
buffered) [5, 23]. Alginate microbeads were allowed to crosslink for an additional 10 minutes, 
washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the 
respective media. Microencapsulated ASCs were cultures overnight in the media they were 
previously cultured. 
A.2.3 Degradable Alginate Microbead Production 
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of 
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml. 
Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was 
mixed at 1000 rpm for one minute to produce 0.22 U alginate lyase/g. The alginate/alginate lyase 
mixture was used to form microbeads using a crosslinking solution containing 75 mM CaCl2, 90 
mM glucose and 10 mM HEPES using the same flow rate, nozzle and electrostatic potential 
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described above. The 0.44 U/g alginate mirobeads were made similarly by starting with 0.44 U 
alginate lyase/ml solution. 
A.2.4  Osteoinductivity of ASCs 
6.2.4.1 Rabbit Ectopic Study 
rbASCs were cultured in MSCGM or OM for 7 days prior to microencapsulation. Non-
degradable (0U/g) and degradable microbeads (0.22 U/g) incorporating these rbASCs were made 
on the day before implantation. Microencapsulated rbASCs were loaded into a gelatin capsule and 
implanted in the gastrocenmious and rectus femoris of both rabbit legs for 6 weeks. 
A.2.4.1.1 Micro CT 
All samples were scanned in air using a µCT 40 (Scanco Medical) at 45 kVp, 200 µA, 600 
ms integration time, and a voxel size of 35 µm. Images were processed using the accompanying 
Scanco medical software. A constant volume of interest representing the absolute volume centered 
at the defect cavity was used for the analysis of each sample.  
A.2.4.2 Athymic Nude Mice Ectopic Study (osteoinductive nature of microencapsulated rASCs) 
 rASCs were cultured in MSCGM, OM, or OM without dexamethasone for 7 days before 
microencapsulation. rASCs from each treatment group were microencapsulated into non-
degradable (0 U/g) and degradable microbeads (0.22 U/g and 0.44 U/g) and stored overnight in 
the respective media that incorporated cells treatment. To investigate the osteoinductive potential 
of rASCs, microencapsulated rASCs (100 ul) were injected to the gastrocenious of both legs for 8 
weeks. In addition, to investigate the time of rASCs release on ectopic bone formation, microbeads 
of different release profiles were used. 
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A.2.4.3 Athymic Nude Mice Ectopic Study (osteoinductive nature of microencapsulated mASCs) 
 mASCs were cultured in MSCGM or OM for 7 days prior to microencapsulation. Cells 
were microencapsulated into degradable microbeads (0.22 U/g) and stored in MSCGM or OM 
overnight. The next day, alginate microbeads were loaded in gelatin capsules with very small 
amounts of demineralized bone matrix for 8 weeks.  
A.2.5 Histology 
After 48 h of fixation in formalin, samples were decalcified for 5 days using .Following 
that samples were dehydrated in a series of 95% and 100% ethanol and xylene washes. Samples 
were embedded in paraffin, and cut into 8-μm thick sections (Shandon Finesse 325, Thermo 
Scientific). The sections were stained with haematoxylin and eosin, and then imaged with a Leica 
DMLB microscope (Leica Microsystems, Bannockburn, IL).  
A.2.6 Statistics 
The results from the  in vivo study were calculated as the means ± SEM of both legs of 4 
animals per variable thus providing an N or 8 for all studies except the rabbit in vivo study where 
an N of was used.. Statistically significant differences between groups were determined by 
Student’s t-test. P values ≤ 0.05 were considered significant. Data presented are from 
representative experiments. 
A.3. Results 
A.3.1 rbASCs are not osteoinductive 
 Demineralized bone matrix, a positive control did not induce ectopic bone (Fig. A.1). Both 
degradable and non-degradable microencapsulated rbASCs produced radio-opaque deposits after 
6 weeks. Microbeads in the non-degradable groups were present after six weeks with no new bone 
tissue present in both GM and OM treated groups The OM pretreated groups produced 
significantly higher amounts of radio-opaque tissue. Degradable microbeads were not present after 
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6 weeks. Differently stained tissue with a non-muscle morphology was also observed in both GM 
and OM groups. None of the samples induced ectopic bone (Fig. A.2).  
 
Figure A.1: H&E staining of DBM implanted in male White New Zealand rabbit after 6 weeks. 
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Figure A.2: H&E staining of microbeads in rabbits after 6 weeks, (A) GM treated rbASCs, (B) 
OM treated rbASCs microencapsulated in non-degradable alginate microbeads and (C) GM treated 
rbASCs, (D) OM treated rbASCs microencapsulated into degradable alginate microbeads. 
 
Figure A.3: Micro CT analysis of osteoinductivity of rbASCs. (A) Volume of radio-opaque tissue. 
A.3.2 rASCs are not osteoinductive 
 DBM induced ectopic bone (Fig. A.4). Non-degradable microencapsulated rASCs were 
still present after 8 weeks in all samples across all treatment groups. Although microbeads were 
injected in the gastrocnemius, the microbeads were present in other portions of the leg due to the 
volume injected compared to the size of the animal’s leg. Non-degradable microbeads did not 
induce the formation of ectopic bone.  
 Degradable microbeads (0.22 U/g) incorporating rASCs, were not present after 8 weeks. 
However remnants of the microbeads were present in very small amounts. In the immediate area 
of the degraded alginate microbead, tissue with different staining and morphology compared to 
muscle was observed, but samples did not induce the formation of ectopic bone (Figs. A.5D – 
A.5E). 
Degradable microbeads with the fastest cell release (0.44 U/g) also did not lead to any 
ectopic bone. Similar new tissue was observed in the muscle with fewer remnants of degraded 
 clv 
 
alginate. Nonetheless these microencapsulated rASCs did not induce any ectopic bone. The 
different degradation time points did not have any correlation to the volume of new tissue formed. 
 
Figure A.4: H&E staining of DBM implanted in male athymic nude mice after 8 weeks 
 
Figure A.5: H&E staining of rASC osteoinductivity in athymic nude mice after 8 weeks, (A) GM 
treated rASCs, (B) OM treated rASCs, (C) OM-d treated rASCs microencapsulated in non-
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degradable alginate microbeads, (D) GM treated rASCs, (E) OM treated rASCs, (F) OM-d treated 
rASCs microencapsulated into degradable alginate microbeads (0.22 U/g), and (G) GM treated 
rASCs, (H) OM treated rASCs, (I) OM-d treated rASCs microencapsulated into degradable 
alginate microbeads (0.44 U/g). 
A.3.3 mASCs are not osteoinductive 
Regardless of the pre-treatment received, both microencapsulated groups resulted in the 
formation of new adipose tissue (Figs. A.6 and A.7). In addition another type of tissue with a non-
muscle or bone-like morphology was also observed directly beside the inactive demineralized bone 
matrix. All the degradable microbeads were not present after 8 weeks. 
 
Figure A.6: H&E of mASC osteoinductivity in the gastrocnemius of athymic nude mice after 8 
weeks, (A) GM treated mASCs and (B) OM treated mASCs microencapsulated into degradable 
alginate microbeads (0.22 U/g). 
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Figure A.7: Area of adipose tissue after microencapsulated mASCs were implanted in the 
gastrocnemius for 8 weeks. 
A.4. Discussion 
The demand for osteoinductive materials is always present. Bone induction is achieved by 
queues that will lead to the recruitment of MSCs to the local area and subsequent osteogenic 
differentiation. The standard for testing the osteoinductive nature of biomaterials is implanting the 
biomaterial into the gastrocnemius (a non-bone site) of an athymic nude mice. Microencapsulated 
ASCs derived from rat, mouse, rabbit and human are able to secrete osteogenic growth factors 
including BMP2 once induced with OM. BMP2 is known to be a potent growth factor in initiating 
bone growth. However, other proteins are also important in the formation of bone. One of the 
advantages the cell-based approach to bone formation is cells are able to secrete a plethora of 
growth factors to aid in bone regeneration. We have quantified BMP2 and VEGF levels secreted 
by microencapsulated ASCs derived from four species. Results showed that rabbits were able to 
secrete higher total levels of VEGF compared to rASCs. Given the importance of angiogenic 
factors in bone formation, we first investigated the ability of microencapsulated rbASCs to induce 
ectopic bone. After 6 weeks our histological analysis did not confirm that the radio-opaque tissue 
was indeed bone. Although VEGF is important for bone formation it is not the only factor needed. 
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In addition, it is possible that a longer time for treatment could be required for rbASCs to induce 
bone in vivo. However the formation of new tissue was observed in few samples. This new tissue 
was not similar to muscle or bone and would therefore requires additional analysis to determine 
the type of tissue formed. In the remaining samples, it is possible that the microbeads were 
displaced to other locations of the muscle since the inactivated demineralized bone matrix could 
not be located on histological sections. 
In addition to VEGF and BMP2, microencapsulated rASCs are known to secrete 
ostreocalcin, FGF and osteoprotegerin, all of which are important in bone formation. We have 
shown a reduction (not detectable in some cases) in angiogenic factor production once 
microencapsulated rASCs were treated with OM. OM-d treatment of microencapsulated rASCs 
showed the production of both angiogenic and osteogenic factors, which are both crucial for bone. 
Therefore, we investigated the osteoinductive nature of microencapsulated rASCs by using the 
ASTM method. After 8 weeks, microencapsulated rASCs previously treated with GM, OM, OM-
d did not form ectopic bone. This could be due to the quantity of microbeads delivered. It is 
possible that a large number of microbeads incorporating cells need to be localized in the same 
area, however this was difficult to achieve because of the small muscle size and delivering the 
microbeads by an injection. In addition, a longer in vitro culture time may be necessary for the 
cells to secrete more growth factors to produce bone.  
 Having used the ASTM standard to determine the osteoinductive nature of 
microencapsulated rASCs which is a xenograft model, we investigated an allograft model using 
the ASTM standard by implanting microencapsulated mASCs. At the end of 8 weeks a large 
amount adipose tissue was formed. This is not surprising since ASCs were implanted. Even though 
mASCS were previously cultured in GM and OM. Similar amounts of adipose tissue was found in 
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both groups (Fig. A.7). This indicates that a longer treatment time with OM may be needed to 
achieve the desirable results. Studies have shown that mineralization occurs at later time points. 
Therefore it is possible that with a longer treatment time ectopic bone could be formed. There was 
newly formed tissue around the inactivated demineralized bone. Additional experiments must be 
done to investigate whether or not the newly formed tissue is bone and whether it was only due to 
the presence of the inactivated bone or delivered ASCs. Some studies have shown that with the 
presence of a rough surface alone can encourage new bone formation therefore it is possible that 
the inactivated DBM provides a rough surface for the ASCs. In that case the ASCs may need to be 
co-delivered with a material that has rough surface. 
A.5. Conclusions 
Microencapsulated ASCs isolated from mice, rats and rabbits did not form bone 
ectopically. Microencapsulated mASCs lead to the engraftment of adipose tissue.  
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APPENDIX B 
 
Microencapsulated rASCs Support Osteogenesis in a Unicortical Diaphyseal 
Defect 
 
Summary  
 Bone graft substitutes have been successful in aiding bone regeneration. Recently, it has 
been shown that based on the chemical composition, bone graft substitutes can alter the bone 
remodeling process and limit the bone marrow cavity regeneration. An alternative approach is to 
use cell-based therapies, however their effect on bone remodeling have not been investigated. One 
cell-based approach is to deliver microencapsulated ASCs using alginate microbeads. 
Microencapsulated ASCs have previously shown to remain viable up to 3 weeks in vitro. In this 
study we investigated the effect of microencapsulated rASCs that were previously pretreated with 
MSCGM or OM. Degradable and non-degradable microbeads incorporating rASCs were placed 
in a 3 mm unicortical diaphyseal defect. Some defects were left either empty or filled with fresh 
frozen allograft as a negative or positive control respectively. Our results showed that all defects 
healed, both cortical bone and bone marrow were recovered. Samples receiving degradable 
microbeads incorporating ASCs that were pretreated with OM produced more bone within the 
defect. 
B.1. Introduction 
Defects in the skeletal system due to injury or disease can be repaired with bone graft 
substitutes. Bone graft substitutes usually have one or more of the following components; 
osteoinductive proteins that are able to initiate bone formation among the surrounding cells, 
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osteoconductive matrix to allow the new bone formed to adhere, and osteogenic cells which have 
the ability to form bone [102]. The bone graft substitutes may be autologous, allografts or other 
materials comprised of hydroxyapatite, PLGA, tricalcium phosphate, and bioglass amongst others. 
An autologous bone graft is normally removed from the iliac crest. This is an excellent solution 
but can be difficult to harvest and may be coupled with complications, thus creating a need for 
alternative solutions. The bone graft substitutes are typically implanted into the defects which may 
be accompanied by external fixation depending on the size of the defect. Once the bone graft 
substitute is placed within the fracture a hematoma forms releasing cytokines and growth factors. 
An inflammatory reaction occurs to the trauma of the surgery and to the material of the substitute. 
This is very important as it leads degranulation and the release of growth factors that will initiate 
migration and proliferation of MSCs and fibrovascular tissue in and around the graft. Blood vessels 
begin to invade through existing Haversioan or Volkman canals leading to osteocalst resorption of 
graft surfaces. Lastly, bone formation occurs on the graft surfaces [12]. Depending on the type of 
material, it may contain inherent factors that will to initiate bone growth. Success of bone graft 
substitutes have been achieved however previous studies have shown that the chemical 
composition is able to inhibit the remodeling of the bone marrow [103]. The bone marrow is 
normally remodeled by a series of capillary invasion in the area which carries the MSCs [104]. 
The main function of the bone marrow is to generate blood cells and store fat. In addition the bone 
marrow has many hemapoetic stem cells and mesenchymal stem cells. Therefore without the 
presence of the bone marrow the complete function of the bone is not possible.  
Another approach to heal fractures is to use cell-based therapies which bring the advantage 
of stem cells secreting factors that may be absent at the fracture site or providing additional cells 
if the host’s stem cells are not enough. Previously, we have developed a system of 
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microencapsulating ASCs into alginate microbeads which allows the cells to remain viable for up 
to 3 weeks in vitro. The microencapsulated stem cells have also shown the ability to secrete 
osteogenic and angiogenic factors once they are treated with differentiation media. One of the 
advantages of this system is that the release of the stem cells can be controlled in a time dependent 
manner by using an enzyme known as alginate lyase. This enzyme works by cleaving the 
glycosidic bonds. As the cells are released from these microbeads they also maintain their viability 
and ability to secrete osteogenic and angiogenic growth factors after induction with differentiation 
media.  
As a stem cell therapy it is important to determine whether the microencapsulated ASCs 
are able to aid in the bone regeneration process and whether or not it inhibits the remodeling of the 
bone marrow. Therefore in this study we created a unicortical diaphyseal defect in the femur and 
delivered microencapsulated rASCs pretreated with MSCGM, OM, or OM-d for 8 weeks to 
determine the effects of this cell-based therapy on osteogenesis and bone marrow remodeling.  
B.2. Methods 
B.2.1 Adipose Derived Stem Cells 
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], under an 
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute 
of Technology and the Virginia Commonwealth University. Briefly, the inguinal fat pad was 
removed and transferred to a container with Dulbecco’s modified Eagle medium (DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 3% sterile-filtered L-glutamine-penicillin-
streptomycin (P/S). The tissue was washed three times with Hank’s balanced salt solution (HBSS) 
(Invitrogen) and then incubated in 0.25% trypsin–ethylenediaminetetraacetic acid (EDTA) for 30 
minutes on a rocker at 37°C. Following trypsinization, the supernatant was discarded. Adipose 
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tissue was cut into small pieces and incubated in a digestive cocktail containing collagenase type 
I (365 units/mL) (Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. 
After incubation, the oily upper layer was removed and the digest was quenched with an equal 
amount of MSCGM. The cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and 
cultured in MSCGM at 37 °C and 5% CO2. For the next two days the monolayers were washed 
with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen) and fed with MSCGM every 24 
hours. Thereafter media were changed every 48 hours and cells were cultured to confluence. ASCs 
were then cultured in either MSCGM, OM or OM without dexametasone for an additional seven 
days before microencapsulation. 
B.2.2 Microencapsulated Cells 
To form microencapsulated cells, rASCs were encapsulated in UV-sterilized medical grade 
alginate (50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC 
BioPolymer) at a concentration of 10 x 106 cells/ml and crosslinked in a calcium solution. Medical 
grade alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a 
concentration of 40 mg/ml. Microbeads incorporating celwere created using a Nisco Encapsulator 
VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle 
with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a calcium crosslinking 
solution. The crosslinking solution contained 75 mM CaCl2, 90 mM osmolyte with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPES-buffered) [5]. 
Alginate microbeads were allowed to crosslink for an additional 10 minutes, washed with 0.9% 
(w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the respective media. 
Microencapsulated ASCs were cultures overnight in the media they were previously cultured. 
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B.2.2.1 Degradable Alginate Microbead Production 
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of 
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml. 
Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was 
mixed at 1000 rpm for one minute to produce 0.22 U alginate-lyase/g alginate. The 
alginate/alginate lyase mixture was used to form microbeads using a crosslinking solution 
containing 75 mM CaCl2, 90 mM glucose and 10 mM HEPES using the same flow rate, nozzle 
and electrostatic potential described above. 
B.2.3 Unicortical Diaphyseal Defect 
To determine if microencapsulated rASCs would prevent the remodeling process 
microbeads were placed in a unicortical defect for 8 weeks. A defect was created on the proximal 
portion of the femur with a trephine (3 mm inner diameter). To reduce the blood flow from the 
marrow cavity, pressure was applied using gauze to the newly created defect before implanting 
microbeads in the defect.  
B.2.4 Histology 
After 48 h of fixation in formalin, samples were decalcified for 5 days using .Following 
that samples were dehydrated in a series of 95% and 100% ethanol and xylene washes. Samples 
were embedded in paraffin, and cut into 8-μm thick sections (Shandon Finesse 325, Thermo 
Scientific). The sections were stained with haematoxylin and eosin, and then imaged with a Leica 
DMLB microscope (Leica Microsystems, Bannockburn, IL).  
B.2.5 Histomorphometrics 
 A region of interest around the defect was chosen or all samples. The area of connected 
cortical bone was measured and unconnected bone in the marrow cavity was also quantified as 
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trabecular bone. The remaining area within the bone marrow was quantified as bone marrow 
cavity. 
B.2.6 Statistics 
The results from the in vivo study were calculated as the means ± SEM of both legs of 4 
animals per variable thus providing an N or 8. Statistically significant differences between groups 
were determined by Student’s t-test. P values ≤ 0.05 were considered significant. Data presented 
are from representative experiments. 
B.3. Results 
B.3.1 Both bone marrow and cortical bone were recovered 
Defects that were not filled with microbeads (empty) during surgery healed within 8 weeks 
with both cortical and bone marrow recovering. The application of fresh frozen allografts to defects 
resulted in cortical bone recovery in 7 of 8 samples, however the bone marrow was not fully 
recovered in most samples where pieces of allograft were still remaining after 8 weeks. 
 
Figure B.1: H&E staining of the defect site in the femur after 8 weeks. 
Non-degradable microbeads as expected were present after 8 weeks in the cortical bone, 
bone marrow cavity, and area directly outside of the defect (opposite to the marrow cavity). In 
non-degradable groups, all samples healed with both cortical bone and bone marrow recovering 
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independent of rASC pretreatment. In the cortical and trabecular bone, bone formed around the 
microbeads making complete contact with the microbead’s surface. 
Degradable microbeads were not present within the defects after 8 weeks. All the defects 
healed completely with one sample either in the GM and OM group generating additional bone 
attached to the femur. Microbeads were not present after 8 weeks and no indications of an 
inflammatory response. The area of new bone in the defect site was significantly higher in the OM 
group compared to the empty. 
 
Figure B.2: H&E staining of unicortical defects receiving non-degradable microencapsulated 
rASCs pretreated with A) GM, B) OM, C) OM-d or degradable microencapsulated rASCs 
pretreated with D) GM, E) OM, F) OM-d after 8 weeks. 
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Figure B.3: Histomorphometric analysis of (A) cortical bone (B) trabecular bone and (C) marrow 
cavity of the unicortical diaphyseal defect after 8 weeks.  
B.4. Discussion 
Therapies for fractures or non-unions have the primary goal of facilitating bone 
regeneration without inhibiting the bone remodeling process. Previously, it has been shown that 
the chemical composition of bone graft substitutes can inhibit the bone remodeling process by 
delaying the marrow recovery [103]. Stem cells are multipotent and can be delivered in vivo by 
using alginate microbeads. The paracrine effect of growth factors produced by stem cells can be 
used to facilitate bone regeneration. This cell-based therapy involves alginate microbeads, ASCs 
and alginate lyase for degradation. However the effects of alginate lyase and the by-products of 
alginate lyase mediated degradation on bone remodeling are known. As this cell-based therapy is 
developed it is important that it does not inhibit the bone remodeling process. Therefore we 
investigated the effect of microencapsulated rASCs on bone remodeling.  
The results showed that microencapsulated rASCs did not inhibit the bone remodeling 
process. All non-degradable sample as healed well more importantly newly formed bone was able 
to form around the alginate microbeads indicating that the surface of alginate beads are 
osteoconductive. There was also a trend of more bone being present in the samples compared to 
empty defect which may be due to the growth factors secreted by encapsulated stem cells. 
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Naturally derived hydrogels have been used for bone repair due their biocompatibility and 
tunability. The mechanical properties of these hydrogels are not well suited for bone. 
All samples receiving degradable alginate microbeads healed well and reflected a similar 
trend of more bone being present within the region of interest. The osteogenic media pretreated 
groups produced more bone which could be due to the cells differentiating along the osteogenic 
path and enhancing the bone healing. In one sample extra bone was present in the GM and OM 
group. This may have resulted from the factors secreted from the encapsulated cells localizing in 
the area just outside the defect and initiating bone formation.  
B.5. Conclusions 
Microencapsulated ASCs supported osteogenesis and did not alter the bone remodeling 
process. The alginate microbeads were able to deliver the cells and their secreted factor to the area 
however they did not alter the bone remodeling process. 
 
 
